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ABSTRACT
Oswal, Pravin Dhawal Ph.D., Biomedical Sciences Ph.D. program, Department of
Biochemistry and Molecular Biology, Wright State University, 2014. Peroxisome
proliferator-activated receptor alpha: Insight into the structure, function and energy
homeostasis

Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the family
of ligand-activated nuclear transcription factors and serves as a lipid sensor to regulate
nutrient metabolism and energy homeostasis. The transcriptional activity of PPARα is
thought to be regulated by the binding of exogenous ligands (example, fenofibrate,
TriCor®), as well as endogenous ligands including fatty acids and their derivatives.
Although long-chain fatty acids (LCFA) and their thioesters (long-chain fatty acyl-CoA;
LCFA-CoA) have been shown to activate PPARα of several species, the true identity of
high-affinity endogenous ligands for human PPARα (hPPARα) has been more elusive.
This two part dissertation is a structural and functional evaluation of human and mouse
PPARα binding to LCFA and LCFA-CoA using biophysical and biochemical approaches
of spectrofluorometry, circular dichroism spectroscopy, mutagenesis, molecular
modelling and transactivation assays.
The first goal of this dissertation was to determine whether LCFA and LCFACoA constitute high-affinity endogenous ligands for full-length hPPARα. Data from
spectrofluorometry suggests that LCFA and LCFA-CoA serve as physiologically relevant
endogenous ligands of hPPAR. These ligands bind hPPARα and induce strong
secondary structural changes in the circular dichroic spectra, consistent with the binding
iv

of ligand to nuclear receptors. Ligand binding is also associated with activation of
hPPARα, as observed in transactivation assays. The second goal of this dissertation was
to determine whether there exist species differences for ligand specificity and affinity
between hPPARα and mouse PPARα (mPPARα). This is important because despite high
amino acid sequence identity (>90%), marked differences in PPARα ligand binding,
activation and gene regulation have been noted across species.
Similar to previous observations with synthetic agonists, we reported differences
in ligand affinities and extent of activation between hPPARα and mPPARα in response to
saturated long chain fatty acids. In order to determine if structural alterations between the
two proteins could account for these differences, we performed in silico molecular
modeling and docking simulations. Modeling suggested that polymorphisms at amino
acid position 272 and 279 are likely to be responsible for differences in saturated LCFA
binding to hPPARα and mPPARα. To confirm these results experimentally,
spectrofluorometry based-binding assays, circular dichroism, and transactivation studies
were performed using a F272I mutant form of mPPARα. Experimental data correlated
with in silico docking simulations, further confirming the importance of amino acid 272
in LCFA binding. Although the driving force for evolution of species differences at this
position are yet unidentified, this study enhances our understanding of ligand-induced
regulation by PPARα.
Apart from demonstrating significant structure activity relationships explaining
species differences in ligand binding, data in this dissertation identifies endogenous
ligands for hPPAR which will further help delineate the role of PPAR as a nutrient
sensor in regulating energy homeostasis.
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INTRODUCTION
The relationship between obesity and metabolic disturbances, including increased
lipids and glucose, cardiovascular disease (CVD), hypertension and diabetes, has been
known and described for decades. A syndrome linking obesity to metabolic
abnormalities, CVD and diabetes was described in 1988 by Dr. Reaven in his Banting
lecture as ‘syndrome X’ (1). Today, this syndrome is referred to as the metabolic
syndrome (named by the World Health Organization; WHO) and has a WHO diagnostic
code of ICD9. The metabolic syndrome includes a group of risk factors that increase the
risk for cardiovascular morbidities and diabetes (2, 3). Obesity, which tops the list in the
metabolic syndrome, affects more than one-third of adults (35.7%) and approximately
17% (or 12.5 million) of children in the US alone (4, 5). It is a major risk factor for
coronary heart disease, hypertension, atherosclerosis, dyslipidemia and diabetes and the
estimated 2012 annual direct medical cost of obesity in the United States (for data from
2000-2005) is $190.2 billion (6). The exact molecular mechanisms underlying these
associations are still not clear.
Obesity is a medical condition defined as an increased mass of adipose tissue and
has often been related to dysregulated lipid homeostasis. It is an illeness where the health
of an individual (and hence life expectancy) is adversely affected by excess body fat.
Under normal energy homeostasis, dietary long chain fatty acids (LCFA) not only serve
as major metabolic fuels and important components of biological membranes, but they
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also play a significant role as gene regulators and signaling molecules that regulate
metabolic pathways governing fuel utilization, storage, transport and mobilization.
Dysregulated LCFA alter this energy homeostasis and thus have been implicated in
various metabolic, endocrine and cardiovascular complications. One of the plausible
explanations of such regulation and mis-regulation includes their interactions with the
nutrient sensing family of transcription factors called the peroxisome proliferatoractivated receptors (PPAR).

Peroxisome proliferator-activated receptors (PPAR)
PPARs belong to the nuclear hormone receptor superfamily of ligand-activated
transcription factors which play important regulatory roles in numerous cellular processes
related to fatty acid metabolism, glucose metabolism, inflammation, differentiation and
proliferation (7-10). PPARs form the group C of subfamily 1 of the superfamily of
nuclear hormone receptors (NR1). There are three members of this subfamily of nuclear
receptors: PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3) (9). The founding
member of the family (PPARα) was identified because a structurally diverse group of
chemicals including fibric acid derivatives, phthalate plasticizers and certain herbicides
resulted in massive proliferation of peroxisomes in rodents (11-13). Reddy et. al. (1987)
used these chemicals as affinity ligands to identify and purify the receptor/protein
responsible for such effects from the cytosolic fraction of rat livers (14). This
protein/receptor was indicative of being isolated as a dimer and was termed as
peroxisome proliferator-binding protein (PPbP) (14). The exact identity of the true
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peroxisome proliferator binding protein (in the dimeric complex) remained elusive until
1990.
Isseman and Green (1990) were the first to clone the receptor activated by
peroxisome proliferators which became named as peroxisome proliferator-activated
receptor alpha (15). Since the discovery of PPARα, two other PPAR subtypes, PPARβ/δ
and PPARγ were identified (16, 17). They are encoded by distinct single copy genes
located on human chromosomes 22 (PPARα), 6 (PPARβ/δ) and 3 (PPARγ) (18-20).
While the splice variants of PPARγ (γ1 and γ2) are generated as a result of alternate
promoter usage and splicing (21), the PPARα splice variant transcript lacks 200 bp
around exon 6 (9.7kb compared to 9.9kb) and gives rise to a premature stop codon
resulting in truncated protein that lacks a large part of the ligand binding region (174
amino acids as compared to 468 in wild-type; Fig. 1) (22). This truncated protein is
present widely in human tissues and when compared to the wild-type PPARα its ratio
varies among individuals (from 1:1 to 1:4 - based on the two subjects tested in a previous
study) (22). The truncated PPARα protein is believed to have a repressive activity on the
wild-type form of the protein (by competing with cofactors that bind the N-terminal
portion of the protein) (22).
The three PPAR subtypes display distinct patterns of tissue distribution (16).
PPARα is expressed in tissues mainly with high metabolism rates such as liver, heart,
muscle, kidney and brown fat where it serves as a potent activator of genes involved in
lipid catabolism. In fact, synthetic agonists of PPARα (example, fenofibrate, TriCor ®;
fenofibric acid, TriLipix®; gemfibrozil, Lopid®) have been used as therapeutic agents in
the treatment of hyperlipidemia (7-10). PPARβ/δ is broadly expressed with highest levels
3

found in intestines and keratinocytes. Apart from exerting metabolic effects similar to
PPARα in gut, skin and brain, it is also involved in neuronal development, inflammation,
keratinocyte differentiation and wound healing (7-10). PPARβ/δ agonists (example,
GW501516 and MBX-2085) have been under clinical investigations (in clinical trials)
(23, 24) but are yet to be seen on the market. PPARγ on the other hand is predominantly
expressed in adipocytes and macrophages where it activates genes involved in
lipogenesis and adipocyte differentiation (7-10). While thiazolidinediones such as
pioglitazone (Actos®) are potent PPARγ agonist used in management of diabetes, others
such as rosiglitazone (Avandia®) have either been taken off the market in some countries
(mainly Europe) or prescribed with caution (U.S.A.), owing to side effects such as weight
gain and increased risks of heart attacks.
PPARα: Structure
The human PPARα gene spans ~93.2 kb on chromosome 22 and gives rise to a
9.9 kb transcript in humans (8.5 kb in mouse). This transcript encodes a 468 amino acid
and 52 kDa protein (18). Like other members of the nuclear hormone receptors, the
PPARα protein structure also consists of distinct functional domains – the N terminal
A/B domain, the DNA binding domain (DBD) or C domain, hinge region or D domain
and the ligand binding domain (LBD) or E/F domain (Fig. 1). The PPAR transcript
reveals common structural organization with the translated region composed of 8-9
coding exons depending on the transcript variant in question (18, 25).
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Fig. 1. Pre-messenger RNA and domain structure of PPARα. Top panel: The premessenger RNA for human PPARα demonstrating splicing events, S wt and Str, that
generate wild-type PPARα (9.9 kb) and truncated PPARα transcripts (9.7 kb; with
premature stop codon in exon 7). Bottom panel: Domain structure of PPARα protein
(wild-type), left to right: the N-terminus A /B domain, the C domain or DNA binding
domain containing two zinc-finger motifs that bind the DNA in the regulatory region of
target genes, the D domain or hinge region that allows for conformational changes upon
ligand binding and the - the E/F domain or the ligand-binding domain (LBD) containing
the ligand-dependent transactivation function (AF-2). The hPPARα ribbon structure is
adopted from PDB code 1K7L (26)
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The A/B region: The N-terminal A/B domain amongst most nuclear hormone
receptors displays the weakest evolutionary conservation and is highly variable, both in
sequence and length. These domains are also poorly structured, and this has been
confirmed using deuterium exchange mass spectrometry, circular dichroism spectroscopy
and NMR spectroscopy (27-29). For this reason, the X-ray crystal structure of the A/B
domain has not been resolved till date. The length of the N-terminal A/B domain in
PPARα is 100 amino acids (Fig. 1), and it harbors a ligand-independent transactivation
function (AF-1) that is responsible for low-level transactivation activity of the receptor
(tested in GAL4-fusion proteins) (30). Although the A/B domain in PPARα has poor
structural organization, it has been suggested that secondary structure formation in this
domain is an important step towards AF1 mediated transactivation (30). This was
demonstrated by two observations 1) AF-1 domain adopts α-helical characteristic in the
presence of a strong α-helix stabilization agent such as trifluoroethanol and 2) mutation
of hydrophobic amino acids in the AF-1 domain (possibly involved in α-helix formation)
impacted the transcriptional activity of the protein (30).
The importance of the A/B domain in PPARα is highlighted by the fact that
deletion of the A/B domain results in a gene-dependent alteration in PPARα
transcriptional activity. For example, deletion of the A/B domain disrupts the PPARαmediated transactivation of the acyl-CoA oxidase promoter, but it does not affect the
transactivation of cytochrome P450 4A6 promoter (30, 31). In addition, the A/B domain
of PPAR is suggested to contribute towards maintaining subtype specificity amongst the
PPAR subtypes. For example, addition of the PPARα A/B domain to PPARγΔAB (A/B
domain truncated) enhances its ability to activate PPARα specific target genes (32) and
6

the addition of PPARγ A/B domain to non-adipogenic PPARβ/δΔAB (A/B domain
truncated) imparts adipogenic potential to the resulting PPARβ/δ protein (33). As far as
its relation/association with other domains in the protein is concerned, a recent research
article demonstrates that mutation of residues in the A/B domain (S112) altered ligand
binding and activity (function of E/F domain) of PPARγ (34). These findings suggest that
studies carried out using individual nuclear receptor domains or truncated forms of
nuclear receptors must be interpreted with caution.
DNA binding domain (DBD) or C domain: The DNA binding domain is the most
conserved domain within the nuclear hormone receptor superfamily (9). The DBD of
nuclear hormone receptors recognizes a 6 nulceotide core motif in the DNA and binds to
two copies of such a motif (constituting a hormone responsive element) as a dimer.
Factors such as the 5’ flanking extension of the core motifs, spacing of the two core
motifs and their relative orientation (direct repeats, inverted repeats or everted repeats)
determine which nuclear receptor dimer binds the hormone response element (35).
Amongst the PPAR subtypes, the DBD bears about 78-86 % amino acid identity and it
encompasses amino acids 101-166 in PPARα (Fig. 1) (8, 36). The PPAR-DBD consists
of two zinc finger motifs and in each motif four cysteine residues coordinate and chelate
one Zn2+ ion. The alpha helical components of the two zinc finger motifs lie
perpendicular to each other. The amino acids that are responsible for registering contacts
with specific nucleotides in the DNA are present towards the C terminus of the first zinc
finger in a region termed as the “P box.” Hydrogen bonding contacts are made between
amino acid residues in this region and the major groove of the DNA. Similarly, the region
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towards the N terminus of the second zinc finger is referred to as the “D box” and amino
acids present in this region are involved in heterodimerization. (25, 29, 37, 38)
PPARα binds DNA as obligate heterodimers with other nuclear receptors, mainly
the retinoid X receptors (RXR). The PPAR-RXR heterodimer recognizes and binds to a
consensus sequence on the DNA, termed the peroxisome proliferator response element
(PPRE). While these PPRE were first characterized using synthetic oligonucleotides (39),
the first natural PPRE was found in the regulatory region (promoter) of the acyl-CoA
oxidase (ACOX) gene (17, 40). In addition, recent genome-wide profiling of PPARα
binding sites has revealed about 46% of PPAR-RXR binding sites within the intronic
regions (41). The PPRE belongs to the direct repeat 1 (DR1) category and consists of two
AGG(A/T)CA half sites separated by one nucleotide (Fig. 2). The binding to the PPRE
occurs in a manner such that PPAR is oriented towards the 5’ end and RXR is oriented to
the 3’end. This is in contrast to other nuclear receptor heterodimers such as the vitamin D
receptor-retinoid X receptor heterodimer (VDR-RXR) or thyroid receptor-retinoid X
receptor heterodimer (TR-RXR) where RXR is oriented towards the 5’end (38, 42).
Detailed analysis of PPRE sequences from PPAR target genes has helped to
define additional PPRE determinants (43). These PPRE determinants impart subtype
specificity as well as DNA binding polarity to the PPAR-RXR heterodimer and include
the spacing nucleotide as well as the COOH-terminal extension (CTE) of the DBD (31,
42-44). The amino acid residues present in the CTE of the PPARs play a significant role
in the recognition of the PPRE and form significant interactions with the 5’ flanking
sequence of the PPRE (Fig. 2) (29, 43). While PPAR binds DNA only as a heterodimer
(and not as a monomer), deletion of its N-terminal A/B domain allows the truncated
8

protein to non-specifically bind DNA as a monomer in in vitro assays (31). While the
physiological significance of such binding is unclear, it serves as evidence of interdomain
communication and the importance of full-length nuclear receptors. The DBD of a
nuclear receptor such as PPAR, forms an interface with its own LBD as well as the LBD
of its heterodimeric partner – thereby influencing ligand binding (29). These data point to
two important conclusions; 1) since PPARs bind to DNA only as a heterodimer it reflects
the evolution and divergence of PPARs from its monomeric nuclear receptor cousins and
2) since the DBD can influence ligand binding, it emphasizes on the importance of
conducting ligand-binding studies with full-length forms of nuclear receptors.

9

Fig. 2. Illustration of PPAR-RXR heterodimer binding to DNA. X-ray crystallized
complex of PPARγ (magenta) and RXRα (green) bound to a PPRE containing AGGTCA
direct repeat separated by one nucleotide (DR1) (Source PBD code 3DZY (29)).
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Hinge region or D domain: Adjacent to the DNA binding domain is the D domain
or the hinge region. As the name suggests the D domain serves as a ‘hinge’ between the
highly structured C and E/F domains (Fig. 1). The hinge region is not well conserved
amongst PPAR subtypes or amongst nuclear receptors in general (45). It allows for
conformational changes in protein structure upon ligand binding. The D domain also
contains the CTE of the DBD which renders polarity and subtype specificity for binding
to the PPRE (31, 42-44). For example, the CTE of the DBD (contained in the hinge
region) interacts with nucleotides in the 5’ flank of the PPRE (29) and conservation of
this 5’ flanking sequence of the PPRE is essential for PPARα binding - thus imparts
subtype specificity (43) This region is also thought to harbor the nuclear localization
signals and contain sites for protein-protein interaction (45).
Ligand binding domain or E/F domain: The C-terminal ligand binding domain
(LBD) or E/F domain for the PPARs is highly structured and contains ligand-dependent
activation function (AF-2). Compared to the DNA binding domain, the LBD bears less
amino acid identity (63-71 %) amongst the PPAR isotypes (9, 36). The X-ray crystal
structures of all the PPAR-LBD isotypes have been resolved and studied in great detail.
Before going in depths of the PPARα structure, it is necessary to clarify some
terminology issues, particularly with the E and F domains. In addition to the A/B, C and
D domains, researchers in the nuclear receptor field often classify receptors as having
only an E domain (46), both E and F domains (46, 47) or an E/F domain (8, 10). It is thus
important to clarify these differences in terminology. Classically, the nuclear receptor
LBD is defined as the domain between the beginning of helix 1 through the end of helix
12 (AF-2) (46). Any region beyond helix 12 (seen in the progesterone, estrogen and
11

retinoic acid receptors) is referred to as the ‘F domain’ (46). Since the PPARα-LBD is
composed of 12 α-helices, with only four amino acids at the C-terminus, for the sake of
simplicity herein the LBD is referred to as the E/F domain.
The human PPARα-LBD extends from amino acids 280-468 (Fig. 1) and contains
a ligand-dependent transactivation function (AF-2), a major dimerization interface and
sites for interaction with coactivator and corepressor proteins (8-10). Recently, it has also
been demonstrated that the PPAR-LBD may have additional interfaces for interaction
with its own DBD as well as the DBD of its heterodimeric partner (29). Structurally the
PPARα-LBD is folded in a three-layered helical sandwich formed by 12 α-helices
(designated H1-H12) and a four stranded β-sheet (26). The central core of this helical
sandwich is packed in way to create a 1400 Å3 cavity, the ligand binding pocket (26). The
volume of the PPARα-LBD pocket is quite comparable to other PPAR isotypes but is
substantially larger than some other nuclear receptors such as thyroid receptor (600 Å3)
and retinoid X receptor (RXR; ~500 Å3) (9, 26, 48-50).
X-ray crystal structures of the PPARs in complex with agonist-bound ligands and
the understanding of nuclear receptor activation has helped in the design of specific
agonists, partial agonists as well as antagonists. The crystal structure of the PPARα-LBD
in complex with GW409544 agonist reveals that the carboxylic acid group of the agonist
forms hydrogen bonds with Y464 on helix 12 and Y314 on helix 5 (Fig. 3) (26). The rest
of the GW409544 ligand is largely lipophilic and is stabilized by hydrophobic
interactions with the amino acids lining the pocket of the PPARα-LBD. These
interactions stabilize the receptor in an “active” conformation. Based on this information,
Xu et al. elegantly designed a potent PPARα antagonist in which the carboxylic acid
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group of the GW409544 agonist was substituted by an ethyl amide such that it would
disrupt the hydrogen bonding with Y464 (51). As a result of this substitution, the
antagonist blocks the helix 12 from adopting the “active” conformation.
The ligand binding pocket of human PPARα assumes a Y-shape and spans
between the C-terminal helix 12 and the 4 stranded β-sheet, splitting into roughly two
arms along helix 3. Compared to the PPARα-LBD structure, the ligand binding pocket of
agonist bound PPARγ-LBD and PPARβ/δ-LBD are ‘T’ and ‘Y’ shaped respectively (49,
50). The amino acids lining their ligand binding pocket bear several conserved and
nonconserved amino acid changes that dictate the shape and volume of the pocket and
thereby impart ligand specificity to the isotypes. For example, H323 in the human
PPARγ-LBD corresponds to Y314 in the human PPARα-LBD and imparts ~1000-fold
greater selectivity for the binding of farglitazar (thiazolidinediones) to PPARγ (26). Also,
a single methionine to valine substitution at 417 (M417V) in human and/or chick
PPARβ/δ imparts fibrate (PPARα specific agonist) binding characteristic to the protein
(52).
Several hydrophilic residues lining the PPARγ or PPARβ/δ pocket are converted
to hydrophobic residues in PPARα – rendering the PPARα pocket much more
hydrophobic as compared to either PPARγ or PPARβ/δ (26). In the ligand bound
(agonist) conformation the human PPARα pocket is lined by a mix of largely
hydrophobic residues (I241, L247, L254, I272, F273, I317, F318, L321, M330, V332,
I339, L344, L347, F351, I354, M355, V444, L456, L460), a few polar residues (S280,
T279, E251, C275, C276, Y314, H440) and is capped by Y464 from the AF-2 helix (26).
However, irrespective of the amino acid changes or the distinct ligand binding
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specificities amongst all PPAR isotypes, they all contain a similar network of hydrogen
bond forming amino acid residues (near the AF-2) that are involved in receptor activation
upon ligand binding (26). PPARα binds to the PPRE in its target genes only as an
obligate heterodimer with RXR (38, 39, 47). The heterodimerization interface is mainly
formed by helices 9 and 10. This was confirmed in studies involving deletion of helix 1012 as well as a L433R mutation in PPARα which caused impaired heterodimerization
with RXR (53, 54).
PPARα: Mode of Action
Conformational changes: Ligand binding induced conformational changes are
hallmarks of nuclear receptor action (53). The human genome contains 48 nuclear
receptors and notably many of their LBD have been crystallized in the holo or liganded
state. This is because the binding of a ligand stabilizes the conformation of a nuclear
receptor, making it convenient to crystallize (26, 49, 50, 55, 56). Nonetheless, a few
nuclear receptors have been crystallized in the unliganded state; including, apo-RXRαLBD and apo-PPARγ-LBD (49, 57). Based on comparison of the apo and holo state of
nuclear receptors, a “mousetrap” model/mechanism of nuclear receptor activation has
been proposed (58).
The “mousetrap” model was first proposed on the basis of x-ray crystal structures
of the apo-RXR-LBD (57) and the holo-retinoic acid receptor LBD (RAR-LBD) (59) and
later extended to other nuclear receptors using apo/holo-state structures of the RXRαLBD and PPARγ-LBD (49, 57). According to this model, in the unliganded nuclear
receptor, the helix 12 (AF-2) is angled away from the body of the LBD. The binding of a
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ligand causes conformational changes and concomitant swinging of helix 12 (AF-2;
moves closer to the LBD) such that it “traps” the ligand and prevents its exit (Fig. 3) (58).
Hydrophobic and electrostatic interactions between the ligand and amino acids lining the
pocket and helix 12 (Y464 in PPARα; (26)) stabilize and reposition helix 12. In some
nuclear receptors, including the PPARs, the AF-2 is stabilized by specific interactions
between the ligand and the amino acids of helix 12 (58), but in others the helix 12 is
stabilized indirectly by other intervening residues (55, 56, 58) (Fig. 3).
While the “mousetrap” model is widely accepted for nuclear receptor activation
(including that for PPARα), recently a “dynamic stabilization” model has also been
proposed to account for the plasticity of the nuclear receptor ligand binding pocket and to
explain the appearance of helix 12 proximal to the LBD, even in absence of ligands (56,
60, 61). According to this model, the AF-2 along with other regions of the LBD are rather
mobile in an unliganded nuclear receptor. The binding of ligand stabilizes overall
conformational dynamics of the receptor along with repositioning of helix 12 via specific
interactions with the ligand (Y464 in PPARα) (60). However, if the helix 12 is stabilized
proximal to the LBD in an unliganded state, then according to this model that nuclear
receptor is likely to show constitutive activity (55, 56, 61). For example, the constitutive
activity of nuclear receptor related protein 1 (NURR1) (62) is explained by this model.
This model helps explain the dynamic/plastic nature of most nuclear receptors including
the PPARs (56) and has been well supported by various solution based biophysical
studies. For example, NMR studies (63), proteolytic sensitivity studies (64, 65),
fluorescence studies (66) as well as secondary structure melting studies (67) have all
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demonstrated that the relatively unstable apo-state nuclear receptor LBD switches to a
more rigid and stable conformation upon ligand binding (60, 61).
Regardless of the “mousetrap” mechanism or the “dynamic stabilization” model,
the helix 12 (AF-2) switches from a rather mobile conformation to a more stable position
proximal to the ligand binding pocket. This results in exposure of a new surface on the
receptor that recruits transcriptional activators and other components of the transcription
machinery, resulting in enhanced/repressed transcription of a specific set of target genes
(68, 69). This phenomenon, mediated by ligand binding, is crucial for receptor activation.
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Fig. 3. Illustration of “mousetrap” model for PPARα activation. In the unliganded state
the helix 12 (AF-2; red) is away from the LBD of PPARα (position 1). Upon ligand
binding the AF-2 is stabilized proximal to the ligand binding pocket (position 2) by
specific interactions between the ligand and amino acids residing in helix 12 (example
Tyr-464). (PDB file (1K7L) adapted from (26))
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Coactivators and Corepressors: Nuclear receptor mediated transcriptional regulation of
genes is a complex process and also involves two classes of transcriptional
cofactors/coregulators (corepressors and coactivators) (68, 69). The development of
squelching experiments and yeast two hybrid have marked the discovery and
identification of a large number of coactivators and corepressors that transmit the nuclear
receptor signals to the transcriptional machinery (70, 71). In the simplest form,
corepressors bind to the PPAR-RXR heterodimer in an unliganded state and render it
inactive. Ligand binding induces specific conformational changes that result in the
release of corepressors and the recruitment of coactivator proteins. Coactivators or
corepressors respectively bring about transcriptional activation or repression of the target
genes by mechanisms including chromatin modification (via intrinsic histone
acetyltransferase activity (HAT) or histone deacetylase activity (HDAC)) and physical
interactions with the transcriptional initiation machinery (68, 69).
The first class of nuclear receptor coregulators includes the coactivators. Binding
of an agonist ligand results in repositioning of helix 12 together with other structural
changes that lead to the creation of a distinct surface on the protein. These novel surfaces
allow for recruitment of coactivator proteins with a conserved LXXLL motifs or (L,
leucine and X, any amino acid; also called ‘NR box’) such as the steroid receptor
coactivator (SRC-1) (68, 69, 72). SRC-1 was the first nuclear receptor coactivator to be
discovered (72), and its interaction with LXXLL motifs were first seen in the crystal
structure of the PPARγ-LBD (49). In addition to interacting with LXXLL motifs in the
LBD of nuclear receptors, coactivator proteins may also interact with the A/B domain of
nuclear receptors. For example, SRC-1 and coactivators belonging to the transcriptional
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mediators/intermediary factor 2 (TIF-2) family also interact with the A/B domain of
nuclear receptors such as the estrogen and androgen receptors (73, 74) . It is thus possible
that the N-terminal A/B domain (AF-1) and the LBD (AF-2) may not always function
independently but may rather serve as a single common recruiting surface for such
coactivators. The molecular mechanism of action of coactivators results from their ability
to reorganize/remodel chromatin. While coactivators such as SRC-1 possess intrinsic
HAT activity that aid in chromatin remodeling, others such as TIF-2 function by
physically recruiting histone acetyltransferases (70, 73, 74). Decondensation of chromatin
is then followed by recruitment of basal transcriptional machinery to the target gene
promoters including TATA binding protein (TBP) and RNA polymerase II (75).
The observation that certain nuclear receptors such as the thyroid receptor (TR)
and retinoic acid receptor (RAR) repress transcription even in the liganded state led to the
discovery of a second class of nuclear receptor coregulators called the corepressors (76).
Examples of corepressor proteins that bind the PPAR-RXR heterodimer in an unliganded
state include nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and
thyroid hormone receptors (SMRT) (76, 77). These corepressors bind to a LXXXIXXXL
motif (also termed as the ‘CoRNR box’) on the surface of the protein that does not
involve helix 12 (78). Although the CoRNR box is similar to the LXXXL coactivator
motif, the three extra amino acids in the CoRNR box cannot be accommodated in the
ligand bound nuclear receptor conformation (with the repositioned helix 12) (78, 79). In
contrast to the mechanism of action for coactivators, corepressors bring about
transcriptional repression through intrinsic or recruited histone deacytylase activity (70,
75, 76), and the phenomenon of coactivator recruitment is accompanied by corepressor
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release. For example, release of NCoR upon binding of Wy-14,643 (agonist) to PPARα
(77).
Since the discovery and cloning of SRC-1 (72) and NCoR (76, 77), more than 300
transcriptional cofactors have been identified that associate with nuclear receptors such as
the PPAR (8, 80). These cofactors allow for the interaction of the PPAR-RXR complex
with other proteins/complexes associated with the basal transcription machinery,
resulting in enhanced/repressed transcription of a specific set of target genes (Fig. 4) (68,
69). However such diversity of 300 or more cofactors not only enhances the multiplicity
of nuclear receptor activation, but also adds complexity in our understanding of nuclear
receptor mediated transcriptional regulation. For example: why are there multiple
coregulators with the same HAT/HDAC activity? Do they bind nuclear receptors in a
sequential or combinatorial manner? Does there exist competition for these coregulators?
How do tissue-restricted distribution and/or regulation of cofactors affect nuclear receptor
action? While many of these questions are still under extensive investigations, some of
the outcomes are presented below.
Tissue restricted distribution and physiological regulation of these cofactors
could be a means of finer regulation of nuclear receptor action. For example, 1) PPARγ
can activate the transcription of uncoupling protein 1 (UCP1) in brown fat but not
fibroblasts. This was because PPARγ coactivator-1 (PGC-1), which serves as a
coactivator for PPARγ, is expressed primarily in brown fat and skeletal muscles (81).
Further PGC-1 expression is also regulated physiologically by body temperature. Thus
exposure of mice to cold temperatures increases the activity of PGC-1 and thereby
increases the transcriptional activity of PPARγ (81). Similarly tissue restricted
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distribution of other cofactors such as SRC-1 may further modulate the transcriptional
activity of nuclear receptors (82).
Irrespective of the vast scope of research in understanding the downstream
molecular mechanism of cofactors, the phenomenon of coactivator-recruitment upon
ligand binding has resulted in the development of coactivator-dependent receptor ligand
binding assays (CARLA) (83, 84). Although these assays have provided valuable
information on the identity of ligands for orphan receptors, many of these assays were
conducted with truncated forms of nuclear receptors (only the LBD). Since coactivators
such as SRC-1 has been demonstrated to interact with the A/B domain of nuclear
receptors (in addition to LXXLL motifs in the LBD) (74), the significance of these
findings are not clear. These data further emphasize the need to conduct such ligand
binding studies with full-length forms of nuclear receptors.
Cellular localization and chain of events: The cellular localization of nuclear hormone
receptors is a result of equilibrium between the nucleus and the cytoplasm (85).
According to the widely accepted dogma, nuclear receptors are predominantly localized
in the nucleus at equilibrium (even in absence of ligand) (46). However, in contrast to
this, unliganded steroid hormone receptors are primarily localized in the cytoplasm where
they are bound/chaperoned to heat-shock protein 90 (HSP90) (86, 87). They translocate
to the nucleus to perform their transcription regulatory function upon ligand binding (86,
87). As far as PPARα is concerned, it is generally agreed that it is predominantly
localized in the nucleus (88-92). However, recent studies demonstrate some evidence for
dynamic shuttling of PPARα between the cytosol and the nucleus (89, 93-95). Umemoto
et al. further demonstrated that the nuclear transport of PPARα is accelerated by the
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addition of ligands (93). These findings suggest that extracellular signals (ligands) could
dissect the PPARα dynamics into discrete nuclear-cytoplasmic shuttling steps.
In addition to this, there is also controversy regarding the chain of events –
particularly heterodimerization and DNA binding. Based on the definition of a “domain”
and information from individual crystal structures of nuclear receptor LBD or DBD, it
was thought that each functions independently (55). However, the intact structure of the
PPAR-RXR heterodimer bound to a PPRE revealed three heterodimerization interfaces
(29). Two of these were already known and included the LBD-LBD interface and the
DNA dependent DBD-DBD interface. What was not known was this third interface (also
DNA dependent) formed between the PPAR-LBD and the RXR-DBD (29). This interface
suggests that PPAR ligands could influence DNA binding through the PPAR-LBD. This
led to the idea that ligands could themselves target a specific subset of genes (55). In
contrast, the fact that the PPAR-RXR complex had two DNA dependent interfaces,
suggests that DNA motifs could allosterically regulate heterodimerization and receptor
activation (29, 55).
Although these finding do not give a clear picture on the chain of events, they do
add to our understanding of the dynamic nature of nuclear receptor activation. The static
model for transcription factor action assumes that upon activation the transcription factor
is either: 1) bound (for a fairly long length of time), or 2) not bound to the DNA (96-98).
However recent studies with chromatin immunoprecipitation and sequencing (ChIP-seq),
fluorescence recovery after photobleaching (FRAP) and fluorescence correlation
spectroscopy (FCS) have given light to the dynamic properties of nuclear receptors (96,
98). These studies gave rise to a dynamic or “hit and run” model of transcription factor
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action where there is a rapid cycling of DNA binding-unbinding with ligand-dependent
cycle/binding time and receptor mobility (96, 98). For example, RXR agonist treatment
largely affected the occupancy time of genomic regions to which RXR bound (96-98). It
is anticipated that other nuclear receptors such as PPARα also follow a similar trend
where they rapidly bind and unbind DNA in the absence of ligands. However, addition of
ligands results in slowing down of such shuttling such that the residence time on the
DNA is significantly increased.
To summarize, PPARα binds to a PPRE in its target genes as a permissive
heterodimer with RXR (PPARα-RXR) (Fig. 4). Ligand binding and recruitment of
cofactors (coactivators or corepressors) mediates the ability of PPARα to regulate
transcription of its target genes. Like mentioned earlier, irrespective of high structural
homology, identical PPRE sequences and shared cofactors, a number of factors determine
isotype specificity among the PPARs. These include: amino acids lining the ligand
binding pocket (26), the 5’ flanking extension (to the DR1), spacing nucleotide (in PPRE)
(31, 42-44), tissue restricted expression of each isoform (7-10, 16), availability of
ligands, competition for mutual dimerization partners (such as RXR), availability and
recruitment of cofactors (8, 9, 81, 82).
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Fig. 4. PPAR mechanism of action. PPARs form heterodimers with retinoid X receptors
(RXR) and bind to DNA sequences called peroxisome proliferator response element
(PPRE) in the promoter region of target genes. Recruitment of cofactors (coactivators or
corepressors) mediates the ability of PPAR’s to stimulate or repress the transcription of
target genes involved in difference cellular functions (modified from (99)).
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PPARα: Ligands, physiological role and knockout mice phenotype
Ligands: Even before the discovery and cloning of the PPARα gene, a vast array of
structurally diverse chemicals were known to lower serum lipids and cause massive
peroxisomal proliferation in mice.

These chemicals included fibric acid and its

derivatives, nafenopin, methyl clofenapate, industrial phthalate-monoester plasticizers
such as, di-(2-ethylhexyl)-phthalate (DEHP; used as a solvent/softner in manufacture of
PVC plastics), certain herbicides, pesticides and industrial solvents (7-13). A mechanistic
search on how these chemicals act lead to the discovery of a protein dimer which was
aptly named peroxisome proliferator-binding protein (PPbP) (14). However, since the
cloning of the receptor responsible for binding to peroxisome proliferators it was
designated as Peroxisome Proliferator-Activated Receptor alpha (PPARα) (15). Today
the ligands of PPARα have been classified into two main categories: endogenous ligands
and exogenous (synthetic) ligands.
Synthetic ligands of PPARα include agonists such as clofibrate, fenofibrate
(TriCor®), fenofibric acid (TriLipix®), gemfibrozil (Lopid®), ciprofibrate, Wy-14,643 and
chemicals such as certain industrial plasticizers (DEHP, di-(2-ethylhexyl)-adipate
(DEHA)), herbicides (phenoxyacetic acid) and pesticides (diclofop-methyl and pyrethrin
family) (7-13). While, short-term administration of synthetic PPARα ligands in mice or
rats leads to transactivation of genes involved in lipid catabolism, chronic administration
leads to peroxisomal proliferation and hepatic carcinomas (7-13). The chronic effects of
PPARα agonists are not seen in non-rodent species like guinea pig, dog, rhesus monkeys,
nonhuman primates or humans (100-104) where they serve as potent hypolipidemic
agents to lower plasma VLDL and triglyceride levels and increase high density
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lipoprotein (HDL) levels. For this reason PPARα agonists have continued to be an
attractive drug target for the pharmaceutical industry and are used in the treatment of
dyslipidemia. In conjunction with statins, they are also prescribed in the treatment of
hypercholesterolemia (high cholesterol) (8-10, 105-107). Other chemicals, particularly
plasticizers (example DEHP - used in the manufacturing of plastics) and herbicides that
activate PPARα are potential environmental toxins that contaminate ground water. While
their acute impact in human health is unclear, they do raise long-term or lifetime health
concerns.
A quest for natural endogenous ligands revealed that PPARα was not an orphan
receptor. Pioneering studies using different reporter assays (GAL4, chloramphenicol
acetyltransferase or CAT assay, luciferase), CARLA assays and competition assays
(radioactive) demonstrated that a variety of fatty acids and their derivatives are able to
interact with, and transactivate PPARα (83, 84, 108-113). These include fatty acid
derivatives obtained via lipoxygenase (leukotriene B4 or LTB4, hydroxyeicosatetraenoic
acid or HETE) or cycloxygenase (prostaglandins) pathways (111, 112), branched chain
fatty acids (phytanic acid) (114) and long chain dietary fatty acids (115-117). As such,
fatty acids and their metabolites that interact with PPARα can be derived from the diet or
obtained via de novo synthesis. Alternatively, it has been proposed that fatty acids and
their derivatives are presented to PPARα in the nucleus by specific intracellular proteins
such as fatty acid binding protein (FABP) or acyl-CoA binding protein (ACBP) (118,
119). This hypothesis is supported by data demonstrating interaction of FABP with fatty
acids and their ability to translocate across to the nucleus to interact with PPARα (88, 89,
95, 120).
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Evidence suggests that PPARα has evolved to primarily sense endogenous lipids
and/or lipid metabolites as ligands and regulate the expression of target genes involved in
their metabolism (111, 114, 121). The first set of evidence for this came from studies
involved the use of fatty acyl CoA oxidase 1 (ACOX1) knockout mice (121). ACOX is
the first and rate limiting enzyme involved in the fatty acid β-oxidation pathway and is
regulated by PPARα. Disruption of ACOX1 caused accumulation of long chain fatty
acyl-CoA and profound activation of PPARα (owing to accumulation of PPARα ligands)
(121). Another study that highlighted the role of PPARα as a lipid sensor was done
utilizing PPARα knockout mice (PPARα-/-). LBT4 is an inflammatory eicosanoid
derived from arachidonic acid that activates PPARα and induces genes that would
neutralize or degrade LBT4 itself (111). Exposure of PPARα-/- mice to LBT4 (or its
precursors) leads to a prolonged inflammatory response (compared to wild-type mice)
because genes involved in neutralizing the inflammatory response are not induced (111).
Today it is established that PPARα plays a crucial role not only in the transport
and β-oxidation (break-down) of fatty acids but also in the inhibition of de novo fatty acid
synthesis (8-10). Since altered levels of fatty acids are associated with the development of
diabetes, obesity, hypertension, cardiovascular diseases and atherosclerosis, misregulation of PPARα activity and/or metabolic pathways may contribute to the pathology
of these disease states. Alternately PPARα activation by pharmacological or dietary
intervention may help combat obesity and its co-morbities.
Physiological role of PPARα in lipid metabolism: Lipid metabolism orchestrated
in the liver primarily involves fatty acid oxidation and lipogenesis. Fatty acid oxidation
primarily occurs in three main subcellular organelles: mitochondria, peroxisomes (β27

oxidation) and microsomes (ω-oxidation). Some of the key enzymes involved in these
processes possess PPRE motifs in their promoters and are under direct control of PPARα.
These include 1) proteins involved in the transport of fatty acids into the cell such as fatty
acid transport protein (FATP), fatty acid translocase (FAT/CD36) (122, 123), fatty acid
binding protein (FABP) (124) and carnitine palmitoyl transferase I (CPT I) (125) (Fig. 5),
2) the enzyme that esterifies free fatty acids into fatty acyl coenzyme A – acyl CoA
synthase (126), 3) enzymes involved in the process of peroxisomal, mitochondrial and
microsomal fatty acid oxidation such as ACOX (17, 40, 127), medium chain acyl CoA
dehydrogenase (MCAD) (128) and cytochrome P450 (129, 130) amongst others (Fig. 5)
(25).
As far as lipogenesis is concerned, PPARα downregulates enzymes involved in de
novo lipid synthesis such as acetyl CoA carboxylase (ACC) and fatty acid synthase
(FAS) (Fig. 5) (25). While this effect appears paradoxical to its well established function
in fat catabolism, it is believed to be an indirect effect brought about by regulation of
other transcription factors such as sterol regulatory element-binding protein (SREBP-1c)
and liver X receptor α (LXRα) (8, 9, 131, 132). SREBP-1c is a transcription factor that
plays crucial role in the regulation of lipogenic genes such as FAS and stearoyl CoA
desaturase (133). In humans, its role in lipogenesis is under direct regulation of PPARα
and LXRα - brought via two LXR response elements (LXRE) and one PPRE in the
SREBP-1c gene (132). Interestingly, LXRα is an ‘oxysterol sensor,’ whose role in
cholesterol homeostasis and lipogenesis (via SREBP-1c) is under direct regulation of
PPARα via an active PPRE found in its regulatory region (134). Thus PPARα regulates
lipogenesis in a dual manner – directly via SREBP-1c and indirectly via LXRα.
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Fig. 5. Example of some genes regulated by PPARα and their role in lipid metabolism.
Upregulated genes are shown in green and include FATP – fatty acid transport protein,
FABP – fatty acid binding protein, MCAD – medium chain acyl CoA dehydrogenase,
P450 – cytochrome P450 fatty acid ω-hydroxylase, ACOX – acyl CoA oxidase, CPTI –
carnitine palmitoyl transferase I and ACC – acetyl CoA carboxylase. Downregulated
genes are shown in red and include FAS – fatty acid synthase and ACS – acyl CoA
synthetase. FFA – free fatty acids.
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Physiological role of PPARα in lipoprotein metabolism: Owing to enhanced β-oxidation
caused by PPARα agonists, triglyceride-rich lipoprotein particles are subjected to
catabolism - resulting in decreased secretion of very low density lipoproteins (VLDL) by
the liver (8). PPARα agonists also induce lipoprotein lipase (LPL) activity resulting in
increased triglyceride hydrolysis. This effect is brought about in a dual manner: 1) they
induce the LPL promoter (containing a PPRE) (135) and 2) they reduce the activity/levels
of apolipoprotein (Apo) C-III (ApoC-III) which is an inhibitor of LPL (136, 137). The
expression of human ApoA-I and ApoA-II is also under direct control of PPARα and
such regulation is not seen in rodents (138, 139). ApoA-I and ApoA-II are major
component of HDL that help clear cholesterol (138, 139). Therefore in humans, PPARα
agonists increase the formation and secretion of HDL, and aid in transport (reverse
cholesterol transport) and excretion of cholesterol (anti-atherosclerotic) (8, 138, 139). In
addition to these effects, PPARα agonists also bring about cholesterol homeostasis
indirectly through LXRα-mediated regulation/induction of ATP-cassette transporter A1
(ABCA1) and cholesterol 7α-hydroxylase (CYP7A) – resulting in an efflux and excretion
of cholesterol into bile (140, 141).
Physiological role of PPARα in inflammation: PPARα brings about anti-inflammatory
actions by two means. First, PPARα directly binds inflammatory fatty acid derivatives
like LBT4 and promotes their breakdown/metabolism by inducing genes involved in such
pathways (111). Second, PPARα agonists decrease/inhibit inflammatory cytokines (IL-1,
IL-6), tumor necrosis factor α (TNFα), inducible nitric acid synthase (iNOS) and
cyclooxygenase-2 (COX-2) indirectly via negative crosstalk with the nuclear factorkappa beta (NfκB) (142, 143). In chronic hyperlipidemia and/or early atherosclerosis
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macrophages engulf oxidized LDL (generated via free oxygen radicals), giving rise to
macrophage foam cells. When these foam cells accumulate at particular foci within the
intima of a blood vessel, it begins the formation of a necrotic, inflammatory
atherosclerotic lesion (144). Owing to the beneficial role played by PPARα in reducing
inflammation (preventing formation of oxidized LDL) and promoting reverse cholesterol
transport (described above), PPARα agonists prevent the formation of macrophage foam
cells and also have anti atherosclerotic effects (8, 138-141).
PPARα knockout mice model: Gonzalez et al. generated the first PPARα knockout mouse
by targeted disruption of the PPARα ligand binding domain coding region (145). These
mice are viable, fertile and display no detectable gross phenotype. However, under
condition of fasting these mice exhibit severe hypoglycemia and hypothermia (145).
While such fasting would normally result in PPARα activation and induction of fatty acid
oxidation, in PPARα knockout mice, fatty acid oxidation is largely impaired, resulting in
enhanced accumulation of fat droplets in the liver (145). The role of PPARα in lipid
homeostatis is further highlighted by the fact that PPARα knockout mice exhibit reduced
capacity to metabolize long chain fatty acids and develop dyslipidemia and steatosis
(146-148). These findings therefore augment the role of PPARα as a lipid sensor in the
regulation of lipid metabolism.
Although PPARα knockout mice display normal basal levels of peroxisomal βoxidation enzymes in the liver, administration of synthetic PPARα agonists fails to
induce PPARα responsive genes such as ACOX (145). In contrast to the normal basal
levels of peroxisomal β-oxidation enzymes in the liver, PPARα knockout mice display
lower levels of mitochondrial fatty acid oxidation enzymes (146). PPARα knockout mice
31

also do not display the ‘classical’ peroxisome proliferator response and fail to develop
hepatic cancers when chronically treated with PPARα agonists such as clofibrate or
WY14,643 (145). Further, transgenic PPARα knockout mice that express human PPARα
in the liver also do not exhibit any liver tumors when chronically exposed to PPARα
agonists such as WY14,643 (149, 150) - suggesting that there exist some species
variation in the structure/function of PPARα. All these findings with PPARα knockout
mice have during the past 18 years have further highlighted the role of PPARα in energy
homeostasis and inflammation.
Development of hypothesis
Although a plethora of exogenous ligands have been shown to activate PPARα,
the identity of high-affinity endogenous ligands has been more elusive. In the last two
decades, an overwhelming amount of data indicate that PPARα is not an orphan receptor,
and that fatty acids and its derivatives are able to regulate PPARα transcriptional activity.
The first endogenous ligands (fatty acids) able to activate PPARα were identified in
transactivation assays that used the glucocorticoid response element or estrogen response
element containing reporters and chimeric receptor constructs of glucocorticoid receptor
DBD and PPARα-LBD or estrogen receptor DBD and PPARα-LBD (109, 110).
However, since such transactivation could result from multiple indirect pathways, the
direct interaction of fatty acids with PPARα had to be tested.
Owing to its important role in regulating metabolism and energy homeostasis, a
number of assays have been developed to study the interaction of fatty acids and their
derivatives with recombinant forms of mouse and xenopous PPARα. These include: 1)
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Radioligand binding assays – these are competition assays based on displacement of
bound radioligand by the ligand of interest (108, 111), 2) Scintillation proximity assays –
uses scintillation to measure the binding of a receptor-bound radioligand to another
molecule localized to a microsphere (151), 3) Limited proteolysis assays – based on the
protease sensitivity of the receptor in presence and absence of ligand (53), 4) Ligand
induced complex (LIC) assays – based on the ligand dependent binding of PPAR-RXR
heterodimer to a PPRE (113), and 5) Co-activator recruitment assays – based on the
ligand dependent recruitment of co-activators (83). A combination of all of these studies
have indicated that fatty acids and their metabolites (fatty acyl-coenzyme A) interact with
this class of nuclear receptors (83, 84, 108-113). These studies utilized the recombinant
LBD of mouse, rat, or xenopous PPARα protein and reported binding affinities (Kd) in
the micromolar ranges (83, 84, 108-113). Although these studies provide a wealth of
information, particularly on the possible endogenous ligands for PPARα, they have
certain limitations. These include limitations in the techniques used, the use of truncated
and tagged form of PPARα-LBD and the lack of consideration of the possible species
differences in the activity and function of the PPARα protein.
In order to be classified as a ligand for a nuclear receptor, mere in vitro physical
interaction is not sufficient. The ligand must also be present within the cell/nucleus in
sufficient amounts (46, 118). The nuclear concentration of fatty acids and their
metabolites have been determined to be in the nanomolar ranges (88, 95, 117, 118, 120,
152) – making these micromolar binding affinities (for FA and FA-CoA) physiologically
irrelevant. Many of the assays described above involve the physical separation of bound
vs. unbound fraction which often disturbs the equilibrium. Therefore dissociation
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constants (Kd) derived by such means often underestimate the binding affinity (115, 117,
118). The binding affinities reported for FA and their derivatives from these studies are in
the micromolar ranges (88, 95, 117, 118, 120, 152) and it is doubtful that local FA
concentrations will ever reach such high levels in vivo (118). Thus the significance of
such findings are not clear.
Pioneering studies by Ellinghaus et al., Lin et al. and Hostetler et al. using
fluorescence based binding assays circumvented this problem and reported binding
affinities for FA and their derivatives in the physiological ranges (114, 115, 117).
However, these studies were again carried out with truncated forms of the mouse protein
which may give rise to anomalous results that may not be representative of the human
PPARα (153, 154). While such studies with truncated/tagged forms of mouse or
xenopous PPARα have led to accumulation of valuable information particularly on ligand
discovery, they also did not account for the A/B domain effects or the likelihood of
interdomain communication.
Classically it was believed that nuclear receptor domains are like individual beads
on a string, such that each domain could function independently. However, an increasing
number of solution based biophysical studies, some of which are listed below, have
suggested that nuclear receptor domains are integrated together such that information or
changes in one part of a domain are transmitted to another (55). For example, 1) Deletion
or mutation in the N-terminal A/B domain of PPARs affects DNA binding (31), ligand
binding (34) and ligand-mediated transcriptional activation, depending on the target gene
(30, 31) and 2) The DBD of nuclear receptors such as androgen receptor, glucocorticoid
receptor and PPARs has been demonstrated to communicate with their respective LBD
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such that the DBD impacts the receptor structure and activity at the LBD (155-157).
These findings emphasize the need to carry out binding studies using putative
endogenous ligands for PPARα and full-length forms of the protein.
While FA and FA-CoA have been demonstrated to serve as ligands for mouse, rat
and xenopous forms of PPARα (16, 108, 110, 113, 115-117) no such studies have been
conducted using the full-length human PPARα (hPPARα). This is an important gap in
research that needs to be addressed, because, based on the type of assays used, these same
studies also demonstrate species differences for ligand specificity and affinity (16, 84,
108, 110, 113, 115-117). For example the xenopus PPARα seems to have a weaker
affinity for fatty acids than hPPARα (84, 108), but higher affinity than rat PPARα (83,
110). Similar differences in the binding and activation of PPARα has also been seen in
response to synthetic agonists (158-160). While a strong divergence in the pattern of
PPARα regulated genes has been seen in humans vs. rodents, differences in the extent of
transcriptional activation of human and mouse PPARα proteins have also been observed
in response to certain hypolipidemic agents and pthalate monoesters (161-163). Since a
single amino acid change in the mouse PPARα-LBD (E282) resulted in altered activity of
the protein (164) and alteration of a single amino acid in human PPARα (V444M)
produced PPARδ ligand binding characteristics (52), it is possible that amino acid
differences affect ligand binding.
Considering the crucial role of PPARα in lipid homeostasis, it is essential to
elucidate its endogenous ligands of full length forms of the protein using an assay whose
functional read-out is not just physiologically relevant, but also sensitive enough to
determine species differences in such binding between the human and mouse forms of the
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protein. Therefore, we hypothesize that long chain fatty acids (LCFA) and/or their
thioesters (LCFA-CoA) constitute high affinity endogenous ligands for full-length
hPPARα and there exist significant differences in such affinity between hPPARα and
mPPARα. Studies that would ascertain the identity of true endogenous ligands of human
PPARα would aid in a deeper understanding of energy metabolism and possible
therapeutic dietary interventions.
The goals of this dissertation are 1) to investigate whether LCFA and LCFA-CoA
constitute high-affinity endogenous ligands for full-length hPPARα. These data will be
important to understand the molecular role of dietary nutrients in hPPARα mediated
regulation of energy homeostasis. 2) To determine if there exist differences in affinity for
ligands between hPPARα and mPPARα and further explore the possible mechanisms for
such differences. This is important because the rodent model has been used as a classical
model to study PPARα. Such differences in ligand binding specificity and affinity
between mouse and human PPARα will call for careful interpretation of data using mouse
as a model for studying this protein. Further, knowledge about the mechanisms of species
differences may help develop better drugs and dietary regimens with greater specificity
for human versus rodent PPARα for combating obesity and its related disorders.
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CHAPTER I
DIVERGENCE BETWEEN HUMAN AND MURINE PEROXISOME
PROLIFERATOR-ACTIVATED RECEPTOR ALPHA LIGAND SPECIFICITIES
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1. Abstract
Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the family of
ligand-dependent nuclear transcription factors which regulate energy metabolism.
Although there exists remarkable overlap in the activities of PPARα across species,
studies utilizing exogenous PPARα ligands suggest species differences in binding,
activation, and physiological effects. While unsaturated long-chain fatty acids (LCFA)
and their thioesters (long-chain fatty acyl-CoA; LCFA-CoA) function as ligands for
recombinant mouse PPARα (mPPARα), no such studies have been conducted with fulllength human PPARα (hPPARα). The objective of the current study was to determine
whether LCFA and LCFA-CoA constitute high-affinity endogenous ligands for hPPARα
or whether there exist species differences for ligand specificity and affinity.

Both

hPPARα and mPPARα bound with high affinity to LCFA-CoA; however, differences
were noted in LCFA affinities. A fluorescent LCFA analogue was bound strongly only
by mPPARα and naturally-occurring saturated LCFA were bound stronger by
hPPARα than mPPARα. Similarly, unsaturated LCFA induced transactivation of both
hPPARα and mPPARα, while saturated LCFA induced transactivation only in
hPPARα expressing cells. These data identified LCFA and LCFA-CoA as endogenous
ligands of hPPARα, demonstrated species differences in binding specificity and activity,
and may help delineate the role of PPARα as a nutrient sensor in metabolic regulation
(165).
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2. Introduction
Whole body energy homeostasis is regulated in part by nutrient-sensing
members of the nuclear hormone receptor superfamily of ligand-dependent
transcription factors, such as the peroxisome proliferator-activated receptor alpha
(PPARα). Like other nuclear hormone receptors, the PPARα protein is comprised of
several distinct domains, including a highly conserved DNA binding domain (DBD)
and a less conserved C-terminal ligand binding domain (LBD). In highly metabolic
tissues such as liver and heart, PPARα heterodimerizes with the retinoid X receptor
alpha (RXRα, and this heterodimer potently activates genes involved in fatty acid
oxidation (39, 110, 166). At a cellular level PPARα regulates fatty acid metabolism,
glucose metabolism, inflammation, differentiation, and proliferation (167-169).
Although a multitude of exogenous ligands have been shown to activate both
human and mouse PPARα (17, 39, 162, 170), the identity of high-affinity endogenous
ligands has been more elusive. Studies utilizing recombinant PPARα proteins have
largely focused on the ligand binding domain of mouse PPARα (mPPARα). These
studies suggest that long-chain fatty acids (LCFA) and their activated metabolites
(long-chain acyl-CoAs, LCFA-CoA) may function as endogenous PPARα ligands
(114-117). Such ligand binding has been shown to induce PPARα conformational
changes and increase transactivation, consistent with expectations for an endogenous
ligand of a nuclear receptor.
While LCFA and LCFA-CoA have been studied as putative ligands for mouse
PPARα (mPPARα), no such studies have been conducted with the full-length mPPARα
or human PPARα (hPPARα). Although there exists remarkable overlap in the activities
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of PPARα across species, human and mouse PPARα proteins promote transcription to a
different extent in response to certain hypolipidemic agents and pthalate monoesters
(161-163), suggesting species difference may exist. Administration of PPARα agonists
(e.g. Wy-14,643) to rodents results in peroxisome proliferation and hepatic cancer –
effects not observed in humans (102). Even though human and mouse PPARα proteins
share 91% identity (18), the observed physiological responses to exogenous activators
suggest that minor sequence differences may be important to PPARα function.
The objective of the current study was to elucidate whether LCFA and/or
LCFA-CoA constitute high-affinity endogenous ligands for full-length hPPARα and to
determine if species differences affect ligand specificity. Since elevated LCFA are
associated with metabolic, endocrine, and cardiovascular complications, these data are
important for understanding the molecular role of dietary nutrients in PPARα mediated
energy homeostasis. As putative ligands of PPARα, LCFA and/or LCFA-CoA may
control their own metabolism by binding PPARα and inducing PPARα regulated genes
important for fatty acid uptake, transport, and oxidation. Thus, dysregulated LCFA
could alter the transcriptional activity of PPARα leading to hyper- or hypo- activation
of these genes and further contributing to the metabolic imbalance.

40

3. Materials and Methods
Chemicals: Fluorescent fatty acid (BODIPY-C12, BODIPY-C16, NBD stearate)
were purchased from Molecular Probes, Inc. (Eugene, OR). Eicosapentaenoyl-CoA,
docosapentaenoyl-CoA, docosahexaenoyl-CoA, BODIPY C12-CoA BODIPY C16CoA were synthesized by Ms. Alagammai Kaliappan (Hostetler lab) and purified by
HPLC as previously described ( 1 1 7 , 1 7 1 ) , and found to be >99% unhydrolyzed.
All other fatty acid ligands and clofibrate were from Sigma-Aldrich (St. Louis, MO).
Rosiglitazone (LKT labs) was a kind gift from Dr Khalid Elased and bovine serum
albumin (lipid-free) was obtained from Gemini Bioproducts (Sacramento, CA).
Purification of Recombinant PPARα protein: Full-length hPPARα (amino
acids 1-468) and full-length mPPARα (amino acids 1-468) were used for all
experiments presented herein. Bacterial expression plasmids for full-length hPPARα
(6xhis-GST-hPPARα) and full-length mPPARα (6xhis-GST-mPPARα) were produced
by Dr. S. Dean Rider, Jr. (Wright State University). Protein expression, purification,
and optimization of hPPARα protein was conducted by Ms. Madhumitha
Balanarasimha (172). Mouse PPARα was purified using the protocol designed by Ms.
Balanarasimha (172). Briefly, 6xhis-GST-PPARα fusions were expressed in Rosetta™2
cells (Novagen, Gibbstown, NJ) and purified by GST affinity chromatography. Eluted
proteins were concentrated, dialyzed, and tested for purity by SDS-PAGE with
Coomassie blue staining and immunoblotting as previously described (116, 117).
Protein concentrations were estimated by Bradford Assay (Bio-Rad Laboratories,
Hercules, CA) and by absorbance spectroscopy using the molar extinction coefficient
for the protein.
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Direct Fluorescent Ligand Binding Assays: Fluorescent ligand (BODIPY C16
or BODIPY C16-CoA) binding measurements were performed as described earlier
(117, 173). Briefly, 0.1 µM hPPARα or mPPARα was titrated with increasing
concentrations of fluorescent ligand. This concentration of PPARα protein was chosen,
because it gave the maximal signal to noise ratio, while allowing saturable binding of
most of the examined ligands to be reached at concentrations below their critical
micellular concentrations. The CMC for fatty acids and fatty acyl-CoA tested herein
ranges from 1-200 µM (174). It decreases with chain length and is highly dependent on
temperature, pressure and presence of electrolytes (175, 176).
Fluorescence emission spectra (excitation, 465 nm; emission, 490-550 nm) were
obtained at 24°C with a PC1 photon counting spectrofluorometer (ISS Inc.,
Champaign, IL) and corrected for background (protein only and fluorescent ligand
only). The dissociation constant (Kd) was calculated from a single site saturation plot of
fluorescence intensity (Fi) versus concentration (C) according to equation 1 as
previously described (117, 177, 178).
(Eq. 1)

where Bmax represents the maximal fluorescence (Fmax) and y is the fluorescence intensity
at a given concentration of ligand, x. The saturation curves were also fitted to a Hill plot
according to equation 2 as described previously (116, 117) to determine the number of
binding sites (n) (117).

(Eq. 2)
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where, a is the maximal fluorescence (Fmax), b is the number of binding sites (n), and c is
the Kd. A double reciprocal plot of 1/(1-Fi/Fmax) and C/(Fi/Fmax) was also used to confirm
the dissociation constant (Kd) equal to the number of binding sites (n). The slope of the
line resulting from such a plot was equal to 1/Kd and the number of linear lines is equal
to the number of binding sites (n) (116, 117).
Displacement of Bound Fluorescent BODIPY C16-CoA by Non-fluorescent
Ligands: Based on the binding affinities obtained with the direct fluorescent ligand
binding assays for BODIPY C16-CoA, 0.1 µM PPARα was mixed with BODIPY C16CoA at the concentration where maximal fluorescence intensity first occurred (75nM
for hPPARα and 130nM for mPPARα). The maximal fluorescence intensity was
measured, and the effect of increasing concentrations of naturally-occurring ligands
was measured as a decrease in fluorescence (115-117, 173). Emission spectra were
obtained and corrected for background as described above for BODIPY. The inhibition
constant (Ki) value for each ligand was estimated according to equation 3 (115-117,
173).

where, EC50ligand represents the concentration of naturally-occurring ligands required for
displacing half of the fluorescent BODIPY-C16-CoA from the protein, Ki,ligand is the
efficiency of the ligand to displace BODIPY C16-CoA, and Kd,BODIPY

C16-CoA

is the

binding affinity of BODIPY C16-CoA obtained as described above.
Quenching of PPARα Aromatic Amino Acid Residues by Non-fluorescent
Ligands: The direct binding of hPPARα or mPPARα to non-fluorescent ligands was
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determined by quenching of intrinsic PPARα aromatic amino acid fluorescence as
described (116, 117).

Briefly, hPPARα or mPPARα (0.1 µM) was titrated with

increasing concentrations of ligand. Emission spectra from 300-400 nm were obtained
at 24°C upon excitation at 280 nm with a PC1 photon counting spectrofluorometer (ISS
Inc., Champaign, IL). Data were corrected for background and inner filter effects, and
a single site saturation plot of the change in fluorescence intensity (Fo-Fi) versus
concentration (C) was used to determine the inhibition constant (Kd) as per equation 1
(117). In this case, Bmax represents the maximal change in fluorescence (Fo-Fmin) and y
is the change in fluorescence intensity (Fo-F) at a given concentration of ligand, x (116,
117). The number of binding sites (n) was determined using a hill plot generated as per
equation 2 where, a is the maximal change in fluorescence (Fmax), b is the number of
binding sites (n), and c is the Kd (116, 117, 173). A double reciprocal plot of 1/(1Fi/Fmax) and C/(Fi/Fmax) was further used to confirm the number of binding sites (n) as
described above. However, in this case Fi represents the change in fluorescence (Fo-F)
and Fmax represents the maximal change in fluorescence.
Secondary Structure Determination Effect of ligand binding on PPARα Circular
Dichroism: Circular dichroic spectra of hPPARα or mPPARα (0.6 µM in 600 µM
HEPES pH 8.0, 24 µM dithiothreitol, 6 µM EDTA, 6 mM KCl and 0.6 % glycerol)
were taken in the presence and absence of LCFA and LCFA-CoA (0.6 µM) with a J815 spectropolarimeter (Jasco Inc., Easton, MD) as previously described (116, 117).
Spectra was recorded from 260 to 187 nm with a bandwidth of 2.0 nm, sensitivity of 10
millidegrees, scan rate of 50 nm/min and a time constant of 1 s. Ten scans were
averaged for percent compositions of α-helices, β-strands, turns and unordered
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structures with the CONTIN/LL program of the software package CDpro (116, 117,
179).
Mammalian Expression Plasmids: Mammalian expression plasmids pSG5hPPARα, pSG5-mPPARα, pSG5-hRXRα, and pSG5-mRXRα were produced by Dr. S.
Dean Rider, Jr. (Wright State University). The reporter construct, PPRE×3 TK LUC
was a kind gift of Dr. Bruce Spiegelman (Addgene plasmid # 1015) and contained
three copies of the acyl-CoA oxidase (ACOX) peroxisome proliferator response
element (PPRE) (180).
Cell culture and Transactivation assays: COS-7 cells (ATCC, Manassas, VA)
were grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand
Island, NY) at 37°C with 5% CO2 in a humidified chamber. Cells were seeded onto
24-well culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand
Island, NY) and 0.4 µg of each full-length mammalian expression vector (pSG5hPPARα, pSG5-hRXRα, pSG5-mPPARα, pSG5-mRXRα) or empty plasmid (pSG5),
0.4 µg of the PPRE×3 TK LUC reporter construct, and 0.04 µg of the internal
transfection control plasmid pRL-CMV (Promega Corp., Dinosaur, WI) as previously
described (117, 173). Following transfection incubation, medium was replaced with
serum-free medium for 2 h, ligands (1µM) were added, and the cells were grown for an
additional 20 h. Fatty acids were added as a complex with bovine serum albumin
(BSA) as described (181). Firefly luciferase activity, normalized to Renilla luciferase
(for transfection efficiency), was determined with the dual luciferase reporter assays
system (Promega, Madison, WI) and measured with a SAFIRE2 microtiter plate reader
(Tecan Systems, Inc. San Jose, CA). Clofibrate treated samples overexpressing both
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PPARα and RXRα were arbitrarily set to 1.
Statistical Analysis: Data were analyzed by SigmaPlot™ (Systat Software, San
Jose, CA) and a one-way ANOVA was used to evaluate overall significance. A Fisher
Least Significant difference (LSD) post-hoc test was used to identify individual group
differences. The results are presented as mean ± SEM. The confidence limit of p < 0.05
was considered statistically significant.
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4. Results
Full-length hPPARα and mPPARα protein purification: Based on recent
demonstrations that truncation of a nuclear transcription factor can significantly affect
ligand binding affinity, specificity, and consequently receptor activity (153, 154), fulllength hPPARα and mPPARα were used for all experiments.

SDS-PAGE and

Coomassie blue staining indicated predominant bands of 52 kDa corresponding to the
expected size of full-length hPPARα and mPPARα, for which densitometry indicated
greater than 85% purity (Fig. 6A). Western blotting confirmed that the predominant
protein bands were PPARα (Fig. 6B).
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Fig. 6. (A) SDS-PAGE and Coomassie blue staining of 3 µg and 6 µg purified
recombinant hPPARα (left) and mPPARα (right) showing relative purity of the protein.
The prominent band at 52 kDa is full-length, untagged recombinant PPARα. (B)
Western blot of 1 µg purified recombinant hPPARα (left) and mPPARα (right)
confirming the 52 kDa band is untagged, full-length PPARα.
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Binding of fluorescent fatty acid and fatty acyl-CoA to PPARα: The sensitivity
of the BODIPY fluorophore to environmental hydrophobicity is useful for determining
if binding represents a direct molecular interaction within the hydrophobic ligand
binding pocket of PPARα. In aqueous buffer without protein, BODIPY fluorescence
was low for each of the examined fluorophores. Titration of hPPARα with BODIPY
C16-CoA resulted in increased fluorescence with an emission maximum near 515 nm
(Fig. 7A). This increased fluorescence was saturable near 100 nM (Fig. 7B, circles),
indicating high affinity binding (Kd = 25 ± 4 nM). These data transformed into a linear
double reciprocal plot (Fig. 7B, inset), consistent with a single binding site (R2 > 0.95).
In contrast, a smaller, non-saturable increase in fluorescence was seen upon titration of
hPPARα with BODIPY C16 fatty acid (Fig. 7C), indicating only weak or non-specific
binding. Binding of hPPAR to BODIPY C12 fatty acid (Fig. 7D, triangles), BODIPY
C12-CoA (Fig. 7D, filled circles) or NBD stearate (Fig. 7E) resulted in non-saturable
changes in fluorescence (Kd > 450 nM).
Titration of mPPARα with BODIPY C16-CoA resulted in a similar increase in
BODIPY C16-CoA fluorescence (Fig. 8A) as noted for hPPARα, with the exception
that slightly higher BODIPY C16-CoA concentrations were required to reach saturation
(Fig. 8B). This resulted in a lower binding affinity (Kd = 65 ± 9 nM), but was still
consistent with a single binding site (Fig. 8B, and inset). While hPPARα binding to
BODIPY C16 fatty acid was non-saturable, mPPARα binding to BODIPY C16 fatty
acid resulted in strong fluorescence changes with saturation near 50 nM (Fig. 8C),
suggesting high affinity binding (Kd = 19 ± 4 nM). Although these data were consistent
with previous data suggesting that a truncated mPPARα protein can bind to both
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BODIPY C16 fatty acid derivative and BODIPY C16-CoA with high affinity (173),
these data also suggested that species differences exist in ligand binding specificity.
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Fig. 7. (A) Corrected fluorescence emission spectra of 0.1 M hPPAR titrated with 0
(filled circles), 10 (open circles), 20 (filled triangles), 50 (open triangles), 75 (filled
squares) and 100 nM (open squares) of BODIPY C16-CoA upon excitation at 465 nm,
demonstrating increased fluorescence intensity upon binding to hPPAR.

Plot of

hPPAR maximal fluorescence emission as a function of BODIPY C16:0-CoA (B) and
BODIPY C16:0 FA (C). Plot of the maximal hPPARα fluorescence emission as a
function of BODIPY C12:0 FA (D, triangles), BODIPY C12:0-CoA (D, filled circles)
and NBD stearate (E, filled circles) concentration. Insets reperesent linear plots of the
binding curves for BODIPY C16-CoA (B), BODIPY C16 FA (C) BODIPY C12-CoA
(D) and NBD stearate (E). All values represent the mean ± S.E., n ≥ 3.
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Fig. 8. (A) Corrected fluorescence emission spectra of 0.1 M mPPAR titrated with 0
(filled circles), 20 (open circles), 50 (filled triangles), 75 (open triangles), 100 (filled
squares) and 200 nM (open squares) of BODIPY C16-CoA upon excitation at 465 nm,
demonstrating increased fluorescence intensity upon binding to mPPAR.

Plot of

mPPAR maximal fluorescence emission as a function of BODIPY C16:0-CoA (B) and
BODIPY C16:0 FA (C). Insets represent linear plots of the binding curve from each
panel. All values represent the mean ± S.E., n ≥ 3.

Binding of endogenous LCFA and LCFA-CoA to hPPARα – Displacement of
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bound BODIPY C16-CoA:

To determine the ligand specificity of hPPARα for

naturally-occurring, endogenous fatty acids, LCFA and LCFA-CoA were examined for
their ability to displace BODIPY C16-CoA from the hPPARα ligand binding pocket,
which was observed as decreased BODIPY fluorescence. With the exception of lauric
acid and lauryl-CoA (Fig. 9U, Fig. 9V), titration with fatty acids and fatty acyl-CoAs
resulted in significantly decreased BODIPY fluorescence (Fig. 9A-R). Quantitative
analyses of these data suggested strong affinity binding (Ki = 10-40 nM, Table I). By
comparison, the synthetic PPARα agonist clofibrate showed slightly weaker affinity
(Fig. 9S; Ki = 48 nM), while the synthetic PPARγ agonist rosiglitazone showed no
displacement (Fig. 9T; Table I). These data revealed that both LCFA and LCFA-CoA
are capable of displacing a fluorescent fatty acyl-CoA, suggesting that both LCFA and
LCFA-CoA could be endogenous ligands of hPPARα. These data are in contrast with
displacement studies conducted with a truncated form of mPPARα, which showed that
only unsaturated LCFA, but not saturated LCFA, could displace a bound fluorescent
fatty acid (115), and suggest that important differences may exist between hPPARα and
mPPARα.
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Fig. 9. Interaction of naturally occurring fatty acids and fatty acyl-CoA with hPPARα
based on displacement of hPPARα-bound BODIPY C16-CoA. hPPARα complexed with
BODIPY C16-CoA at mole ratio corresponding to the number of binding sites was
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic
acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic acid, (H) oleoylCoA, (I) linoleic acid, (J) linoleoyl-CoA (K) arachidonic acid, (L) arachidonoyl-CoA (M)
eicosapentaenoic acid, (N) eicosapentaenoyl-CoA, (O) docosapentanoic acid, (P)
docosapentanoyl-CoA, (Q) docosahexanoic acid, (R) docosahexanoyl-CoA, (S)
clofibrate, (T) rosiglitazone, (U) lauric acid and (V) lauryl-CoA. The maximal
fluorescence emission of BODIPY C16-CoA was measured at 515 nm (excitation at 465
nm). Data are presented as percent change of initial fluorescence plotted as a function of
ligand concentration. All values represent mean ± S.E., n ≥ 3.
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Binding of endogenous LCFA and LCFA-CoA to mPPARα – Displacement of
bound BODIPY C16-CoA: To compare the ability of naturally-occurring LCFA and
LCFA-CoA to displace BODIPY C16-CoA from the binding pocket of mPPARα
(versus hPPARα), we first mixed mPPARα with a saturating concentration of BODIPY
C16-CoA. Since the BODIPY C16-CoA binding affinity for mPPARα is much weaker
than for hPPARα, a higher concentration of BODIPY C16-CoA is needed to reach
saturation and ensure BODIPY C16-CoA-bound mPPARα (130 nM). This was
followed by titration with naturally occurring LCFA and LCFA-CoA. Displacement of
bound BODIPY C16-CoA was observed as a decrease in BODIPY fluorescence. With
the exception of lauric acid and lauryl-CoA (Fig 10O, 10P), titration with fatty acids
and fatty acyl-CoA resulted in significantly decreased BODIPY fluorescence (Fig.
10A-L). Quantitative analyses of these data suggested that, with the exception of the
saturated LCFA (palmitic acid, Ki = 135 nM and stearic acid, Ki = 134 nM), most
LCFA and LCFA-CoA demonstrated strong affinity binding (Ki = 13-38 nM, Table II)
for mPPARα. The mPPARα showed similar displacement and affinity for the synthetic
PPARα agonist clofibrate (Fig 10M; Ki = 46 nM, Table II) as compared hPPARα
(Table I), and the synthetic PPARγ agonist rosiglitazone showed no displacement (Fig.
10N; Table II). These data show that LCFA and LCFA-CoA are both capable of
displacing a fluorescent fatty acyl-CoA, suggesting that both LCFA and LCFA-CoA
could be endogenous ligands of mPPARα. When compared to binding data from
hPPARα (Table I), these data also suggest differences in the ligand binding specificity
between hPPARα and mPPARα, particularly for saturated LCFA.
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Fig. 10. Interaction of naturally occurring fatty acids and fatty acyl-CoA with mPPARα
based on displacement of mPPARα-bound BODIPY-C16 CoA. mPPARα complexed
with BODIPY C16-CoA at mole ratio corresponding to the number of binding sites was
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic
acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic acid, (H) oleoylCoA, (I) eicosapentaenoic acid, (J) eicosapentaenoyl-CoA, (K) docosahexanoic acid (L)
docosahexanoyl-CoA, (M) clofibrate, (N) rosiglitazone (O) lauric acid and (P) laurylCoA. The maximal fluorescence emission of BODIPY C16-CoA was measured at 515
nm (excitation at 465 nm). Data are presented as percent change of initial fluorescence
plotted as a function of ligand concentration. All values represent mean ± S.E., n ≥ 3.
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Binding of endogenous LCFA and LCFA-CoA to hPPARα – Quenching of
intrinsic aromatic amino acid fluorescence: Since previous data has suggested that
fluorescent fatty acid analogues are not always bound the same as endogenous fatty
acids due to bulky side chains altering the energy minimized state of the molecule (117,
173), the binding of LCFA and LCFA-CoA to hPPARα was also measured directly by
spectroscopically monitoring the quenching of hPPARα aromatic amino acid emission.
Titration of hPPARα with the saturated LCFA palmitic acid (Fig. 11A) and stearic acid
(Fig. 11E) yielded sharp saturation curves with maximal fluorescence changes at 100
nM, and both transformed into linear reciprocal plots (insets), indicating high affinity
binding at a single binding site (R2 > 0.9). Similar results were obtained for all
examined LCFA and LCFA-CoA (Fig. 11A-R), with single site binding affinities in the
10-30 nM range (Table I), similar to affinities determined by displacement assays.
Titration with lauric acid (Fig. 11U) and lauryl-CoA (Fig. 11V) did not significantly
alter hPPARα fluorescence, and no binding was detected (Table I).

The PPARα

agonist clofibrate strongly quenched hPPARα fluorescence (Fig. 11S), but displayed
weaker affinity than the LCFA (Table I), while the PPARα agonist rosiglitazone
showed no binding (Fig. 11T), further confirming that hPPARα bound saturated,
monounsaturated, and polyunsaturated LCFA and LCFA-CoA with high affinity.
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Fig. 11. Interaction of naturally-occurring fatty acids and fatty acyl-CoA with hPPAR.
Direct binding assay based on quenching of hPPAR aromatic amino acid fluorescence
emission when titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA,
(C) palmitoleic acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic
acid, (H) oleoyl-CoA, (I) linoleic acid, (J) linoleoyl-CoA (K) arachidonic acid, (L)
arachidonoyl-CoA

(M)

eicosapentaenoic

acid,

(N)

eicosapentaenoyl-CoA,

(O)

docosapentanoic acid, (P) docosapentanoyl-CoA, (Q) docosahexanoic acid, (R)
docosahexanoyl-CoA, (S) clofibrate, (T) rosiglitazone, (U) lauric acid and (V) laurylCoA. Data are presented as the change in fluorescence intensity (F0- Fi) plotted as a
function of ligand concentration. Insets represent linear plots of the binding curve from
each panel. All values represent mean ± S.E., n ≥ 3.
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Table I. Affinity of hPPAR for non-fluorescent ligands determined by quenching of
hPPAR aromatic amino acid fluorescence and by displacement of hPPAR-bound
BODIPY C16-CoA.
Ligand
Chain length:
Kd (nM) Kd (nM)
Ki (nM)
Ki (nM)
double bonds
Fatty
Fatty
Fatty
Fatty acyl(position)
acid
acyl-CoA
acid
CoA
Lauric acid/CoA
C12:0
ND
ND
ND
ND
Palmitic acid/CoA
C16:0
22±3
11±1
16±2
10±2
Palmitoleic acid/CoA C16:1 (n-7)
16±2
29±4
26±6
46±8
Stearic acid/CoA
C18:0
14±2
16±2
13±3
15±2
Oleic acid/CoA
C18:1 (n-9)
19±3
13±1
13±2
16±3
Linoleic acid/CoA
C18:2 (n-6)
12±1
12±2
26±6
40±8
Arachidonic
C20:4 (n-6)
24±5
23±3
24±3
17±2
acid/CoA
Eicosapentanoic
C20:5 (n-3)
34±4
16±2
38±5
26±5
acid/CoA
Docosapentanoic
C22:5 (n-3)
13±2
18±4
10±2
30±6
acid/CoA
Docosahexanoic
C22:6 (n-3)
30±5
14±1
18±3
28±5
acid/CoA
Clofibrate
58±6
48±6
Rosiglitazone
ND
ND
Values represent the mean ± S.E. (n ≥ 3). ND, not determined.
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Binding of endogenous LCFA and LCFA-CoA to mPPARα – Quenching of
intrinsic aromatic amino acid fluorescence: Binding of full-length mPPARα to LCFA
and LCFA-CoA was also measured by spectroscopically monitoring the quenching of
mPPARα aromatic amino acid emission. Although titration with the saturated LCFA
palmitic acid (Fig. 12A) and stearic acid (Fig. 12E) resulted in decreased mPPARα
fluorescence, the slopes of these curves were much shallower than that of hPPARα with
palmitic acid (Fig. 11A) or stearic acid (Fig. 11E), with the change in fluorescence
intensity plateauing off at approximately 300 nM. Transformation of these data into
double reciprocal plots yielded single lines (Fig. 12A, Fig. 12E, insets), indicating
single binding sites for both.

However, multiple replicates yielded much weaker

binding affinities for mPPARα (Kd = 92 nM for palmitic acid and 81 nM for stearic
acid, Table II) than hPPARα (Table I). Titration of mPPARα with the other examined
LCFA and LCFA-CoA yielded sharp saturation curves with the maximal change in
fluorescence intensity noted at approximately 100 nM (Fig. 12A-L) indicating high
affinity binding (Kd = 14-37 nM, Table II).

These data transformed into linear

reciprocal plots (insets), indicating binding at a single binding site (R2 > 0.9). Similar
to hPPARα, no significant mPPARα binding was noted for lauric acid (Fig. 7O), laurylCoA (Fig. 12P), or rosiglitazone (Fig. 12N), while clofibrate binding resulted in the
strongest fluorescence changes (Fig. 12M). Although the weak binding of palmitic
acid and stearic acid to full-length mPPARα was consistent with previous data using
mPPARΔAB (115-117), it was significantly different from the binding of hPPARα
with the same ligand (Table I). On the other hand, while mPPARΔAB demonstrated
weak binding towards polyunsaturated fatty acids (PUFA), such as eicosapentanoic
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acid and docosahexaenoic acid, our data employing full-length mPPARα and hPPARα
demonstrated high-affinity binding for both these PUFA (Table I and Table II). These
findings suggest two important conclusions. There exist species dependent differences
in the ligand binding specificity and affinity between human and mouse PPARα, and
the N-terminal domain of PPARα plays an unexpected, but important, role in the ligand
binding function of the protein.
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Fig. 12. Interaction of naturally-occurring fatty acids and fatty acyl-CoA with mPPAR.
Direct binding assay based on quenching of mPPAR aromatic amino acid fluorescence
emission when titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA,
(C) palmitoleic acid, (D) palmitoleoyl-CoA (E) stearic acid (F) stearoyl-CoA, (G) oleic
acid, (H) oleoyl-CoA, (I) eicosapentaenoic acid, (J) eicosapentaenoyl-CoA, (K)
docosahexanoic acid (L) docosahexanoyl-CoA, (M) clofibrate, (N) rosiglitazone (O)
lauric acid and (P) lauryl-CoA.

Data are presented as the change in fluorescence

intensity (F0- Fi) plotted as a function of ligand concentration. Insets represent linear
plots of the binding curve from each panel. All values represent mean ± S.E., n ≥ 3.
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Table II. Affinity of mPPAR for non-fluorescent ligands determined by quenching of
mPPAR aromatic amino acid fluorescence and by displacement of mPPAR-bound
BODIPY C16-CoA.
Ligand
Chain length: Kd (nM)
Kd (nM)
Ki (nM)
Ki (nM)
double bonds
Fatty
Fatty acylFatty
Fatty acyl(position)
acid
CoA
acid
CoA
Lauric acid/CoA
C12:0
ND
ND
ND
ND
Palmitic acid/CoA
C16:0
135±13
23±4
92±13
14±2
Palmitoleic acid/CoA C16:1 (n-7)
35±3
31±4
32±3
24±5
Stearic acid/CoA
C18:0
134±30
37±5
81±15
28±5
Oleic acid/CoA
C18:1 (n-9)
37±4
38±6
22±5
37±5
Eicosapentanoic
C20:5 (n-3)
33±5
21±3
24±6
17±3
acid/CoA
Docosahexanoic
C22:6 (n-3)
34±3
13±3
31±2
24±2
acid/CoA
Clofibrate
39±6
46±3
Rosiglitazone
ND
ND
Values represent the mean ± S.E. (n ≥ 3). ND, not determined.
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Effect of endogenous fatty acids and fatty acyl-CoAs on hPPARα secondary
structure: Ligand-activated receptors, such as PPARα, undergo conformational changes
upon ligand binding, which allows for altered co-factor interactions (10, 117, 182).
Circular dichroism was used to examine whether the binding of LCFA or LCFA-CoA
altered the hPPARα secondary structure. The far UV circular dichroic spectrum of
hPPARα suggested the presence of substantial α-helical content, exhibiting a large
positive peak at 192 nm and two negative peaks at 207 and 222 nm (Fig. 13A-K, filled
circles). Quantitative analyses of the circular dichroic spectra confirmed that hPPARα
was composed of approximately 32 % α-helix, 18 % β-sheets, 21 % β-turns and 29 %
unordered structures (Table III).
Since most of the examined ligands were shown to bind at a single binding site,
ligand effects were measured at a molar concentration equivalent to that of hPPARα.
The addition of high-affinity LCFA and LCFA-CoA ligands resulted in alterations in
molar ellipticity at 192, 207, and 222 nm (Fig. 13B-J), demonstrating hPPARα
conformational changes. Although both increases and decreases of the 192 nm peak
were noted, most of the examined LCFA and LCFA-CoA resulted in less negative
peaks at 207 and 222 nm (Fig. 13B-J), suggestive of decreased α-helical content.
Quantitative analyses confirmed that most high-affinity LCFA and LCFA-CoA ligands
significantly decreased the estimated fraction of α-helical content and concomitantly
increased the estimated fraction of β-sheets (Table III). However, lauric acid and its
CoA thioester, which showed no binding, resulted in only minor, non-significant
changes to the hPPARα secondary structure (Fig. 13A, Table III).

Contrary to

previously published mPPARα data (116, 117), the strongest conformational changes
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were noted with palmitic acid, stearic acid, eicosapentaenoic acid, and docosahexaenoic
acid (Fig. 13, Table III). These changes in spectra and percent composition were
stronger than those observed with the addition of clofibrate (Fig. 13K, open circles,
Table III), and no changes were observed with the addition of rosiglitazone (Fig. 13K,
filled triangles, Table III), consistent with the decreased affinity of hPPARα for these
compounds.
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Fig. 13. Far UV circular dichroic (CD) spectra of hPPAR in the absence (filled circles)
and presence of added ligand: (A) lauric acid (open circles) or lauryl-CoA (filled
triangles); (B) palmitic acid (open circles) or palmitoyl-CoA (filled triangles); (C)
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); (D) stearic acid
(open circles) or stearoyl-CoA (filled triangles); (E) oleic acid (open circles) or oleoylCoA (filled triangles); (F) linoleic acid (open circles) or linoleoyl-CoA (filled triangles);
(G) arachidonic acid (open circles) or arachidonoyl-CoA (filled triangles); (H)
eicosapentaenoic acid (open circles) or eicosapentaenoyl-CoA (filled triangles); (I)
docosapentanoic acid (open circles) or docosapentanoyl-CoA (filled triangles); (J)
docosahexanoic acid (open circles) or docosahexanoyl-CoA (filled triangles); and (K),
clofibrate (open circles) or rosiglitzone (filled triangles). Each spectrum represents an
average of 5 scans for a given representative spectrum from at least three replicates.
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Table III. Effect of ligands on the relative proportion of hPPAR secondary structure
determined by CD. These structures were as follows: total helices (H; a sum of regular αhelices and distorted α-helices), total sheets (S; a sum of regular β-sheets and distorted βsheets), turns (Trn; β-turns), and unordered (Unrd) structures.
Average
Total H ±
Total S ±
Trn ± S.E.
Unrd ±
S.E.
S.E.
S.E.
32±1
19±1
21.3±0.3
29.3±0.5
hPPAR
30±1
20±2
21.8±0.4
28.7±0.3
hPPAR + lauric acid
31±3
18.2±0.2
20±1
29±1
hPPAR + lauryl-CoA
**
**
16±3
32±2
21.7±0.4
30±1
hPPAR + palmitic acid
**
**
13±3
34±2
22.5±0.2
30±1
hPPAR + palmitoyl-CoA
*
*
22±4
28±3
21±1
28±1
hPPAR + palmitoleic acid
#
*
27±3
21±1
29±1
hPPAR + palmitoleoyl-CoA 24±5
**
**
14±3
33±2
22.0±0.2
31±2
hPPAR + stearic acid
#
*
24±4
27±2
21±1
29±1
hPPAR + stearyl-CoA
**
**
18±2
31±2
22±1
29±1
hPPAR + oleic acid
#
26±3
25±2
21±1
28.3±0.3
hPPAR + oleoyl-CoA
*
*
27±6
28±2
19±2
26±3
hPPAR + linoleic acid
#
*
24±3
26±2
21±1
28.8±0.1
hPPAR + linoleoyl-CoA
*
**
19±1
30±1
21.8±0.3
28.9±0.1
hPPAR + arachidonic acid
#
23.4±0.4
19.4±0.5
26.9±0.4
hPPAR + arachidonoyl-CoA 30±1
**
14±7
24±6
23±2
33±5
hPPAR + EPA
*
*
21±1
29±1
21.6±0.3
29±1
hPPAR + EPA-CoA
**
**
17±4
32±3
21.9±0.1
30±1
hPPAR + DPA
*
**
20±1
30±1
21±1
29.6±0.2
hPPAR + DPA-CoA
**
**
12±3
38±4
21±1
30±1
hPPAR + DHA
*
*
20±2
29±2
22±1
28.9±0.2
hPPAR + DHA-CoA
*
33±1
15±1
22±1
30±1
hPPAR + Clofibrate
29±1
22±2
20±1
28±1
hPPAR + Rosiglitazone
Asterisks represent significant differences between hPPAR only and hPPAR in the
presence of added ligand (* P < 0.05, ** P < 0.001 and # P = 0.07).
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Effect of endogenous fatty acids and fatty acyl-CoAs on mPPARα secondary
structure: Consistent with hPPARα the far UV circular dichroic spectrum of mPPARα
suggested the presence of substantial α-helical content, exhibiting a large positive peak
at 192 nm and two negative peaks at 207 and 222 nm (Fig. 14A-K, filled circles).
Quantitative analyses of the circular dichroic spectra confirmed that mPPARα was
composed of approximately 30 % α-helix, 19 % β-sheets, 22 % β-turns, and 29 %
unordered structures (Table IV), similar to hPPARα (Table III). With the exception of
lauric acid and lauryl-CoA (Fig. 14A), the addition of fatty acids (Fig. 14B-J, open
circles) and fatty acyl-CoA (Fig. 14B-J, filled triangles) resulted in mPPARα
conformational changes consistent with decreased molar ellipticity at 192 nm and
increased molar ellipticity at 207 and 222 nm. Addition of clofibrate resulted in the
strongest changes to the mPPARα spectrum, but consistent with binding data, no
changes were seen with the addition of rosiglitazone (Fig. 14K). Quantitative analyses
of multiple replicates indicated that LCFA and LCFA-CoA significantly decreased the
mPPARα estimated α-helical content and concomitantly increased the estimated
percentage of α-sheets (Table IV), a trend similar to that seen with hPPARα. However,
for several ligands the magnitude of the change was different between the two proteins.
While palmitic acid and stearic acid resulted in some of the strongest changes to the
hPPARα structure, addition of these same ligands resulted in some of the weakest
changes seen to the mPPARα structure. Moreover, clofibrate had the strongest effect
on mPPARα secondary structure and a very small effect on hPPARα secondary
structure.

The changes in circular dichroic spectra and estimated percentage

composition were consistent with the affinity of mPPARα for each ligand. These data
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further suggest that species differences in ligand specificity and affinity exist between
mouse and human PPARα.
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Fig. 14. Far UV circular dichroic (CD) spectra of mPPAR in the absence (filled circles)
and presence of added ligand: (A) lauric acid (open circles) or lauryl-CoA (filled
triangles); (B) palmitic acid (open circles) or palmitoyl-CoA (filled triangles); (C)
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); (D) stearic acid
(open circles) or stearoyl-CoA (filled triangles); (E) oleic acid (open circles) or oleoylCoA (filled triangles); (F) linoleic acid (open circles) or linoleoyl-CoA (filled triangles);
(G) arachidonic acid (open circles) or arachidonoyl-CoA (filled triangles); (H)
eicosapentaenoic acid (open circles) or eicosapentaenoyl-CoA (filled triangles); (I)
docosapentanoic acid (open circles) or docosapentanoyl-CoA (filled triangles); (J)
docosahexanoic acid (open circles) or docosahexanoyl-CoA (filled triangles); and (K),
clofibrate (open circles) or rosiglitzone (filled triangles). Each spectrum represents an
average of 10 scans for a given representative spectrum from at least three replicates.
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Table IV. Effect of ligands on the relative proportion of mPPAR secondary structure
determined by CD. These structures were as follows: total helices (H; a sum of regular αhelices and distorted α-helices), total sheets (S; a sum of regular β-sheets and distorted βsheets), turns (Trn; β-turns), and unordered (Unrd) structures.
Average
Total H ±
Total S ±
Trn ± S.E. Unrd ± S.E.
S.E.
S.E.
mPPAR
30±1
19±2
22±1
29±1
mPPAR + lauric acid
29±1
20±1
22±1
28.8±0.1
mPPAR + lauryl-CoA
27±3
23±3
22.1±0.1
28.9±0.1
*
mPPAR + palmitic acid
23±3
23±2
21±2
30±2
**
**
mPPAR + palmitoyl-CoA
16±1
32±1
23±1
29.2±0.2
mPPAR + palmitoleic acid
14±1**
29±1*
23±1
34±5
*
**
mPPAR + palmitoleoyl-CoA 19±1
34±5
21±1
28±1
*
*
mPPAR + stearic acid
21.8±0.5
28±0.5
21.2±0.1
28.6±0.2
*
*
mPPAR + stearyl-CoA
21±2
30±4
21±1
29.7±0.3
mPPAR + oleic acid
10±4**
36±3**
23±2
31±1
*
*
mPPAR + oleoyl-CoA
22±4
28±2
20±1
29±1
*
*
mPPAR + linoleic acid
21±1
30±1
22±1
28.5±0.3
**
**
mPPAR+ linoleoyl-CoA
17±2
33±2
22.0±0.5
28.7±0.1
mPPAR + arachidonic acid
18±1**
31±1*
22.5±0.5
28.7±0.2
*
*
mPPAR + arachidonoyl-CoA 22±3
28±3
21.7±0.1
28±1
**
*
mPPAR + EPA
15±2
31±3
21±1
30±1
*
*
mPPAR + EPA-CoA
22.5±1.5
28±2
20.1±0.3
30±1
mPPAR + DPA
20±1*
29±1*
22±1
29.1±0.3
**
**
mPPAR + DPA-CoA
16±3
34±3
22.1±0.2
27.9±0.5
**
*
mPPAR + DHA
16±5
30±4
21±1
30±2
**
**
mPPAR + DHA-CoA
9.5±0.5
37±1
21.9±0.2
31.8±0.2
mPPAR + Clofibrate
13±3**
34±3**
22.4±0.1
31±1
mPPAR + Rosiglitazone
27±2
24±3
25.5±3.5
23±2
Asterisks represent significant differences between mPPAR only and mPPAR in the
presence of added ligand (* P < 0.05, ** P < 0.001).
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Effect of fatty acids and fatty acyl-CoA on transactivation of PPARα-RXRα
heterodimers: Since PPARα heterodimerizes with RXRα to induce transactivation (7),
COS-7 cells were cotransfected with pSG5 empty vector, PPARα alone, RXRα alone,
or PPARα with RXRα and analyzed for transactivation of an acyl-CoA oxidase PPREluciferase reporter construct in the absence or presence of ligands (Fig. 15).
Transactivation was measured as percent firefly luciferase activity normalized to
Renilla luciferase (internal control). In comparison to cells overexpressing RXRα alone
(extremely low transactivation; Fig. 15A, 15B), cells overexpressing PPARα alone (Fig
15A, 15B) had significant transactivation even in the absence of ligands. While these
findings could be a result of some basal endogenous levels of RXRα, they also suggest
that transactivation is indeed mediated by PPARα. In cells overexpressing only
hPPARα (Fig. 15A) or mPPARα (Fig. 15B), docosahexaenoic acid and clofibrate
significantly increased transactivation. Although normalized activity was extremely
low in hRXRα (Fig. 14A) and mRXRα (Fig. 15B) over-expressing cells,
docosahexaenoic acid significantly increased transactivation in both, suggesting that
this ligand (or its metabolite) is a strong activator of endogenous PPARα. While cells
over-expressing hPPARα and hRXRα (Fig. 15A) or mPPARα and mRXRα (Fig. 15B)
both showed increased activity, even in the absence of ligand, differences were noted in
their ligand-induced effects. For cells over-expressing hPPARα and hRXRα, addition
of palmitic acid, palmitoleic acid, stearic acid, oleic acid, eicosapentaenoic acid, and
docosahexaenoic acid resulted in similar effects on transactivation as the PPARα
agonist, clofibrate (Fig. 15A). These data further validated LCFA or their metabolites
as endogenous ligands of hPPARα needed to induce PPARα activity.
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However,

addition of only the examined unsaturated LCFA and clofibrate significantly increased
activity levels in COS-7 cells overexpressing mPPARα and mRXRα (Fig. 15B). The
addition of the palmitic acid and stearic acid resulted in no significant changes in
activity (Fig. 15B), consistent with the weak binding affinity of mPPARα for these
ligands. In addition to suggesting that LCFA and LCFA-CoA represent high-affinity
ligands for mPPARα, these data also suggested that differences in binding affinity for
saturated LCFA could significantly affect the activity of PPARα.
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Fig. 15. PPARα ligands alter PPARα transactivation. COS-7 cells transfected with
pSG5 empty vector, PPARα, RXRα, and both PPARα and RXRα were analyzed for
transactivation of the acyl-CoA oxidase-PPRE-luciferase reporter construct in the
presence of vehicle (open bars), 1 µM palmitic acid (diagonally upward bars), 1 µM
palmitoleic acid (diagonally downward bars), 1 µM stearic acid (cross-hatched
bars), 1 µM oleic acid (horizontal lined bars), 1 µM eicosapentaenoic acid
(vertically lined bars), 1 µM docosahexanoic acid (hatched bars), and 1 µM
clofibrate (open bars). For comparison between human and mouse effects, COS-7 cells
were transfected with human versions of these proteins (A) or mouse versions of these
proteins (B). The y-axis represents values for firefly luciferase activity that have been
normalized to Renilla luciferase (internal control), where PPARα and RXRα
overexpressing cells in the presence of 1 µM clofibrate were arbitrarily set to 1.
The bar graph represents the mean values (n ≥ 3) ± standard error. * P < 0.05, ** P
< 0.01.
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5. Discussion
Although lipids have been shown to be endogenous ligands of PPARα from
several species, including mouse, studies with hPPARα have focused on exogenous
ligands. Since an increasing number of studies suggest species differences exist for
ligand specificity and affinity (102, 161-163), this study focused on LCFA and/or
LCFA-CoA as putative endogenous ligands of hPPARα. These data are the first to
demonstrate full-length hPPARα binding to LCFA and LCFA-CoA at physiologically
relevant concentrations. Human PPARα displayed high affinity binding for saturated,
monounsaturated, and polyunsaturated LCFA and LCFA-CoA (Kd = 11-40 nM),
consistent with previously reported nuclear concentrations (3-68 nM) of LCFA and
LCFA-CoA (88, 120). These high affinity ligands significantly altered the secondary
structure of hPPARα, while ligands that did not bind hPPARα (lauric acid, lauryl-CoA,
and rosiglitazone) did not demonstrate any significant change in the structure of the
protein.

LCFA that bound to hPPARα in vitro transactivated the ACOX PPRE-

luciferase reporter in a PPARα dependent manner in COS-7 cells, further suggesting
that LCFA and LCFA-CoA are endogenous ligands of hPPARα.

These data are

consistent with experiments using peroxisomal ACOX and/or PPARα knockout mice
which also suggest that LCFA and their thioester derivatives serve as natural ligands
for PPARα in vivo (145, 146, 183).
Apart from identifying LCFA and LCFA-CoA as physiologically relevant
endogenous ligands for hPPARα, these data highlight important species differences
with respect to ligand specificity and affinity. While affinities for LCFA-CoA and
unsaturated LCFA were similar between full-length human and murine PPARα,
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mPPARα only weakly bound the saturated palmitic acid and stearic acid, yet hPPARα
strongly bound both. Similarly, some of the strongest changes in hPPARα secondary
structure occurred with the addition of saturated and polyunsaturated LCFA, whereas
saturated LCFA had only minor effects on mPPARα secondary structure. Consistent
with these data, COS-7 cells overexpressing mPPARα and mRXRα treated with these
saturated LCFA did not transactivate the ACOX-PPRE-luciferase reporter at the
examined concentrations, while unsaturated LCFA did. Taken together, these data
suggested that the human and mouse PPARα proteins bind and respond differently to
specific ligands.
Given the high evolutionary rate exhibited by PPARα (184), it is not surprising
to see such differences between hPPARα and mPPARα.

In addition, strong

physiological differences exist between human and rodent PPARα activation. Longterm administration of PPARα agonists are associated with hepatic carcinomas in
rodents, but “humanized” PPARα mice are resistant to PPARα agonist induced
hepatocellular adenomas and carcinomas (102, 150). The potency and efficacy of
many hypolipidemic agents and phthalate monoesters on the activation of human and
mouse PPARα are also different (161-163). As previous microarray experiments have
demonstrated a strong divergence between PPARα regulated genes in mouse and
human hepatocytes (163), it is likely that a combination of ligand binding differences
and target gene differences are responsible for the overall physiological variations.
Other factors, including differences in ligand uptake and ligand metabolism between
cell types, may account for some of these differences as well. However, this same
study showed a high conservation in PPARα regulation of genes involved in lipid
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metabolism (163), suggesting that differences in these processes must be due to another
mechanism – not just variation in target genes. Since a single mutation in the mouse
PPARα ligand binding domain (E282G) results in altered activity but displays similar
DNA binding capacity, protein levels, and protein localization (164), it suggests that
individual amino acid differences in the ligand binding domain can affect activity
through ligand binding. Such differences in specificity of mouse and human PPARα
for specific nutrients could reflect an adaptation to different physiological and/or
nutritional patterns of the species.
Additionally, these data suggest that differences exist in the binding affinity of
full-length versus truncated PPARα. Data presented herein indicate that both fulllength hPPARα and mPPARα bound polyunsaturated LCFA with strong affinity. This
data challenges previously published data indicating that mouse PPARα does not bind
saturated LCFA in the physiological range, and only weakly interacts with PUFA (115117). While such differences may exist due to variations in protein preparation, ligand
binding techniques, or changes in the protein’s secondary structure, it should be noted
that the previously published data was generated using a truncated mouse PPARα
protein that lacked the N-terminus (mPPARΔAB). Therefore, it is possible that the Nterminal domain of PPARα influences ligand binding. This hypothesis is supported in
the case of PPARα, where it was shown that mutation of specific residues within the Nterminal A/B domain affects the binding affinity of a synthetic PPARα agonist (34).
In summary, LCFA and LCFA-CoA function as endogenous hPPARα ligands;
binding with high affinity, altering PPARα secondary structure, and affecting
transactivation. Although LCFA-CoA similarly bound both hPPARα and mPPARα,
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several ligands (including fluorescent LCFA/LCFA-CoA analogues, saturated LCFA,
PUFA, and clofibrate) resulted in significant species differences. These data suggest
that even though there is overlap in the endogenous ligands for mouse and human
PPARα, significant species differences exist, and these differences may affect
downstream gene regulation. These findings corroborate the importance of PPARα in
allosteric regulation of fatty acid metabolism, where PPARα acts as a sensor to monitor
the levels of fatty acids and their metabolites, then transcriptionally activates enzymes
involved their metabolism.
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CHAPTER II
A SINGLE AMINO ACID CHANGE HUMANIZES LONG-CHAIN FATTY
ACID BINDING AND ACTIVATION OF MOUSE PEROXISOME PROLIFERATORACTIVATED RECEPTOR 
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1. Abstract
Peroxisome proliferator-activated receptor α (PPARα) is an important regulator of
hepatic lipid metabolism which functions through ligand binding. Despite high amino
acid sequence identity (>90%), marked differences in PPARα ligand binding, activation
and gene regulation have been noted across species. Similar to previous observations
with synthetic agonists, we have recently reported differences in ligand affinities and
extent of activation between human PPARα (hPPARα) and mouse PPARα (mPPARα) in
response to long chain fatty acids (LCFA). The present study was aimed to determine if
structural alterations could account for these differences. The binding of PPARα to LCFA
was examined through in silico molecular modeling and docking simulations. Modeling
suggested that variances at amino acid position 272 are likely to be responsible for
differences in saturated LCFA binding to hPPARα and mPPARα. To confirm these
results experimentally, LCFA binding, circular dichroism, and transactivation studies
were performed using a F272I mutant form of mPPARα. Experimental data correlated
with in silico docking simulations, further confirming the importance of amino acid 272
in LCFA binding. Although the driving force for evolution of species differences at this
position are yet unidentified, this study enhances our understanding of ligand-induced
regulation by PPARα and demonstrates the efficacy of molecular modeling and docking
simulations (185).
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2. Introduction
Peroxisome proliferator-activated receptor alpha (PPARα) belongs to the nuclear
hormone receptor superfamily of ligand-dependent transcription factors and has emerged
as one of the central regulators of nutrient-gene interactions. Structurally similar to other
members of the nuclear hormone receptor family, the PPARα protein structure consists of
an N-terminal ligand-independent transactivation function (AF-1), a highly conserved
DNA binding domain (DBD), a hinge region and the C-terminal ligand binding domain
(LBD) containing a ligand-dependent transactivation function (AF-2).

The LBD of

PPARα constitutes a large hydrophobic ligand-binding pocket (1300-1400 Å3) that
allows interaction with a broad range of natural and synthetic ligands (25, 26). PPARα
interacts with a variety of endogenous ligands, including fatty acids and fatty acid
metabolites, as well as synthetic compounds such as hypolipidemic fibrate drugs, to
regulate cellular processes related to fatty acid metabolism, glucose metabolism,
inflammation, differentiation and proliferation (83, 108, 113, 186).
While long-chain fatty acids (LCFA) serve as major metabolic fuels and important
components of biological membranes, they also play a significant role as signaling
molecules and gene regulators in response to food intake and nutritional changes.
Recently, we have demonstrated that LCFA and their thioesters (long-chain fatty acylCoA; LCFA-CoA) constitute high-affinity endogenous ligands of human PPARα
(hPPARα) and mouse PPARα (mPPARα). Such ligand binding induces PPAR
conformational changes and increases transactivation, consistent with expectations for an
endogenous ligand of a ligand-activated nuclear receptor (165). Thus, PPARα in
conjunction with LCFA and their metabolites could serve to regulate metabolic pathways
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governing fuel utilization, storage, transport and mobilization. However, we also reported
differences in binding affinities and the extent of ligand-induced transactivation between
mPPARα and hPPARα in response to saturated LCFA (165).
Species differences in PPARα-mediated downstream regulation of target genes have
been noted previously (163, 187). Human and mouse PPAR proteins promote
transcription to a different extent in response to certain hypolipidemic agents and pthalate
monoesters (161, 162). Furthermore, it is well established that long-term administration
of PPARα agonists result in hepatic cancer in rats and mice – an effect that is not seen in
guinea pigs, canines, non-human primates, or even humans (102). While a single cause
for the existence of such differences is highly unlikely, possible explanations include:
differences in expression levels of PPARα or differences in PPARα target genes,
alternatively spliced or mutant forms of PPARα protein, mutations or polymorphisms in
target gene response elements, increased expression of oncogenes and/or inhibition of
apoptosis (102, 103, 188, 189). However, transgenic mice that express human PPARα
mainly in the liver do not exhibit hepatocarcinogenesis upon administration of PPARα
agonists (149, 150). This observation suggests that structural differences in the PPARα
protein could be the underlying cause of such species variation.
Comparison of the PPARα amino acid sequence across species, particularly of the
LBD, resulted in >90% homology (18). However it should be noted that a single amino
acid change can result in marked alterations in ligand selectivity of nuclear receptors. For
example, a single amino acid change in the mouse PPARα-LBD (E282) results in altered
activity of the protein (164), and a valine to methionine substitution in human PPARα
(V444M) produced PPARδ ligand binding characteristics, resulting in loss of fibrate
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responsiveness (52). While we have reported differences in mPPARα and hPPARα in
response to saturated LCFA (165), the goal of this study was to explore the mechanisms
underlying such divergence. We have used methods including: molecular modeling and
in silico docking, mutagenesis, spectrofluorometry, circular dichroism spectroscopy and
transactivation studies to identify a single amino acid change at position 272 that is
largely responsible for the altered saturated LCFA binding.
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3. Material and Method
Molecular modeling simulations: The crystal structure of the ligand binding domain
(LBD) of hPPARα complexed with a synthetic agonist (GW409544) was retrieved from
RCSB Protein Data Bank (PDB identifier 1K7L) (26). The apo form of hPPARα-LBD
was generated by extracting the ligand (GW409544) from the 1K7L model (using Swiss
PDB Viewer, http://www.expasy.org/spdbv/). This structural model was used in all
docking simulations. Since the structure of mPPARα has not been crystallized, a
homology modeling approach was used to generate the mPPARα-LBD structure. We
compared the amino acid sequence of hPPARα to mPPARα and substituted all amino
acid residues that were different in the hPPAR-LBD crystal structure. In total, 23 amino
acid residues in the hPPARα-LBD were replaced with the corresponding mPPARα
residues, followed by energy minimization of the resulting model. This model was used
as an initial structure of mPPARα-LBD for all docking simulations. All energy
computations were done in vacuo using GROMOS96 43B1 parameters without reaction
field, implemented in Swiss PDB Viewer (190). An energy minimized model of the
F272I

mPPARα-LBD

was

also

generated

using

the

Swiss

PDB

Viewer

(http://www.expasy.org/spdbv/).
Molecular docking simulations: In silico docking studies were performed using both
AutoDock Vina 1.1.2 (191) and the FlexiDock™ module available on SYBYL®-X 2.0
(Tripos, St. Louis, MO). While AutoDock Vina 1.1.2 allows only the ligand to have
flexible/rotatable bonds, the FlexiDock™ module on SYBYL®-X 2.0 permits both
protein (sidechains) and ligands to carry flexible/rotatable bonds. For docking with both
AutoDock Vina 1.1.2 and FlexiDock™, a search space or putative binding site was
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defined in a restricted region of the protein. In the present study, the ligand binding
pocket was defined based on the experimentally obtained structure of the GW409544
ligand bound to hPPARα-LBD (26). Once the hPPARα and mPPARα models were
energy minimized, docking simulations were carried out using both AutoDock Vina 1.1.2
and FlexiDock™. Docking simulations were first validated using the GW409544 ligand
by comparing the x-ray crystal structure 1K7L (hPPARα-LBD + GW409544) with that of
the docking output generated using apo-hPPARα with GW409544 ligand. Both
AutoDock Vina 1.1.2 and FlexiDock™ generated multiple docking poses (differentiated
by RMSD’s relative to the best pose) that were subjected to careful visualization and only
the most energetically favorable conformation was chosen for further analysis.
Docking of LCFA was carried out using both AutoDock Vina 1.1.2 and FlexiDock™.
For each binding conformation, the binding energies were calculated using the FlexiDock
scoring function based on the Tripos Force Field, as implemented by FlexiDock. The
resulting docking conformations were visualized using the PyMOL Molecular Graphics
System (Version 1.5.0.4 Schrödinger, LLC) and the program LIGPLOT (192). Further, in
order to determine the volumes of the ligand binding pockets of PPARα, we took
advantage of the POVME algorithm (193). Based on the occupancy of GW409544 within
the hPPARα ligand binding pocket we defined the ligand binding pocket using 37
overlapping inclusion spheres. This pocket was visualized using the Visual Molecular
Dynamics (VMD) program (194), and volume-grid points near the protein atoms were
systematically deleted with a padding variable of 1.09 (radius of a hydrogen atom) or 0.5
(half of a carbon-hydrogen bond length) using POVME (193). This was followed by
volume measurement of each resultant binding pocket.
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Chemicals: Fluorescent fatty acid (BODIPY-C16) was purchased from Molecular
Probes, Inc. (Eugene, OR).

Docosahexaenoyl-CoA and BODIPY C16-CoA were

synthesized and purified by HPLC as previously described (in Chapter I and ( 1 1 7 ,
1 7 1 ) ) , and found to be >99% unhydrolyzed. All other fatty acid ligands and clofibrate
were from Sigma-Aldrich (St. Louis, MO). Rosiglitazone (LKT labs) was a kind gift
from Dr Khalid Elased and bovine serum albumin (lipid-free) was obtained from Gemini
Bioproducts (Sacramento, CA).
Purification of Recombinant F272I mutant mPPAR protein: The cloning and
purification of wild-type 6xHis-GST-mPPARα has already been described in (165) and in
chapter I of this dissertation. A mutant form of full-length mPPARα (amino acids 1-468)
in which the phenylalanine residue at 272 in helix 3 was replaced by isoleucine (F272I; to
mimic hPPARα) was used for all experiments presented herein. The bacterial expression
plasmid for full-length F272I mutant mPPARα (6xhis-GST-F272I mPPARα) was
produced by Dr. S. Dean Rider, Jr. (Wright State University). The full-length
recombinant mutant F272I mPPARα protein was expressed in RosettaTM2 cells
(Novagen, Gibbstown, NJ) and purified as described previously in chapter I and (165) for
the wild-type. The protein purity was verified using SDS-PAGE with Coomassie blue
staining and immunoblotting. Protein concentrations were estimated by Bradford Assay
(Bio-Rad Laboratories, Hercules, CA) and by absorbance spectroscopy using the molar
extinction coefficient for the protein.
Fluorescence based Ligand Binding Assays: The binding affinity of F272I mPPARα
to a fluorescent 16 carbon fatty acid analogue (BODIPY C16) or its CoA thioester
(BODIPY C16-CoA) was determined as described previously for wild-type mPPARα and
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hPPARα in chapter I and (165). Based on the binding affinities obtained herein,
displacement assays were performed in the presence of BODIPY C16-CoA (110 nM)
using non-fluorescent LCFA and LCFA-CoA as described in chapter I and (165). The
maximal fluorescence intensity was measured, and the effect of increasing concentrations
of naturally-occurring non-fluorescent ligands was measured as a decrease in
fluorescence. The direct binding of F272I mPPAR to non-fluorescent ligands was also
determined by quenching of intrinsic PPARα aromatic amino acid fluorescence as
described in chapter I of this dissertation for wild-type mPPARα and hPPARα (165, 173).
For all measurements, emission spectra were corrected for background and inner-filter
effects were avoided. Changes in fluorescence intensity were used to calculate the
dissociation constant (Kd), inhibition constant (Ki) and the number of binding sites (n) as
described in chapter 1 of this dissertation.
Circular Dichroism: Circular dichroic spectra of F272I mPPAR (0.6 M in 600 µM
HEPES pH 8.0, 24 M dithiothreitol, 6 M EDTA, 6mM KCl and 0.6 % glycerol) were
recorded in the presence and absence of LCFA and LCFA-CoA (0.6 M) with a J-815
spectropolarimeter (Jasco Inc., Easton, MD) as previously described in chapter I for the
wild-type mPPARα and hPPARα (165). Spectra were recorded from 260 to 187 nm with
a bandwidth of 2.0 nm, sensitivity of 10 millidegrees, scan rate of 50 nm/min and a time
constant of 1 s. Ten scans per replicate were averaged, and the average spectrum was
used to determine the percent composition of -helices, β-strands, turns and unordered
structures with the CONTIN/LL program of the software package CDpro (117, 179).
Mammalian Expression Plasmids: The pSG5-hPPAR pSG5mPPARpSG5hRXRα and pSG5-mRXRα plasmids have been described in chapter I of this dissertation
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(165). The F272I mutant mPPAR was amplified from 6xhis-GST-F272I mPPAR
using the following primers: 5’-cggatccaccATGGTGGACACAGAGAGCCC-3’ and
ctcctcgagTCAGTACATGTCTCTGTAGA-3’. In these primers, lowercase represents
nucleotides outside of the PPAR open reading frame and restriction sites are underlined.
The PCR product was cloned into the pGEM®-T easy vector (Promega Corp., Madison,
WI). A Bam HI / end-filled Xho I F272I mutant mPPAR fragment was subcloned into
the Bam HI / end-filled Bgl II multiple cloning site of pSG5 (Stratagene, La Jolla, CA) to
produce pSG5-F272I mPPAR The reporter construct, PPRE×3 TK LUC was a kind
gift of Dr. Bruce Spiegelman (Addgene plasmid # 1015) and contained three copies of
the acyl-CoA oxidase (ACOX) peroxisome proliferator response element (PPRE) (180).
Cell culture and Transactivation assay: COS-7 cells (ATCC, Manassas, VA) were
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand Island,
NY), at 37°C with 5% CO2 in a humidified chamber. Cells were seeded onto 24-well
culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand Island, NY)
and 0.4 g of each full-length mammalian expression vector (pSG5-hPPAR and pSG5hRXR, pSG5-mPPAR and pSG5-mRXRpSG5- F272I mPPAR and pSG5mRXR) or empty plasmid (pSG5), 0.4 g of the PPRE×3 TK LUC reporter construct,
and 0.04 g of the internal transfection control plasmid pRL-CMV (Promega Corp.,
Madison, WI) as previously described in chapter 1. Following transfection incubation,
medium was replaced with serum-free medium for 2 h, ligands (1M) were added, and
the cells were grown for an additional 20 h. Fatty acids were added as a complex with
bovine serum albumin (BSA) as described (117, 195).

Firefly luciferase activity,

normalized to Renilla luciferase (for transfection efficiency), was determined with the
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dual luciferase reporter assays system (Promega Corp., Madison, WI) and measured with
a SAFIRE2 microtiter plate reader (Tecan Systems, Inc. San Jose, CA). The clofibrate
treated samples in each case, overexpressing both PPAR and RXR were arbitrarily set
to 1.
Statistical Analysis: Data were analyzed using a one-way ANOVA to evaluate
overall significance (SigmaPlot™, Systat Software, San Jose, CA). A Fisher Least
Significant Difference (LSD) post-hoc test was used to identify individual group
differences. The results are presented as mean ± SEM. The confidence limit of p < 0.05
was considered statistically significant.
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4. Results and Discussion
Since its discovery and cloning, PPARα has been shown to be activated by
structurally diverse ligands, including the fibrate class of drugs, some herbicides,
phthalate monoesters, fatty acids and fatty acid derivatives (83, 108, 113, 117, 186).
However, a vast array of studies have highlighted species differences not just with respect
to gene regulation (163, 187), but also in binding or activation of PPARα (102, 161, 162).
For example, mouse and human PPARα display differences in ligand binding, activation
and physiological responses upon administration of certain hypolipidemic agonists,
phthalate monoesters and LCFA (161, 162, 165). The present study examines structural
differences in the PPARα proteins, which could be an underlying cause of species
differences in ligand binding.
Molecular modeling simulations of hPPARα-LBD and mPPARα-LBD: The X-ray
crystal structure of hPPARα is composed of a helical sandwich and a four-stranded βsheet. The Y-shaped PPARα ligand binding pocket (≈ 1400 Å3) spans between the Cterminal helix 12 (containing the AF-2) and the 4 stranded β-sheet, splitting into 2 arms
roughly parallel to helix 3 (26). In order to investigate the mechanisms underlying
differential binding and activation of mouse and human PPARα in response to LCFA, the
amino acid sequences of mPPARα and hPPARα were compared. While human and
mouse PPARα proteins (468 amino acids) bear approximately 92% sequence identity,
there are 35 amino acid differences (Fig. 16).
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Fig. 16. Primary amino acid sequence of human and mouse PPARα. The N-terminal
domain in depicted in black, DNA binding domain in red, hinge region in green and
ligand binding domain in blue. The different amino acids between human and mouse
PPARα are highlighted in yellow.
Human PPARα
1
51
101
151
201
251
301
351
401
451

MVDTESPLCP
FTEYQYLGSC
ECRICGDKAS
NKCQYCRFHK
ADLKSLAKRI
EKTLVAKLVA
DLNDQVTLLK
FCDIMEPKFD
QEGIVHVLRL
ESDAALHPLL

LSPLEAGDLE
PGSDGSVITD
GYHYGVHACE
CLSVGMSHNA
YEAYLKNFNM
NGIQNKEAEV
YGVYEAIFAM
FAMKFNALEL
HLQSNHPDDI
QEIYRDMY

SPLSEEFLQE
TLSPASSPSS
GCKGFFRRTI
IRFGRMPRSE
NKVKARVILS
RIFHCCQCTS
LSSVMNKDGM
DDSDISLFVA
FLFPKLLQKM

MGNIQEISQS
VTYPVVPGSV
RLKLVYDKCD
KAKLKAEILT
GKASNNPPFV
VETVTELTEF
LVAYGNGFIT
AIICCGDRPG
ADLRQLVTEH

IGEDSSGSFG
DESPSGALNI
RSCKIQKKNR
CEHDIEDSET
IHDMETLCMA
AKAIPGFANL
REFLKSLRKP
LLNVGHIEKM
AQLVQIIKKT

LSPLEADDLE
PGSEGSVITD
GYHYGVHACE
CLSVGMSHNA
HEAYLKNFNM
NGVEDKEAEV
YGVYEAIFTM
FAMKFNALEL
HLQSNHPDDT
QEIYRDMY

SPLSEEFLQE
TLSPASSPSS
GCKGFFRRTI
IRFGRMPRSE
NKVKARVILA
RFFHCCQCMS
LSSLMNKDGM
DDSDISLFVA
FLFPKLLQKM

MGNIQEISQS
VSCPVIPAST
RLKLVYDKCD
KAKLKAEILT
GKTSNNPPFV
VETVTELTEF
LIAYGNGFIT
AIICCGDRPG
VDLRQLVTEH

IGEESSGSFG
DESPGSALNI
RSCKIQKKNR
CEHDLKDSET
IHDMETLCMA
AKAIPGFANL
REFLKNLRKP
LLNIGYIEKL
AQLVQVIKKT

Mouse PPARα
1
51
101
151
201
251
301
351
401
451

MVDTESPICP
FADYQYLGSC
ECRICGDKAS
NKCQYCRFHK
ADLKSLGKRI
EKTLVAKMVA
DLNDQVTLLK
FCDIMEPKFD
QEGIVHVLKL
ESDAALHPLL
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In the X-ray crystal structure of hPPARα-LBD employed in this study (1K7L;
267 amino acids), 23 amino acids are different between the hPPARα-LBD and the
modeled structure of the mPPARα-LBD. Regardless of this difference in amino acids,
when we compared the energy minimized apo forms of hPPARα-LBD and mPPARαLBD using Swiss PDB Viewer or the PyMOL Molecular Graphics System, there was no
significant 3 dimensional structural difference between the two proteins (Cα atoms
RMSD < 0.05 Å3; Fig. 17). Similarly, no differences were noted in the Ramachandran
plots of the two proteins (data not shown). This was consistent with circular dichroism
spectroscopy data from chapter I that demonstrated no significant differences in the
secondary structural content of hPPARα and mPPARα (165).
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Fig. 17. An overlay of the energy minimized structures of hPPARα-LBD (red; adopted
from PDB code: 1K7L) and mPPARα-LBD (blue; modeled using 1K7L). No significant
structural difference was observed between the two proteins (Cα atoms RMSD < 0.05
Å3).
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Molecular docking simulations with hPPARα-LBD and mPPARα-LBD: For all
docking simulations we utilized both AutoDock Vina (191) and the FlexiDock™ module
available on SYBYL®-X 2.0. In order to validate our docking simulations, we compared
the energy minimized structure of hPPARα-LBD + GW409544 obtained using our
docking approaches to the experimentally obtained X-ray crystal structure of the same
(26). There was no significant difference between the two structures (Cα RMSD < 0.01
Å3). Furthermore, the orientation of GW409544, as well as the amino acids participating
in the interaction between GW409544 and the protein, were quite comparable in the two
structures (Fig. 18A and 18B). Thus, this docking protocol was considered suitable for
subsequent docking runs. We next simulated the docking of GW409544 to our energy
minimized model of mPPARα-LBD. Although there was no significant difference
between the RMSD value for the Cα atoms (RMSD < 0.05 Å), the orientation of
GW409544 was remarkably different in the hPPARα-LBD and mPPARα-LBD (Fig. 18C
and 18D). This was consistent with previous molecular modeling data which reported
similar variations in the orientation and position of GW409544 within the ligand binding
pockets of mPPARα-LBD and hPPARα-LBD (159). It was proposed that part of these
variances could be attributed to the bulky phenylalanine residue at 272 in mPPARα-LBD
(Isoleucine in hPPARα-LBD), and that this may cause a large shift in the phenyloxazol
arm of GW409544 (Fig. 18D).

110

111

Fig. 18. (A) An overlay of the optimized structure of hPPARα-LBD in complex with
GW409544 (magenta) along with its crystal structure (PDB code: 1K7L; GW409544
shown in yellow). The right-hand figure is a close-up of the panel on the left, with key
amino acids Tyr-314, Tyr-464 and Ile-272 labeled. (B) An overlay of GW409544 in the
hPPARα-LBD generated using our docking approach (magenta) and/or obtained from
PBD code 1K7L (yellow). (C) The binding pose for the energy minimized structure of
mPPARα-LBD in complex with GW409544 with a close-up view around the ligand
(magenta). (D) An overlay of GW409544 conformations from docking poses generated
using hPPARα-LBD (yellow) and mPPARα-LBD (magenta).
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Upon validation of the docking parameters, the docking of LCFA to hPPARαLBD and mPPARα-LBD were examined. Docking of saturated LCFA (palmitic and
stearic acid) were preferentially examined, because mPPARα and hPPARα have been
shown to bind with different affinities to such LCFA (165). Based on reported crystal
structures and structure-activity relationships, most PPARα agonists bind to PPARα with
the acidic head group forming hydrogen bonds with Y314 on helix 5 and Y464 on the
AF-2 of helix 12. The hydrophobic tails of these ligands are stabilized by numerous
hydrophobic interactions extending upward or downward in the 2 arms of the PPARα
pocket (26). Based on these observations and the fact that LCFA serve to activate
PPARα, we expected the carboxylic acid group of the LCFA to form a specific hydrogen
bonding network with Y314 and Y464 to stabilize the AF-2 helix, permitting PPARα
activation.
The binding mode of palmitic acid to hPPARα-LBD demonstrated striking
resemblance to that of other PPARα agonists – stabilized by a combination of hydrogen
bonds and hydrophobic interactions. The carboxylic acid group of palmitic acid was
oriented towards the AF-2 helix forming hydrogen bonds with Y314 and Y464, and its
hydrophobic tail was stabilized by numerous hydrophobic interactions in the core PPARα
pocket (Fig. 19A, Fig. 19B). Similar docking poses were generated for another saturated
(stearic acid; C18:0; Fig. 20A), monounsaturated (palmitoleic acid; C16:1; Fig. 20B) and
polyunsaturated (docosohexaenoic acid; C22:6; Fig. 20C) LCFA. The binding energies
estimated by the docking software are presented in Table V. Although both AutoDock
Vina and the SYBYL®-X 2.0 gave consistent and similar output for the docking modes,
the FlexiDock™ module on SYBYL®-X 2.0 was used to obtain binding energies
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associated with this docking. The FlexiDock™ module on SYBYL® - X 2.0 was chosen
because 1) it permits both protein (sidechains) and ligands to carry flexible/rotatable
bonds, and 2) the FlexiDock™ energy evaluation function is based on the Tripos Force
Field and estimates the binding energy of ligand, the receptor binding pocket, as well as
the interaction between them. These results demonstrated that LCFA are bound in a
similar manner as other PPARα ligands and further support previous observations that
suggest LCFA are high affinity endogenous ligands of hPPARα (108, 117, 165).
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Fig. 19. Comparison of the binding modes of C16:0 complexed with (A) hPPARα LBD,
(C) mPPARα LBD and (E) F272I mPPARα LBD. All docking poses presented here were
generated using the FlexiDock™ module available on SYBYL® - X 2.0 and are
comparable to those generated using AutoDock Vina. In the left-hand figures AF2 helix
12, helix 3 and helix 5 are depicted in red, cyan and green respectively. The right-hand
figures are close-up views of respective panels from the left. The ligand is colored in
magenta and the amino-acids Tyr 314, Tyr 464 and Ile-272 or Phe-272 are labeled. Twodimensional representations of key hydrogen bonding (green dotted lines) and
hydrophobic interactions (red dashed lines) between C16:0 and hPPARα LBD (B) or
mPPARα LBD (D) or F272I mPPARα LBD (F) were produced using LIGPLOT (192).
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Fig. 20. Energy minimized structures of hPPARα-LBD in complex with (A) palmitoleic
acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right panels are
close-up views of respective panels on the left. All docking poses presented here were
generated using the FlexiDock™ module available on SYBYL® - X 2.0 and are
comparable to those generated using AutoDock Vina.
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Table V. Comparison of binding energies (kcal/mol) for mouse and human PPARα LBD
complexed with LCFA ligands.
Ligand
Chain length: double
hPPARα mPPARα
F272I
bonds (position)
kcal/mol kcal/mol
mPPARα
kcal/mol
Palmitic acid
C16:0
-1150
-284
-1089
Palmitoleic acid
C16:1 (n-7)
-1149
-1143
-1149
Stearic acid
C18:0
-1153
-298
-1112
Docosahexanoic
C22:6 (n-3)
-1187
-932
-1039
acid
Binding energies were derived using the FlexiDock™ module available on SYBYL® - X
2.0 (Tripos, St. Louis, MO).
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While experimental results have shown that mPPARα binds with strong affinity to
monounsaturated and polyunsaturated LCFA, it binds only weakly to saturated LCFA
(165). Consistent with these observations, our docking simulations demonstrated that,
with the exception of saturated LCFA, the binding modes and energies generated for the
mPPARα-LBD in complex with monounsaturated (C16:1; Fig. 21A) and polyunsaturated
(C22:6; Fig. 21C) LCFA are quite comparable to that of hPPARα-LBD. However, the
conformation and position of saturated palmitic (Fig. 19C, 19D) and stearic acid (Fig.
21B) in the mPPARα-LBD are remarkably different, demonstrating 4-fold higher binding
energies (weaker binding) when compared to the docking poses in hPPARα-LBD (Table
V).

119

Fig. 21. Energy minimized structures of mPPARα-LBD in complex with (A) palmitoleic
acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right panels are
close-up views of respective panels on the left. All docking poses presented here were
generated using the FlexiDock™ module available on SYBYL® - X 2.0 and are
comparable to those generated using AutoDock Vina.
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Two striking features were noted between the binding orientation of palmitic acid
and stearic acid to mPPARα-LBD compared to hPPARα-LBD. Although multiple
docking poses were generated, suggesting several possible conformations of the palmitic
(or stearic) acid within the binding pocket, these characteristics were consistently seen in
all poses for the mPPARα-LBD. First, the carboxylic acid group does not form hydrogen
bonds with the C terminal amino acids - possibly raising the binding energy (less
negative or less favorable). Second, the alkyl chain is not fully extended in the mPPARαLBD pocket (Fig. 19C, 19D), and the fatty acid was unable to orient along the same axis
as seen with the hPPAR-LBD. This may raise the binding energy, resulting in weaker
binding affinity of saturated LCFA to mPPARα-LBD. It is known that saturated alkyl
chains normally prefer a fully extended conformation (196). These results were consistent
with the weaker binding affinities of saturated LCFA reported for mPPARα (165).
While the computational and experimental binding trends are similar, it is
noteworthy that binding energies obtained in this study do not necessarily convert into
the same nanomolar binding affinities reported experimentally. Such differences between
computational binding energies and experimental binding affinities could in part be
explained by parameters that are not taken into consideration in the docking simulations,
including the contribution of entropy, effects of solvation and the dynamic nature of
proteins in solution. It is worth noting that in the human and mouse PPARα comparison
of LCFA binding, solvation by itself is not likely to be of paramount importance. This is
because the solvation energy of palmitic or stearic acid are about the same regardless of
the protein to which they bind (197). We anticipate that the hydration of the binding
pocket is also similar given the similar polarity of the amino acid substitutions at 272 and
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270 (F272I and T279M). However, the overall protein flexibility and the role of water in
this process is of particular importance. While these possibilities were not tested in this
study, another factor that may play a crucial role in explaining such differences is the use
of full-length PPARα protein in experimental ligand binding studies as compared to the
use of PPARα-LBD in computational docking simulations.
Comparison of the amino acid sequences from the human and mouse PPARαLBD, especially in helices 3, 5, 7 and 12 which form the central core of the ligand
binding pocket, exhibit two major differences in helix 3, which occur at amino acid 272
(isoleucine to phenylalanine) and 279 (threonine to methionine). While both of these
substitutions are fairly conservative, the amino acid at 272 in hPPARα is an isoleucine
with a small isobutyl group, whereas in mPPARα this residue is a phenylalanine with a
bulkier benzyl side chain. We speculated that the electron rich bulkier benzyl group of
F272 in mPPARα might cause steric hindrance and change the shape and volume of the
mPPARα ligand binding pocket. In order to test this hypothesis, we substituted the
phenylalanine residue at 272 in the mPPARα-LBD structure with an isoleucine (F272I
mPPARα-LBD). The binding modes and energies generated using such an energy
minimized model of F272I mPPARα-LBD in complex with palmitic acid (Fig. 18E, 18F),
as well as palmitoleic, stearic and docosahexaenoic acids (Fig. 22A, 22B, 22C) were
similar to that obtained using the hPPARα-LBD structure (Table V). These results
suggest that the amino acid residue at position 272 of helix 3 plays a critical role in
determining species specificity and selectivity of PPARα ligands.
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Fig. 22. Structural determinants of endogenous LCFA selectivity for mouse and human
PPARα. Energy minimized structures of F272I mPPARα-LBD in complex with (A)
palmitoleic acid, (B) stearic acid and (C) docosahexaenoic acid. The figures in the right
panels are close-up views of respective panels on the left. All docking poses presented
here were generated using the FlexiDock™ module available on SYBYL® - X 2.0 and
are comparable to those generated using AutoDock Vina.
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In order to confirm the importance of the amino acid residue at position 272,
docking simulations were also performed with an energy minimized point mutant model
of I272F hPPARα-LBD in the presence of palmitic or stearic acid (Fig. 23). Although
such binding/docking displayed weaker binding affinity (higher binding energies; -866
kcal/mol, C16:0 and -745 kcal/mol, C18:0) than the wild-type hPPARα (Table V), it was
not as weak as the F272I mPPARα (-284 kcal/mol, C16:0 and -298 kcal/mol, C18:0). The
differences in the binding energy between I272F hPPARα-LBD and F272I mPPARαLBD complexed with C16:0 or C18:0 may be attributed to the manner in which the
ligands orient around the amino acid at 279 (threonine in hPPARα and methionine in
mPPARα) (Fig. 23). For example, if the threonine 279 in I272F hPPARα-LBD is mutated
to methionine (like in F272I mPPARα-LBD) the binding mode/energy generated with
palmitic or stearic acid mimics that of F272I mPPARα-LBD.
Similarly, the orientation of the ligand around the amino acid residue at 279 also
explains the slight difference in binding energies seen between human and mouse PPARα
for C22:6 (Table V). This T279M substitution has previously been reported to cause
differences in the activation of human and mouse PPARα in response to synthetic PPARα
agonists (160). A schematic explaining the significance of these amino acids in relation to
saturated LCFA binding is presented below (Fig. 23). Depending on the chemistry of the
ligand both amino acid residues at 272 as well as 279 could be crucial determinants of
PPARα ligand specificity. However for LCFA binding to mPPARα-LBD, the amino acid
residue at 272 plays an important role in imparting ligand specificity.
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Fig. 23. Illustration of saturated LCFA binding to human and mouse PPARα –
Importance of amino acid residues at position 272 and 279. A) Human PPARα binds
saturated fatty acids with high affinity. B) Owing to stearic hindrance due to
phenylalanine at 272 (F272) mPPARα binds this ligand relatively weakly. C) Reversal of
phenylalanine at 272 to isoleucine (F272I) in mPPARα results in high affinity binding of
saturated LCFA. D) Mutation of isoleucine at 272 to phenylalanine in hPPARα (I272F)
results in weaker binding of the saturated fatty acids but it is not as weak as F272I
mPPARα in C. These differences are a result of how the ligand orients around T279 (in
hPPARα) such that mutation of both amino acids (I272F and T279M) results in binding
mode similar to B.
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In order to determine the contribution of these amino acids to the PPARα ligand
binding pocket, we evaluated binding pocket volume calculations using the POVME
algorithm. Based on the occupancy of the GW409544 ligand (in 1K7L) and a padding
variable set to 0.5 (deduced based in a carbon-hydrogen bond length of 1.09 Å) the ligand
binding pocket of hPPARα-LBD was 1177 Å3 (Fig. 24A) In contrast, owing to I272F
and T279M substitutions, the binding pocket of mPPARα-LBD was 1073 Å3(Fig. 24B).
A single mutation of F272I or two mutations including both F272I and M279I in
mPPARα-LBD resulted in binding pocket volumes of 1130 Å3 (Fig. 24C) and 1161 Å3
(Fig. 24D) respectively. It is apparent from these results that the amino acid differences at
residues 272 and 279 do alter the size of the pocket. However, as the average volume of a
fatty acid (e.g. palmitic acid) is < 300 Å3, there is plenty of space within each of these
pockets for fatty acid binding. This suggests that favorable interactions with the AF-2
domain (which are based on the orientation of the ligand) are more important for
determining PPAR ligand specificity, with regards to LCFA, than the total volume
available within the pocket.
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Fig. 24. Ligand binding pocket volumes for (A) hPPARα-LBD, (B) mPPARα-LBD, (C)
F272I mPPARα-LBD and (D) F272I, M279T mPPARα-LBD determined using the
POVME algorithm (193).
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Purification of full-length recombinant F272I mPPARα:

In order to

experimentally determine the effect of a phenylalanine to isoleucine substitution at amino
acid 272 of mPPARα, full-length recombinant F272I mPPARα protein was expressed and
purified as described for full-length mPPARα and hPPARα (165). SDS-PAGE and
Coomassie blue staining indicated a predominant band of 52kDa corresponding to the
expected size of full-length F272I mPPAR (>85% purity; Fig. 25B), with similar purity
as mPPARα (Fig. 25A). The low intensity band at 75 kDa represents a small fraction of
un-cut/tagged protein (< 10%).
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Fig. 25. SDS-PAGE and Coomassie blue staining of 1 µg, 3 µg and 6 µg of purified
recombinant (A) mPPARα (left) and (B) F272I mPPARα showing relative purity of the
protein. The prominent band at 52 kDa represent full-length, untagged recombinant
mPPARα and F272I mPPARα.
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Binding of fluorescent fatty acids and fatty acyl-CoAs to F272I mPPARα. While
BODIPY fluorescence was low for each examined fluorophore in the absence of protein,
titration of F272I mPPAR with BODIPY C16-CoA resulted in increased fluorescence
which approached saturation near 200 nM. (Fig. 26A, 26B). This data transformed into a
linear double reciprocal plot (Fig. 26B, inset), consistent with a single binding site (R2 >
0.90). Binding of BODIPY C16 fatty acid was also strongly saturable at a single binding
site (Fig. 26C). Multiple replicates yielded Kd values of 55 ± 4 nM and 18 ± 3 nM for
BODIPY C16-CoA and BODIPY C16 fatty acid, respectively, indicating high-affinity
binding. These results were consistent with previously reported binding affinities of wildtype mPPARα (165), suggesting that this amino acid change did not disrupt or alter the
binding of these ligands.
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Fig. 26. (A) Corrected fluorescence emission spectra of 0.1 M F272I mPPARα titrated
with 0 (filled circles), 20 (open circles), 50 (filled triangles), 100 (open triangles), 200
(filled squares) and 300 nM (open squares) of BODIPY C16-CoA upon excitation at 465
nm. These results demonstrate increased fluorescence intensity upon binding to F272I
mPPARα. Plot of F272I mPPARα fluorescence emission at 515 nm (excitation 465 nm)
as a function of BODIPY C16:0-CoA (B) and BODIPY C16:0 FA (C). Insets represent
double reciprocal plots of the binding curve from each panel. All values represent the
mean ± S.E., n ≥ 3.
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Binding of endogenous LCFA and LCFA-CoA to F272I mPPARα: In order to
experimentally test the hypothesis that the F272I substitution could explain the
differences in binding affinity of human and mouse PPARα for saturated LCFA, the
ligand specificity of F272I mPPAR for naturally-occurring, endogenous LCFA and
LCFA-CoA was examined. The binding affinities for naturally-occurring LCFA and
LCFA-CoA were estimated by monitoring their ability to compete and displace BODIPY
C16-CoA from F272I mPPARα, which was observed as decreased BODIPY
fluorescence. With the exception of lauric acid and lauroyl-CoA (Fig. 27K, 27L), titration
with the fatty acids and fatty acyl-CoA examined here resulted in significantly decreased
BODIPY fluorescence (Fig. 27A-H).

Quantitative analyses of these data suggested

strong binding (Ki = 17-29 nM, Table VI). By comparison, the synthetic PPAR agonist
clofibrate showed slightly weaker binding affinity (Fig. 27I; Ki = 51 nM), and the
synthetic PPAR agonist rosiglitazone did not displace BODIPY C16-CoA (Fig. 27J,
Table VI).
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Fig. 27. Interaction of naturally-occurring fatty acids and fatty acyl-CoA with F272I
mPPARα based on displacement of BODIPY C16-CoA. F272I mPPARα complexed with
BODIPY C16-CoA was titrated with the following ligands: (A) palmitic acid, (B)
palmitoyl-CoA, (C) palmitoleic acid, (D) palmitoleoyl-CoA, (E) stearic acid, (F) stearoylCoA, (G) docosahexaenoic acid, (H) docosahexaenoyl-CoA, (I) clofibrate, (J)
rosiglitazone, (K) lauric acid and (L) lauroyl-CoA. The maximal fluorescence emission
of BODIPY C16-CoA was measured at 515 nm (excitation at 465 nm). Data are
presented as percent change of initial fluorescence plotted as a function of ligand
concentration. All values represent mean ± S.E., n ≥ 3.
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To confirm the ligand binding specificity of F272I mPPARα, the binding affinity
of LCFA and LCFA-CoA was also measured by spectroscopically monitoring the
quenching of F272I mPPAR aromatic amino acid emission.

Titration of F272I

mPPAR with both palmitic (Fig. 28A) and stearic (Fig. 28E) acid (saturated LCFA)
effectively quenched F272I mPPARα fluorescence, yielding a sharp saturation curve with
a maximal change at 100 nM. These data transformed into linear reciprocal plots (Fig.
28A, 28E insets), indicating high affinity binding at a single binding site (Kd of 20 nM
and 11 nM for palmitic and stearic acids, respectively). With the exception of lauric acid
(Fig. 28K) and lauryl-CoA (Fig. 28L), similar results were obtained for all examined fatty
acids and fatty acyl-CoA (Fig. 28A-H), with single site binding affinities in the 11-27 nM
range (Table VI). The PPAR agonist clofibrate strongly quenched F272I mPPAR
fluorescence (Fig. 28I), but displayed weaker affinity than the LCFA (Table VI), while
the PPAR agonist rosiglitazone showed no binding (Fig. 28J, Table VI).
While the binding affinities obtained for F272I mPPARα with saturated LCFA
were comparable to those obtained with hPPARα (Kd = 14-22 nM), they are significantly
different (4-5 fold) from those obtained using wild-type mPPARα (Kd = 81-135 nM)
(165). These data further corroborate the importance of amino acid residue 272 in
determining species selectivity for endogenous PPARα ligands. LCFA-CoA binding was
similar to previous reports for both mPPARα and hPPARα (165), suggesting that amino
acid 272 is not as important for the orientation of these ligands within the pocket.

136

0
0

0
0

150
300
[(L)/(Fi/Fmax)]

0

100
200
300
Palmitic acid, nM (C16:0)
150
[1/(1-(Fi/Fmax))]

50
0

8
0
0

50
0

150
300
[(L)/(Fi/Fmax)]

0
100
200
300
Palmitoleic acid, nM (C16:1)

Fo - Fi (a.u.)

150
16

100
50
0
0

100

8
0
0

75

150

[(L)/(Fi/Fmax)]

15
10
5
0
0

100

200

[(L)/(Fi/Fmax)]

0
100
200
300
Palmitoleoyl-CoA, nM (C16:1-CoA)

E
[1/(1-(Fi/Fmax))]

Fo - Fi (a.u.)

150

0

D

100

16

5

0
100
200
300
Palmitoyl-CoA, nM (C16:0-CoA)

C

100

10

50

Fo - Fi (a.u.)

Fo - Fi (a.u.)

150

10

100

[1/(1-(Fi/Fmax))]

50

20

B

50
0

100
200
[(L)/(Fi/Fmax)]

100
200
300
Stearic acid, nM (C18:0)

F
[1/(1-(Fi/Fmax))]

100

Fo - Fi (a.u.)

150

[1/(1-(Fi/Fmax))]

A
[1/(1-(Fi/Fmax))]

Fo - Fi (a.u.)

150

8
4
0
100 200
[(L)/(Fi/Fmax)]

0
100
200
300
Stearoyl-CoA, nM (C18:0-CoA)

137

100

0

5
0
0

150

50
0

300

[(L)/(Fi/Fmax)]

0
100
200
300
Docosahexanoic acid, nM (C22:6)

50

I
[1/(1-(Fi/Fmax))]

150
100
50
0
0

20
10
0

0
-50

0

50

50

Fo - Fi (a.u.)

-50

-100
-150

[1/(1-(Fi/Fmax))]

Fo - Fi (a.u.)

K
10
5

0
-50

-100

0
0
250
500
[(L)/(Fi/Fmax)]

100

200

[(L)/(Fi/Fmax)]

10
5
0
0 250 500
[(L)/(Fi/Fmax)]

-150

100 200 300 400 500
Clofibrate, nM

0

0

J

-100

0
250
500
[(L)/(Fi/Fmax)]

6

0
100
200
300
Docosahexanoyl-CoA, nM (C22:6-CoA)

Fo - Fi (a.u.)

Fo - Fi (a.u.)

200

12

[1/(1-(Fi/Fmax))]

10

50

H

-150

100 200 300 400 500
Rosiglitazone, nM

L
[1/(1-(Fi/Fmax))]

100

Fo - Fi (a.u.)

150

[1/(1-(Fi/Fmax))]

G
[1/(1-(Fi/Fmax))]

Fo - Fi (a.u.)

150

10
5
0
0
500 1000
[(L)/(Fi/Fmax)]

0
100 200 300 400
Lauryl-CoA, nM (C12:0-CoA)

0
100 200 300 400
Lauric acid, nM (C12:0)

138

Fig. 28. Interaction of naturally-occurring fatty acids and fatty acyl-CoA with F272I
mPPAR. Direct binding assay based on quenching of F272I mPPAR aromatic amino
acid fluorescence emission (excitation = 280 nm and emission = 300-400 nm) when
titrated with the following ligands: (A) palmitic acid, (B) palmitoyl-CoA, (C) palmitoleic
acid, (D) palmitoleoyl-CoA, (E) stearic acid, (F) stearoyl-CoA, (G) docosahexaenoic
acid, (H) docosahexaenoyl-CoA, (I) clofibrate, (J) rosiglitazone, (K) lauric acid and (L)
lauroyl-CoA. Data are presented as the change in fluorescence intensity (F0- Fi) plotted
as a function of ligand concentration. Insets represent linear plots of the binding curve
from each panel. All values represent mean ± S.E., n ≥ 3.
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Table VI. Affinity of F272I mPPARα for non-fluorescent ligands determined by
quenching of hPPARα aromatic amino acid fluorescence and by displacement of F272I
mPPARα-bound BODIPY C16-CoA.
Ligand
Chain length:
Kd
Kd (nM)
Ki
Ki (nM)
double bonds
(nM)
Fatty acyl- (nM)
Fatty acyl(position)
Fatty
CoA
Fatty
CoA
acid
acid
Lauric acid/CoA
C12:0
ND
ND
ND
ND
Palmitic acid/CoA
C16:0
20±3
17±2
19±2
18±2
Palmitoleic acid/CoA C16:1 (n-7)
19±3
21±2
22±3
28±3
Stearic acid/CoA
C18:0
11±2
18±2
15±1
19±2
Docosahexanoic
C22:6 (n-3)
17±3
27±3
17±2
29±3
acid/CoA
Clofibrate
42±6
51±3
Rosiglitazone
ND
ND
Values represent the mean ± S.E. (n ≥ 3). ND, not determined.
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Effect of endogenous fatty acids and fatty acyl-CoAs on F272I mPPAR
secondary structure. Circular dichroism (CD) was used to examine whether the binding
of LCFA or LCFA-CoA altered the F272I mPPARα secondary structure. The far UV CD
spectrum of F272I mPPAR suggested the presence of substantial -helical content,
exhibiting a large positive peak at 192 nm and two negative peaks at 207 and 222 nm
(Fig. 30A-E, filled circles). Quantitative analyses confirmed that F272I mPPAR was
composed of approximately 30 % -helix, 18 % β-sheets, 22 % β-turns and 29 %
unordered structures (Table VII). A comparison of the CD spectra (Fig. 29) and relative
proportions of the secondary structures for wild-type hPPARα, mPPARα and F272I
mPPARα suggested no significant differences in the structure of these proteins - a finding
consistent with our observations from the modeling data. This suggested that the F272I
mutation in mPPARα does not disrupt the secondary structure or folding of the protein.
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Fig. 29. An overlay of the far UV circular dichroic (CD) spectra of hPPARα (filled
circles), mPPARα (open triangles) and F272I mPPARα (filled squares) in the absence of
any ligands. Each spectrum represents an average of 10 scans for a given representative
spectrum from at least three replicates.
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The addition of high-affinity ligands to F272I mPPARα resulted in
conformational changes demonstrated by alterations in the molar ellipticity at 192, 207,
and 222 nm (Fig. 30B-E), indicative of ligand binding. Conversely, no changes were
observed with the addition of lauric acid (Fig. 30A), lauroyl-CoA (Fig. 30A) or
rosiglitazone (Fig. 30F), consistent with the lack of binding of F272I mPPAR to these
ligands. While saturated LCFA do not induce secondary structural changes to mPPARα
(165), there was a significant decrease in the fraction of -helical content and a
concomitant increase in the fraction of β-sheets for F272I mPPARα (Table VII), similar
to those reported for hPPARα (Table III) (165). Similar helix-sheet transitions have been
previously reported with other nuclear receptors and transmembrane proteins (117, 177,
198).

Most of the examined LCFA and LCFA-CoA resulted in F272I mPPARα

structural changes (Table VII) similar to those previously reported for hPPARα (Table
III) (165), further indicating the importance of residue 272 in LCFA binding. However,
palmitoyl-CoA and docosahexaenoic acid changes (Table VII) were more similar to those
reported for mPPARα (Table IV) (165), suggesting that ligand structure may also be
important in determining ligand orientation and binding.
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Fig. 30. Far UV circular dichroic (CD) spectra of F272I mPPARα in the absence (filled
circles) and presence of added ligand: A, Lauric acid (open circles) or Lauryl CoA (filled
triangles); B, palmitic acid (open circles) or palmitoyl CoA (filled triangles); C,
palmitoleic acid (open circles) or palmitoleoyl-CoA (filled triangles); D, stearic acid
(open circles) or stearoyl-CoA (filled triangles); E, docosahexanoic acid (open circles) or
docosahexaenoyl-CoA (filled triangles); and F, clofibrate (open circles) or rosiglitzone
(filled triangles).

Each spectrum represents an average of 10 scans for a given

representative spectrum from at least three replicates.
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Table VII. Effect of ligands on the relative proportion of F272I mPPARα secondary
structure determined by CD. These structures were as follows: total helices (H; a sum of
regular α-helices and distorted α-helices), total sheets (S; a sum of regular β-sheets and
distorted β-sheets), turns (Trn; β-turns), and unordered (Unrd) structures.
Average
Total H ±
Total S ±
Trn ±
Unrd ±
S.E.
S.E.
S.E.
S.E.
F272I mPPARα
30 ± 2
18.3 ± 2.3
21.8 ± 0.2 28.8 ± 0.2
F272I mPPARα + C12:0
29 ± 1
21 ± 2
21.8 ± 0.1 28.9 ± 0.2
F272I mPPARα + C12:0-CoA
30 ± 1
20 ± 1
21.7 ± 0.3 29.1 ± 0.1
**
**
F272I mPPARα + C16:0
18.1 ± 0.2
31.5 ± 0.5
22 ± 0.1
28.6 ± 0.3
F272I mPPARα + C16:0-CoA
21 ± 2*
29 ± 1*
22.1 ± 0.3 29.1 ± 0.2
F272I mPPARα + C16:1
20 ± 1#
30 ± 1#
21.7 ± 0.1 28.7 ± 0.2
*
*
F272I mPPARα + C16:1-CoA
22 ± 2
28 ± 1
21.4 ± 0.2 28.5 ± 0.5
**
**
F272I mPPARα + C18:0
18.3 ± 0.1
31.1 ± 0.1
21.9 ± 0.1 28.5 ± 0.1
F272I mPPARα + C18:0-CoA
20 ± 1*
29 ± 1*
21.5 ± 0.2 28.7 ± 0.3
**
**
F272I mPPARα + C22:6
19 ± 1
30.8 ± 0.3
21.5 ± 0.1 28.7 ± 0.1
#
**
F272I mPPARα + C22:6-CoA
19.1 ± 0.1
30.6 ± 0.3
22 ± 1
28.6 ± 0.1
**
**
F272I mPPARα + Clofibrate
17.1 ± 0.1
31.9 ± 0.3
22 ± 1
29.0 ± 0.2
F272I mPPARα + Rosiglitazone
31 ± 1
19 ± 1
21.9 ± 0.1 28.6 ± 0.1
Asterisks represent significant differences between F272I mPPARα only and F272I
mPPARα in the presence of added ligand (* P < 0.05, ** P < 0.001 and # P = 0.001).
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Effect of fatty acids on transactivation of PPAR-RXR heterodimers. In order to
determine whether residue 272 is also responsible for variances observed between
mPPARα and hPPARα transactivation in response to saturated LCFA (165), luciferase
reporter assays utilizing hPPARα, mPPARα and F272I mPPARα were performed. Since
PPAR heterodimerizes with RXR to induce transactivation, COS-7 cells were
cotransfected with either pSG5 empty vector or a combination of hPPARα and hRXRα,
mPPARα and mRXRα or F272I mPPARα and mRXRα. The transactivation of a PPRE×3
TK LUC reporter construct was analyzed in the absence or presence of ligands (Fig. 31).
Transactivation was measured as percent firefly luciferase activity normalized to Renilla
luciferase (internal control).
Cells overexpressing hPPARα and hRXRα demonstrated significantly increased
transactivation of the PPRE×3 TK LUC reporter in response to high-affinity ligands of
hPPARα (Fig. 31). In contrast, for cells overexpressing mPPARα and mRXRα, only the
examined unsaturated LCFA and clofibrate significantly increased transactivation.
Consistent with the weak binding affinity of saturated LCFA for mPPARα, addition of
these ligands did not affect the activity in COS-7 cells. However, in cells overexpressing
F272I mPPARα and mRXRα the addition of saturated LCFA (palmitic and stearic acid),
as well as unsaturated LCFA (palmitoleic, and docosahexaenoic acid) resulted in
significantly increased transactivation similar to clofibrate treated cells (Fig. 31). This
was consistent with the high-affinity binding of these ligands to F272I mPPARα. In all
treatments the addition of lauric acid, which consistently did not bind to hPPARα,
mPPARα or F272I mPPARα, had no significant effect on activity. These findings
suggested that only high-affinity endogenous ligands increase PPARα activity and, more
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importantly, the amino acid at 272 could be responsible for the differences in saturated
LCFA-mediated transactivation of the PPRE×3 TK LUC reporter in cells overexpressing
hPPARα and mPPARα.
These results are consistent with previous transactivation studies and gene
expression studies which demonstrate species differences in the activity of human and
mouse PPARα in response to synthetic agonists such as 5, 8, 11, 14-eicosatetraynoic acid
(ETYA), WY-14,643 and 2-ethylphenylpropanoic acid derivative (KCL), among others
(158, 160-163, 187, 199). While an I272F substitution diminished the agonistic activity
of KCL, a T279M substitution increased the agonistic activity of WY-14,643 in hPPARα
(158). Our studies with endogenous LCFA ligands suggested that, to a large extent, only
amino acid 272 plays an important role in determining species differences, particularly
for saturated LCFA. We speculate that based on the structure of ligands and their
potential orientation and interactions within the PPARα pocket, both amino acids at 272
and 279 are crucial determinants of species differences exhibited by PPARα across
species.
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Fatty acids mediate species-selective transactivation of PPARα-RXRα

heterodimers.

Cos7 cells transfected with either both hPPARα and hRXRα, both

mPPARα and mRXRα, or both F272I mPPARα and mRXRα analyzed for transactivation
of the acyl-CoA oxidase reporter construct in presence of vehicle (open bars), 1 µM
lauric acid (diagonally upward bars), 1 µM palmitic acid (hatched bars), 1 µM
palmitoleic acid (diagonally downward bars), 1 µM stearic acid (horizontally lined bars),
1 µM docosahexanoic acid (open bars) and 1 µM clofibrate (diagonally upward bars).
The y-axis represents values for firefly luciferase activity that have been normalized to
Renilla luciferase (internal control) as well as controls for cells transfected with empty
pSG5 vector. The bar graph represents the mean values (n ≥ 3) ± standard error. * P <
0.01, ** P < 0.001.
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Computational and experimental data support the notion that amino acid
substitutions could be responsible for differences in binding affinity and activation
observed between human and mouse PPARα. It is believed that during the course of
evolution, emerging nuclear receptors acquired the ligand-binding capacities and further
refined their specificities for a particular biologically signficiant ligand (184, 200, 201).
Among 117 vertebrate PPARα protein coding sequences identified by BLAST, isoleucine
272 is conserved from bony fish to primates, with the exception of mouse (Mus
musculus), rat (Rattus norvegicus) and two unrelated rodents: the naked mole rat
(Heterocephalus

glaber)

and

the

thirteen-lined

ground

squirrel

(Ictidomys

tridecemlineatus). The distribution of these species suggests that the substitution of
isoleucine for phenylalanine has evolved at least three times. A simple transversion (A to
T) in the first position of the codon is enough to convert an isoleucine to a phenylalanine
codon.

However, given the high evolutionary rate of PPARα (184, 200, 201), the

conservation of isoleucine in this position implies that there are functional and
evolutionary consequences associated with this change (e.g. it is under purifying
selection).
Consistent with this, our results indicated that compared to humans, the I272F
amino acid change seen in mouse represents a partial loss of function mutation
(hypomorphic) with respect to LCFA binding. Whether this change is responsible for the
increased sensitivity of mouse to peroxisome proliferation or hepatic cancer remains to be
determined, but the single F272I substitution in mPPARα recapitulates the human-like
LCFA binding and trans-activation functions. Other amino acid positions examined that
were not predicted to alter LCFA binding energies (such as position 279) displayed much
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greater variation among species, suggesting more relaxed functional and evolutionary
constraints at those positions. One could speculate that PPARα underwent strong
selective pressure that was directly affected by dietary changes and that this eventually
provided crucial structural and functional changes like I272F in mouse. However, there
is no clear dietary or metabolic relationship uniquely shared among the four species that
harbor the I272F amino acid change, and compensatory mechanisms that may allow this
mutation to persist within these species are not clearly established.

Therefore, the

important question that still remains unsolved is why such differences in PPARα
structure would exist.
Nonetheless, we demonstrated for the first time that differences in amino acids in
the LBD of PPARα contribute to species selectivity and specificity for endogenous
PPARα ligands. The importance of PPARα in human disease is validated by the lipid
lowering effects of synthetic PPARα agonists. The data presented herein enhances our
understanding of dietary effects on PPARα and may aid in the development of more
targeted therapeutics. Moreover, these data demonstrate the efficacy of molecular
modeling and docking simulations for examining the effect of structural variations on
ligand binding.
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Summary and Conclusions:
The importance of dietary fat has been acknowledged ever since Burr and Burr
(1929) examined the effects of fat-free diets in rats (202). They noticed that, as compared
to rats on normal diet, rats on fat-free diets (with same calories via proteins and vitamins)
failed to thrive and developed various physiological problems including skin disorders
and kidney problems (202). Further, these rats were reverted to good health when dietary
fats were added to their food (202). It is known today that dietary fatty acids are
ubiquitous molecules that serve as major metabolic fuels, important components of
biological membranes and signaling molecules, and play significant roles as gene
regulators. The regulation of lipid metabolism is thus crucial for whole-body energy
homeostasis. Since the amount of available nutrients do not always match their energetic
demands, it is important that living organisms continuously adapt their metabolism to
their nutritional status, such that energy intake and expenditure remain adjusted.
Unfortunately, the rate of fat oxidation is not necessarily determined by the amount of fat
intake, but rather by the energy gap resulting post carbohydrate metabolism (203).
Therefore the regulation of lipid metabolism in mammals is complex in nature. It consists
of a short/rapid component involving rapid modulation of protein activity/stability (by
allosteric means or post-translational modifications) and a long-term component
involving transcription factors.
PPARα is a ligand-activated nuclear transcription factor that plays an important
regulatory role in cellular processes such as fatty acid metabolism, glucose metabolism,
inflammation, differentiation and proliferation (7-10). In 2015 we will be celebrating the
25th year anniversary of the PPARα discovery. Initially isolated as a receptor that serves
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as a target for a diverse class of peroxisome proliferators in rodents, today it is regarded
as a lipid sensor that regulates the expression of several proteins/enzymes involved in
fatty acid metabolism. Although fatty acids and their derivatives has been shown to
activate PPAR of several species including mouse PPARα (mPPARα) (8, 108, 110,
113-117), the identity of high-affinity endogenous ligands for human PPARα (hPPARα)
have been more elusive. In order to understand the molecular role of dietary LCFA in
human PPARα mediated regulation of energy homeostasis we set out with two main
goals for this dissertation: 1) to determine whether LCFA and LCFA-CoA constitute
high-affinity endogenous ligands for full-length hPPARα and 2) to investigate whether
there exist differences in such affinity between hPPARα and mPPARα. The main
outcomes and conclusions of this dissertation are discussed below:
LCFA and their thioesters serve as high affinity physiological ligands for PPARα
–metacrine signaling and transcriptional control. For the first time we demonstrated that
LCFA and LCFA-CoA represent high affinity ligands for full-length recombinant
hPPARα. Such binding occured at physiologically relevant concentrations (Kd = 11-40
nM) and was associated with strong secondary structural changes in the protein
(hallmarks of nuclear receptor ligand binding). Ligand binding also resulted in a PPARαdependent transactivation of the ACOX PPRE-luciferase reporter in COS-7 cells,
suggesting that these ligands could in fact activate PPARα in vivo. While it is
acknowledged that PPARα has evolved as a lipoid sensor that regulates the expression of
target genes involved in lipid metabolism (111, 114, 121), the identification of LCFA and
LCFA-CoA as ligands for PPARα further substantiates our knowledge on PPARα
function. Such a link between nutrient/metabolite and transcriptional regulation has been
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long appreciated in bacteria. For example, the lac repressor in bacteria binds a lactose
metabolite (allolactose) and coordinates the synthesis of the enzymes required for the
breakdown/catabolism of lactose or its metabolites (204). It is possible that such
allosteric regulation is in place in higher organism as well. For example, LCFA or their
metabolites bind PPARα and induce feed-forward activation or feedback inhibition in the
expression of genes involved in their metabolism. The first evidence or proof for such
theory came from genetically engineered mouse models. For example, in ACOX knockout mice (ACOX-/-; first enzyme involved in β-oxidation) there is accumulation of
PPARα ligands (LCFA and LCFA-CoA) and hyperactivity of PPARα because these
ligands cannot enter the β-oxidation pathway (121). Also, peroxisomal bifunctional
enzyme (second enzyme involved in β-oxidation) knockout mice have up-regulated
PPARα target genes because intermediates of peroxisomal β-oxidation serve as PPARα
ligands (205). Liver-specific fatty acid synthase (FAS; first enzyme involved in fatty acid
biosynthesis) knockout mice on a zero-fat diet exhibit severe hypoglycemia and fatty
liver similar to the PPARα knockout mice phenotype (206). These effects were reversed
upon administration of either dietary fat or a PPARα agonist (206). All these findings
along with our results further confirm the role of PPARα as a lipid sensor.
While in most studies, LCFA and LCFA-CoA activate PPARα, Murakami et al.
suggested that LCFA-CoA interact with PPARα and have an inhibitory effect on PPARα
activity (84). Assuming that this is the case, it is possible that metabolites such as LCFACoA could increase or decrease PPARα activity depending on the target gene or the
effect desired. For example, LCFA are rapidly converted to LCFA-CoA by an enzyme
called long chain acyl-CoA synthase 1 (ACSL1) - a PPARα target. It is possible that
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while LCFA induces the expression of ACSL1 (through a PPRE in its promoter),
depending on the relative ratio of LCFA/LCFA-CoA, LCFA-CoA may repress ACSL1
by a negative feedback mechanism. Although this possibility has not been tested in this
dissertation, it will be interesting to test this angle of nutrient mediated PPARα regulation
of target genes. It is necessary to mention that the inhibitory activities of LCFA-CoA
reported by Murakami et al. were derived on the basis of their inability to recruit a
coactivator peptide of SRC-1 to the hPPARα-LBD. Since only one coactivator peptide
was tested for binding to hPPARα-LBD in response to LCFA-CoA binding (no fulllength coactivator or protein), the significance of these findings are not clear. It is
possible that LCFA-CoA bound PPARα recruits SRC-1 to the coactivator binding motif
on the A/B domain (PPARα-LBD used in these studies) as discussed in the introduction
of this dissertation. Alternatively, LCFA-CoA bound PPARα may selectively recruit
other coactivators other than SRC-1.
Although our in vitro experiments using multiple fluorescence-based approaches
and CD spectroscopy demonstrated binding of both LCFA and LCFA-CoA to hPPARα,
data from our transactivation assays did not differentiate the effects of LCFA on hPPARα
activity from that of LCFA-CoA. One way to do this would be to use cells that do not
express long chain acyl-CoA synthase (ACSL) - the cellular enzyme that converts LCFA
to LCFA-CoA. However, there are 5 isoforms of ACSL numbered as 1, 3, 4, 5 and 6 that
belong to a much larger family of acyl-CoA synthases (26 members including ACSLs)
(207, 208). Owing to the many isoforms of this protein, it will be challenging to knockdown the activity of this enzyme. Another way to approach this problem is to
pharmacologically inhibit ACSL activity in the cell by using inhibitors such as triascin C
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(209). Such experiments involving the use of triascin C attempted in our lab as well as by
others, resulted in significant cell death (unpublished data Ms. Jeanette Loyer, Hostetler
lab and (210)). Another way that one might address this issue is to treat cells with nonmetabolizable forms of LCFA (e.g. bromopalmitic acid) and LCFA-CoA (e.g. Shexadecyl-CoA) and determine the expression of PPARα target genes such as ACSL1.
While this approach has not been tested in this dissertation, it will be interesting to
determine 1) whether these ligands bind with equivalent affinity as the natural ligands
and 2) whether these ligands exhibit any difference in PPARα mediated transactivation
(using the ACOX PPRE×3 reporter construct) or gene expression.
It is essential to mention that all ligand binding studies in this dissertation were
carried out using recombinant full-length forms of human and mouse PPARα. These
proteins were expressed in bacteria and subsequently purified using affinity
chromatography. That being said, an important consideration must be given to the fact
that since these proteins were expressed in bacteria, they may lack post-translational
modifications that are commonly seen in eukaryotic organisms. PPARα undergoes posttranslational modifications in the form of phosphorylation (211), ubiquitination (212) and
SUMOylation (213). While it is not clear whether post translational modifications have
any observable effects on ligand binding, such modifications definitely have an impact on
the activity of PPARα. For example, phosphorylation increases the ligand-induced
transcriptional activity of PPARα, whereas SUMOylation decreases it. However, posttranslational modifications mainly influence PPARα activity through preferential
recruitment of cofactors (coactivators or corepressors) (211, 213). Likewise ligand
binding also influences the occurances of post translational modifications. For example
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ligand binding decreases PPARα ubiquination and SUMOylation (214). Recombinant
proteins have been widely used to study various aspects of PPARα function for a long
time. Although we cannot rule out the effect of post-translational modifications on ligand
binding, data from transactivation assays done in COS-7 cells (where post-translational
modifications could occur) corroborate and confirm ligand mediated activation of
PPARα.
We utilized the ACOX PPRE×3 reporter construct in all our transactivation
assays. Although this reporter has been widely used to test the PPARα activity, it
represents an artificial reporter system where three copies of the ACOX PPRE along with
the thymidine kinase (TK) minimal promoter have been cloned upstream of a firefly
luciferase gene (39, 180). Such reporter assays essentially determine whether a nuclear
receptor (PPARα) can activate or repress gene transcription (in response to ligands) when
it binds to its response element (PPRE) (215). Since sequences around the PPRE could be
a determinant in PPARα specificity (29, 43), it will be interesting to see how LCFA
ligands affect the transcription of the luciferase gene driven by a much larger promoter of
a PPARα target gene. Alternatively, it would also be interesting to determine the actual
transcript or protein levels of PPARα target genes upon administration of such ligands.
LCFA and their thioesters serve as high affinity physiological ligands for PPARα
– binding affinity number considerations. In addition to demonstrating the binding of
LCFA and LCFA-CoA to hPPARα, we also report binding affinities for such ligands.
The interaction of ligands with their binding site on the receptor is characterized in terms
of binding affinity. Higher binding affinity means that a lower concentration of ligand is
sufficient to maximally occupy all the binding sites. Binding affinity is represented in
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terms of a dissociation constant or Kd – the concentration of the ligand at which 50% of
the receptor binding sites are occupied (178). Binding affinity numbers reported here for
LCFA and LCFA-CoA interaction with full-length PPARα are consistent with the
physiological concentrations of these ligands in the cell (88, 95, 117, 118, 120, 152). This
comparison of receptor-ligand binding affinity and physiological concentration of the
ligands serves as a guideline to confirm the relevance of the ligand for receptor function.
For example, vitamin D receptor (VDR) binds vitamin D at nanomolar concentrations
(consistent with cellular concentrations), but it is also activated by bile acids at much
higher concentrations (216). It is possible that bile acids either do not represent true
ligands for VDR (or bring about VDR activation indirectly) or VDR may have some
other functions in the gut where the concentration of bile acids could be considerably
higher than other organs (216). In a similar manner, LCFA and LCFA-CoA may activate
PPARα in tissues with high involvement in fat metabolism and/or nanomolar
concentrations of these ligands (such as liver, muscle, heart, adipose) but they may not
play a role in other tissues which are not as dependent on fat metabolism, such as the
brain (152, 217).
In the case of drug molecules, binding affinity numbers are indicative of drug
specificity and efficacy, and it helps determine the effective dose of the drug. Along with
structure-activity relationship, binding affinity numbers help design better drugs with
selective affinity to the targeted receptor and lesser side-effects. Knowing the binding
affinities for different fatty acids and their derivatives will help determine the kind of
competition a synthetic agonist or a therapeutic drug may encounter. The degree of
PPARα activation in vivo may not result from its interactions with a single high affinity
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fatty acid ligand but may instead arise from the pool of fatty acids and/or its metabolites.
Thus when a drug is administered (example, a PPARα agonist such as clofibrate) it has to
compete with this pool of endogenous ligands. Since the nutritional status of each
individual varies greatly owing to dietary parameters and physiological/disease state, the
anticipated therapeutic response may not be achieved in each and every individual. For
example, clinically it is observed that fibrate treatment improves the lipid profile for the
majority of the patients but there is always a fraction of patients, who do not respond to
such therapy (218). Similarly differences in responses are also observed with mice strain
variations. It is possible that in addition to genotype, diet-drug interactions could also
result in such differences in responses to therapeutic treatments. Thus, better knowledge
of these affinity numbers along with the metabolic/nutritional status of a patient will
allow for careful dose adjustments for effective therapeutic treatments.
There exist differences in activation of human and mouse PPARα in response to
saturated LCFA – species differences considerations. One of the most important
outcomes of this dissertation is the species differences in the ligand binding specificity
and affinity between the full-length forms of hPPARα and mPPARα. Species differences
in the binding of endogenous ligands for other nuclear receptors such as the estrogen
receptors have also been observed (219). Before going into depths comparing the two
full-length proteins, it is essential to compare our LCFA binding data from full-length
mPPARα to that of truncated mPPARαΔAB (lacking the N-terminal A/B domain). In
contrast to our study with full-length mPPARα, previous studies with mPPARαΔAB
indicate very weak binding to saturated and polyunsaturated LCFA (but strong binding to
their thioester derivatives) (115-117). While these differences could arise from
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differences in the protein preparation or techniques used, it should also be noted that one
of the main differences lies in the fact that these data were generated using truncated
form of PPARα (115-117). The N-terminal A/B domain of PPARα not only contributes
to transcriptional activity of PPARα (30, 31) but also determines DNA binding (31) and
ligand specificity (34). Mutations of residues in the A/B domain (particularly S112)
altered ligand binding and activity (function of E/F domain) of PPARγ (34). Berbaum et
al. also reported differences in coactivator recruitment and fibrate-induced transcriptional
activation between the full-length and LBD forms of PPARα (153). These results provide
evidence to the interdomain communications between the various domains structures of
the protein.
We have reported significant differences in the ligand binding affinities and
activity of hPPARα and mPPARα in response to saturated LCFA. A careful examination
of the existing literature demonstrated that: 1) species differences in the activity of human
and mouse PPARα in response to synthetic agonists such as WY-14,643 have been
observed by others researchers (158, 160-163, 187, 199) and 2) differences in the target
gene profiles and activity of human and mouse PPARα have also been reported (158,
160-163, 187, 199). Since the discovery of peroxisomal proliferators, it has been
established that long-term administration of PPARα agonists result in hepatic cancer only
in rodents (102). Further, transgenic mice that express human PPARα mainly in the liver
do not exhibit liver tumors upon administration of PPARα agonists (149, 150). All these
observations suggest that structural differences in the PPARα protein could be one
possible underlying cause of such species variation. Owing to the use of the rodent
models for toxicological evaluation of therapeutics, and the importance of PPARα as a
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pharmaceutical target, we decided to focus on the structural aspects of the human and the
mouse protein to explain possible mechanisms of such differences.
Comparison of the primary sequence of PPARα from more than 100 vertebrate
species demonstrated that they harbor the same amino acids at 314 and 464 (tyrosine) that
participate in direct hydrogen bonding interactions with synthetic agonists as well as
LCFA ligands. Despite these similarities, there were differences in the binding affinities
as well as binding energies for interaction of human and mouse PPARα with saturated
LCFA (palmitic and stearic acids). This suggested that other amino acid residues may
also play a role in ligand specificity. Using the strategies of molecular modeling, docking,
pocket volume estimations and mutagenesis, we were able to narrow down two amino
acid residues at 272 and 279 as crucial determinants of such ligand specificity. The amino
acid residue at 272 (isoleucine in human and phenylalanine in mouse) was especially
critical for determining ligand specificity for saturated LCFA. These findings were
consistent with other researchers who have also demonstrated similar species differences
with PPARα (158, 160-163, 187, 199).
While it is still not clear is why such differences would exist, one hypothesis
includes the nuclear receptor evolution of ligand binding capacity. It is speculated that
nuclear receptors evolved from a common ancesteral orphan receptor (no ligand) (184,
200, 201). During the course of evolution, emerging nuclear receptors acquired ligandbinding capacities and underwent very subtle changes (typically due to just a few
mutations) resulting in further refining their specificities for a given ligand (184, 200,
201). Except for rats and mice, the isoleucine at 272 in hPPARα is highly conserved
across more than 100 vertebrate species. Owing to the high evolutionary rate of PPARα
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(184, 200, 201), one could speculate that the receptor underwent evolutionary adaptations
by mutations in response to a different range of ligands in different species. While it is
not obvious what could have been the source of such adaptation, dietary changes have
also been proposed to be one of the strong driving forces for such adaptation (220). For
example, the persistence of lactase expression in populations with a long history of milk
consumption (220). It is tempting to speculate that genes that were directly affected by
dietary changes came under strong selective pressures which eventually lead to crucial
structural and functional changes (example I272F).
With that being said, the bigger question that one needs to address is whether the
rodent model is ideal for studying proteins with such species diversity. Mice as a model
system have several advantages. For example, 1) their genome is fairly similar to the
human genome, 2) their small size facilitates high through-put studies in a cost effective
manner and 3) the availability of genetically engineered mice (such as the PPARα -/mice) provides a wealth of information on disease processes (and functional aspects of
the PPARα protein). However, there are also drawbacks – they are not humans (221). In
addition to structural and functional differences in the mouse and human forms of
PPARα, long-term administration of PPARα agonists results in rodent specific
hepatocarcinogenesis (102). Since amino acid residues at 272 and 279 in the PPARα
ligand binding domain are crucial determinants of ligand specificity, quantitative
structure activity relationship must be utilized extensively to screen potential PPARα
drug candidates that are more specific for the human form of the protein. Further, in order
to carry out pharmacological and toxicological evaluation of potential PPARα drug
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candidates, other model organisms (which do not display such diversity) or humanized
mouse models of PPARα should be employed.
In conclusion, fatty acids are essential dietary components that serve as metacrine
signals transducing metabolic parameters into regulatory events. Elevated levels of
triglycerides or fatty acids are a major component of obesity and its co-morbidities
including the metabolic syndrome. PPARα serves to sense the total flux of fatty acids and
regulate various metabolic pathways associated with fatty acid metabolism. The
importance of PPARα in human disease is validated by the lipid lowering effects of
synthetic PPARα agonists. Our data suggests that LCFA serve as high affinity ligands for
PPARα and thus help regulate lipid homeostasis. However special consideration must be
given to differences in ligand binding specificity and affinity between mouse and human
PPARα. Our results, along with others, call for careful interpretation and extrapolation of
data that use mouse as a model for studying this protein. Further, they emphasize on the
need to develop drugs that have greater specificity for human versus rodent PPARα.
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Abstract
Adiponectin is an adipocyte-secreted adipokine that has attracted much attention due to
its salutary effects on obesity related cardiovascular complications. Adiponectin plays a
large role in maintaining energy homeostasis by interacting with its receptors to increase
fatty acid oxidation, glucose uptake and decrease gluconeogenesis. Recent studies have
reported adiponectin expression from other tissues such as heart, liver and muscle, where
it is believed to act in a local manner to regulate homeostasis. In addition, numerous
studies have reported decreased expression of adiponectin associated with cardiovascular
and metabolic complications. Clinical and preclinical studies have suggested regulation
of adiponectin by PPAR α and γ agonists. While PPARγ agonists are thought to act by
mediating adipogenesis and transactivating adiponectin, the role of PPARα and its
underlying mechanisms in regulating the expression of adiponectin is not clear. PPARα
binds endogenous ligands (long chain fatty acids (LCFA)) as well as exogenous ligands
(fibrates) to regulate the transcription of genes involved in fatty acid oxidation. The goal
of this study was to determine whether ligand-activated human PPARα regulates the
expression of adiponectin in cultured human hepatoma cells (HepG2). Although not
convincing, data from electrophoretic mobility shift assays (EMSA) and transactivation
assays suggest that PPARα may bind PPRE sequences in the adiponectin promoter and
may contribute towards regulation of the adiponectin gene (either directly or indirectly).
Since we were not able to detect the expression of adiponectin in HepG2 cells, future
studies investigating the role of PPARα in adiponectin regulation must be carried out in a
cell line that constitutively expresses adiponectin.
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Introduction
Obesity is defined as an increased mass of adipose tissue and is a major risk factor
for coronary heart disease, hypertension, atherosclerosis, dyslipidemia and diabetes (1).
The prevalence of obesity is associated with a surge in the metabolic syndrome in
industrialized or developing countries (2, 3). For this reason, there has been a great
scientific interest in studying the physiology of the adipose tissue. The adipose tissue has
been traditionally considered as a site of triglyceride (TG) storage and free fatty acid
release in response to increased energy demands (1, 4). However in the past decade,
adipose tissue has been recognized to have endocrine functions regulating energy
homeostasis and inflammation by releasing a number of biologically active peptides. The
term adipokine or adipocytokine was coined to describe these signaling messengers that
are secreted by the adipose tissue, some of which include leptin (5), resistin (6), tumor
necrosis factor α (TNFα) (7) and adiponectin (8-11).
Adiponectin was originally reported independently by four groups using different
approaches and is also referred to as AdipoQ (11), Acrp30 (30 kDa adipocyte
complement related protein) (8), apM1 (adipose most abundant gene transcript) (9) and
gelatin binding protein of 28 kDa (GBP28) (10). Today, the most widely accepted name
is adiponectin, which will therefore be used hereafter. The human adiponectin is a 30 kDa
and 247 amino acid protein that consists of an N-terminal signal sequence/peptide (SS), a
hypervariable region (VR), a collagenous domain and a C-terminal globular domain (11,
12) (Fig. 32). The collagenous domain consists of 22 Gly-X-Y repeats (where X and Y
are any amino acid) along with prolines and lysine residues that are subjected to posttranslational modifications including glycosylation and hydroxylations (11). The
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carboxy-terminal globular domain on the other hand is similar to complement factor C1q,
VIII and X and also bears structural homology (but no amino acid sequence homology)
with TNFα (12).
The human adiponectin gene spans a length of 17 kb and is localized to
chromosome 3q27, a region highlighted as a genetic susceptibility locus for type 2
diabetes and metabolic syndrome (13). Its transcript is most abundantly found in
adipocytes and consists of three exons and two introns (14). It exists abundantly in
human blood (5-30 μg/ml) forming about 0.05 % of all plasma proteins and the molar
concentration of 5 µg/ml adiponectin in human plasma corresponds to approximately 3
nM (8-11). Adiponectin circulates in the blood predominantly in three different
oligomeric forms – trimer, hexamer and high molecular weight oligomer (12-18
protomers; Fig. 32). Three adiponectin monomers come together via hydrophobic
interactions in the globular domain to form a trimer, which is also referred to as the low
molecular weight adiponectin (LMW). Two trimers then associate to form hexamers
(medium molecular weight; MMW) and high molecular weight oligomers comprised of
12-18 protomers/monomers (high molecular weight; HMW) (8-11). The disulfide bridges
formed by cysteine residues at position 39 are responsible for the oligomerization of
adiponectin and mutation of this residue (C39S) abolishes the formation of such
oligomers (15). Post-translational modifications in the collagenous domain are also
required for the assembly of the HMW oligomers (16).
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Fig. 32 - Primary structure of adiponectin consisting of signal sequence (SS),
hypervariable region (VR) collagen-like domain prolines (P) and lysines (K) and Cterminal globular domain. Multimer formation of adiponectin where monomer forms
trimer (hydrophobic interactions) and trimers come together to form hexamers and high
molecular weight oligomers (disulphide bonds via C39). Figure modified from (17)
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While it is speculated that different forms of adiponectin (monomeric, trimeric,
oligomeric) have distinct tissue specific levels biological activities, many of these results
are controversial and not clear at this stage. For example, several studies indicate that the
HMW form of adiponectin is the most bioactive form of adiponectin (18-20). Kadowaki
at al. have reported that populations with rare mutations in the adiponectin gene (G90S,
G84R) have lower levels of HMW adiponectin and are associated with insulin resistance
and type 2 diabetes (18). While these findings suggest that HMW may be the most
bioactive form of adiponectin, mutant recombinant adiponectin (G90S, G84R) expressed
in NIH-3T3 fibroblasts fail form the HMW multimers (18). Thus lower levels of HMW
oligomers in these populations could just be a result of impaired multimerization.
Besides, other researchers have suggested that monomeric or trimeric forms of
adiponectin may be important in mediating the pleotropic effects of adiponectin in
skeletal muscles (19, 21-23). Since the significance of the different oligomeric forms of
adiponectin are not clear, the total plasma adiponectin measurements are the most
commonly reported (24).
Irrespective of their oligomeric state, adiponectin exerts its effects by binding to
two isoforms of adiponectin receptors (AdipoR) – AdipoR1 and AdipoR2. While the
AdipoR1 gene encodes a 42.4 kDa and 375 amino acid protein, the AdipoR2 gene
encodes a 311 amino acid protein of 35.4 kDa (25). These proteins bear about 67%
sequence homology and they also share about ~95 % homology between mice and
humans. As far as the expression of these receptors is concerned, they are ubiquitously
expressed, with the expression of AdipoR1 highest in skeletal muscle and AdipoR2
highest in the liver (25, 26). Structurally, both AdipoR1 and AdipoR2 contain seven
204

transmembrane domains but are distinct from G protein coupled receptors (GPCR) in
structure and function. Unlike GPCRs, adipoR1 and adipoR2 have inverted membrane
topologies with an extracellular C-terminal domain and an intracellular N-terminal
domain (25). The expression of the adiponectin receptors is speculated to be regulated by
various factors including the presence of adiponectin, insulin (27), and nuclear receptors
such as PPARα and PPARγ (28-31). However, the cause/effect relationship of such
regulation is largely unknown. For example, the increase in levels of adiponectin
receptors observed with a PPARγ agonist could be result of increased expression of
adiponectin or vice versa (31).
In the past decade, adiponectin has attracted much attention due to its beneficial
effects on obesity-related cardiovascular and metabolic complications. Upon binding to
its receptors, adiponectin mediates a cascade of intracellular signaling events, including
the activation of adenosine monophosphate (AMP)-activated protein kinase (AMPK) – a
key enzyme involed in maintaining cellular energy homeostasis. AMPK is activated
under conditions of reduced cellular ATP or increased levels of AMP (32). Activation of
AMPK on one hand stimulates ATP generating processes such as fatty acid oxidation and
glycolysis, it also shuts down ATP consuming processes such as lipogenesis (32). For
example, under conditions of starvation/fasting fatty acids are mobilized from the adipose
tissue along with activation of AMPK in the liver and skeletal muscles – resulting in ATP
generation from fatty acid oxidation (32). These effects are very similar to the pleotrophic
effects caused by PPARα agonists. It is tempting to speculate that PPARα, in addition to
its role in lipid metabolism, may also upregulate adiponectin and cause additive effects
on fatty acid oxidation and inflammation pathways (via adiponectin).
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Recently, it was suggested that an adaptor protein containing a pleckstrin
homology domain, a phosphotyrosine domain and a leucine zipper motif (APPL1)
mediates the intracellular signaling events that occur following binding of adiponectin to
its receptors (33, 34). APPL1 binds to the intracellular N-terminal part of adiponectin
bound AdipoR and mediates the activation of AMPK (33, 34). The net result of AMPK
activation includes increased fatty acid oxidation (due to increased activity of carnitine
palmitoyl transferase), glucose uptake (increased activity of insulin receptor substrate and
GLUT4 glucose transporter), production of nitric oxide (activation of nitric oxide
synthase) and decreased gluconeogenesis (suppression of gluconeogenic enzymes) and
diminished activity of nuclear factor κ B (NfκB; due to activation of inhibitory κ B) (26,
32, 33).
Indeed adiponectin exhibits cardioprotective, antidiabetic, antiatherosclerotic and
anti-inflammatory effects (26, 33, 35, 36) and this is further supported by decreased
circulating levels of adiponectin observed in patients with obesity (37, 38),
cardiovascular diseases (39-42), hypertension (26, 40, 43), type 2 diabetes (38, 44) and
metabolic syndrome (26, 36, 45). Conversely, it has been observed that increased plasma
adiponectin levels are associated with a lowered risk for obesity related co-morbidities
(46, 47). Consistent with clinical observations, adiponectin deficient mice are prone to
atherosclerosis, hypertension, hyperglycemia, insulin resistance and also show delayed
clearance of free fatty acids from plasma (35, 43, 48, 49). The levels of adiponectin are
also downregulated in mice models of obesity and type 2 diabetes (48, 50-52). Further,
administration of recombinant adiponectin in these mice improves insulin sensitivity,
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glucose tolerance, increases fatty acid oxidation, glucose uptake and decreases
gluconeogenesis (48, 53).
Consistent with the association of hypoadiponectinemia with obesity and its comorbidities, several single nucleotide polymorphisms (SNPs) in the adiponectin gene are
also associated with aspects of metabolic disorders (54). The most commonly identified
SNPs in the adiponectin gene locus include T → G transversions at codon 45 and 276
(55, 56). These SNPs are associated with obesity, insulin resistance, type 2 diabetes,
altered blood pressure, coronary artery disease and dyslipidemia (54-56). Owing to all
these experimental and clinical investigations, adiponectin has emerged as a potential
pharmaceutical target and/or a biomarker in the context of a spectrum of metabolic
disorders. Administration of recombinant adiponectin in preclinical models has resulted
in improved metabolic parameters that combat insulin resistance, obesity related
disorders and inflammation (48, 53). However, production of recombinant adiponectin on
a large scale, along with its short half-life (1 hour in mice and 2 hours in humans (57))
and high circulation levels, makes it difficult to obtain high levels of the protein at a
reasonable price (24). Thus, strategies that would improve/increase the expression of
adiponectin (or its signaling) or prevent its down-regulation could result in improvements
in insulin sensitivity, decrease cardiovascular risk and reduction in many parameters of
obesity-linked disorders.
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Development of hypothesis
Based on the clinical and preclinical evidence from above and numerous other
epidemiological studies (58), hypoadiponectinemia is an independent risk factor for
obesity-related disorders including cardiovascular diseases, atherosclerosis, dyslipidemia
and type 2 diabetes – most of which are coupled with metabolic imbalances with respect
to fatty acid metabolism. For example, elevated fatty acids are associated with metabolic
and cardiovascular complications that also foresee decreased expression of adiponectin.
Thus “factors” regulating fatty acid metabolism may play an important role in the
regulation of adiponectin. The adiponectin gene contains several putative transcription
factor binding sites and is thus speculated to be under complex regulation by various
upstream signals (59). Amongst binding sites for other transcription factors such as
CCAAT/enhancer binding protein (C/EBP) (59), adipocyte determination and
differentiation-dependent factor 1/Sterol regulatory element-binding protein 1c
(ADD/SREBP1-c) (60) and cAMP response element binding protein (61), the
adiponectin promoter also contains binding site for the peroxisome proliferator-activated
receptors (59).
As discussed in the earlier portions of this dissertation, the peroxisome
proliferator activated receptors (PPAR; α, β/δ and γ) are a class of ligand dependent
nuclear transcription factors that play crucial roles in the transcriptional regulation of
energy metabolism and homeostasis (62-65).

While PPARα (expressed predominantly

in liver, heart, muscle) and PPARβ/δ (expressed predominantly in intestines and
keratinocytes) are potent activators of genes involved in fatty acid oxidation, PPARγ
(expressed predominantly in adipose tissue) activates genes involved in lipogenesis and
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adipocyte differentiation (62-65). A substantial body of evidence has suggested that
PPAR α and γ agonists increase the expression of adiponectin (52, 66-73). While the
mechanism by which PPARγ agonists induce the expression of adiponectin mainly
includes adipogenesis and transactivation of adiponectin gene (67, 74), the role of
PPARα and its underlying mechanisms in regulating adiponectin is unclear.
A direct role of PPARγ in adipogenesis was suggested based in two main forms of
evidences: 1) the expression of PPARγ was very low in preadipocytes cell lines (such as
3T3-L1) but its expression surges when these cell lines undergo differentiation (even
before other differentiation markers such as activating protein 2; aP2) (75) and 2) PPARγ
agonists such as thiazolidinidiones were able to promote the differentiation of
preadipocytes to adipocytes (76). The secretion of adipocytokines from the adipose tissue
is a function of the adipocyte state/size (74). While smaller adipocytes secrete insulin
sensitizing and anti-inflammatory molecules such as adiponectin, larger hypertrophied
adipocytes secrete inflammatory molecules such as TNFα (74). As potent inducers of
adipogenesis, PPARγ agonists are capable of promoting the secretion of adiponectin. In
addition, Iwaki et al. demonstrated that PPARγ may also transactivate the adiponectin
gene and thereby induce the expression of this protein (67).
There is very little information regarding the role and involvement of PPARα in
the expression of adiponectin. Clinical and preclinical studies have demonstrated that
administration of PPARα specific agonists (fibrates) results in pleotropic increases in the
expression of adiponectin (69-71, 73, 77). Such an effect was not observed in PPARα
deficient adipocytes or PPARα knockout mice (PPARα-/-) (73). In fact, even the basal
expression of adiponectin in PPAR-/- mice and diet-induced obese mice was significantly
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lower when compared to age matched wild-type littermates (52, 57, 78). Administration
of PPARα agonists promotes revascularization in response to ischemia in an
AMPK/endothelial nitric oxide synthase (eNOS) dependent manner (downstream
effectors of adiponectin) – an effect that was abrogated in adiponectin knockout mice
(71). Further, Hiuge et al. demonstrated that the fibrates (PPARα agonists) induce the
expression of adiponectin in white adipose tissue of mice and that this effect was
abolished in PPARα -/- mice (73). All these findings suggest that PPARα plays a direct
role in the regulation of adiponectin expression, particularly in pathological states such as
diabetes, obesity and dyslipidemia.
While the adipose tissue serves as a primary source of adiponectin, Maddineni et.
al. demonstrated that in chickens, the pituitary gland, liver, skeletal muscle, kidney, ovary
and spleen can also secrete adiponectin (79). Similar to these observations, in humans
and rodents its expression was also found in tissues other than the adipocytes. These
include the bone marrow (80), osteoblasts (81), fetal tissue (82), skeletal muscle (83),
cardiomyocytes (84-87), salivary glands (88) and the liver (89, 90). These findings
suggest an autocrine or paracrine role of adiponectin in these tissues. In fact, cardiac
adiponectin is demonstrated to act in an autocrine/paracrine manner (independent of
serum levels) to regulate cardiac metabolism and functionality, and that deregulation of
this could be a determinant in the development of various cardiac pathologies (84, 87,
91). For example, cardiac adiponectin has been shown to protect against myocardial
ischemia-reperfusion injury and hypertrophy (87, 91). In addition, Skurk et. al. have
further demonstrated that cardiac adiponectin is downregulated independent of its serum
levels in diabetic cardiomyopathy (84). There is compelling evidence which supports the
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role of PPARα and adiponectin as regulators of energy homeostasis. However, the
regulation of a local adiponectin system at the level of the liver has not been explored yet.
Kaser et al. reported no correlation between circulating adiponectin levels and liver
adiponectin expression in patients with steatohepatitis (89). Considering the predominant
expression of PPARα in the liver and its important role in lipid homeostasis (62-65), it
may play a significant role in the possible regulation of adiponectin at the level of the
liver.
Elevated long chain fatty acids (LCFA) are associated with metabolic and
cardiovascular complications that also foresee decreased expression of adiponectin. The
fact that LCFA have been suggested to be ligands for PPARα (92, 93), implicates an
important role of ligand-activated PPARα in the regulation of adiponectin. We thus
hypothesize that LCFA that serve as ligands for hPPARα regulate the expression of
adiponectin in HepG2 cells (human hepatoma cells). Therefore, the main goal of this part
of the dissertation was to determine whether ligand-activated hPPARα directly regulates
the expression of adiponectin in HepG2 cells. It is likely that endogenous ligands found
in Chapter I of this dissertation could have a profound effect on the expression of
adiponectin. The outcome of this research could help explain the importance of dietary
nutrients and their correlation to differential transcription, expression or activity of
proteins involved in the pathophysiology of the metabolic syndrome.
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Materials and Methods
Chemicals: While fatty acid ligands and clofibrate were purchased from SigmaAldrich (St. Louis, MO), bovine serum albumin (lipid-free) was obtained from Gemini
Bioproducts (Sacramento, CA). Rosiglitazone (LKT labs) was a kind gift from Dr
Khalid Elased.
Electrophoretic mobility shift assays (EMSAs): Promoter analysis for adiponectin
revealed two putative PPRE at -2345/-2358 (PPRE1) and -335/-368 (PPRE2) base pairs
upstream of the transcription start site. Gel-shift assays were performed to measure the
DNA-binding ability of hPPARα-hRXRα heterodimers in the presence and absence of
ligands using in vitro reactions. Purified recombinant hPPARα was purified as described
in chapter I of this dissertation. The bacterial expression plasmid for full-length hRXRα
(6xhis-GST-hRXRα) was produced by Dr. S. Dean Rider, Jr. (Wright State University)
and the recombinant hRXRα protein purification was conducted by Ms. Frances Soman
(Hostetler Lab). Double-stranded oligonucleotides spanning from -2337/-2366 and -327/376 were obtained from the adiponectin promoter. Additional mutant oligonucleotides
were also be generated to confirm the binding of the heterodimeric complex to the
putative PPRE tested. Double-stranded oligonucleotides of the following sequences were
used:

wild-type

adiponectin

PPRE

1,

5’

–

CAGACTCCTGACCTCAAGTGATCTGCCCG-3 and wild-type adiponectin PPRE 2,
5’ -TGTGGTTTTGACTTTTGCCCCATCTTCTG-3; mutant adiponectin PPRE 1, 5’ –
CAGACTCCCTTAATGGTCTGATCTGCCCG – 3 and mutant adiponectin PPRE 2, 5’
– TGTGGTTTCATATATGTCGACATCTTCTG – 3’. In vitro reactions containing 39
nM of each recombinant protein (hPPARα and hRXRα) along with 2.1 pmol of double
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stranded oligonucleotides (wild-type or mutant) in 13 mM Tris pH 8.0, 40mM KCl, 35
mM NaCl, 1 mM dithiothreitol, 0.1 mM EDTA, 0.05 % nonidet P-40 and 8 % glycerol
were incubated at room temperature for 20 minutes, cross-linked and loaded onto 7%
nondenaturing polyacrylamide gels. The gels containing separated DNA, protein or both
were stained using an EMSA kit (Molecular Probes, Eugene OR) containing two
fluorescent dyes for detection, SYBR Green EMSA stain (DNA) and SYPRO Ruby
EMSA stain (Protein). The bands were visualized on the Fujifilm LAS 4000 and
quantified densitometrically using Image J.
Cell culture and treatments: HepG2 cells (ATCC, Manassas, VA) cultured in
Eagle’s minimum essential medium (EMEM) with 10% fetal bovine serum (FBS) at
37°C with 5% CO2 in a humidified chamber were used in this study. Cell were seeded
onto 6-well culture plates and upon reaching 70-80% confluency, media was replaced
with serum-free media followed by incubation for 2 hours. Next, confirmed hPPARα
ligands (stearic acid, C18:0; oleic acid, C18:1; docosahexanoic acid, C22:6; from chapter
I) were added to the media and the cells were allowed to grow for 22-24 hours. Fatty
acids were added to the cells as a complex with BSA (as described in chapter I of this
dissertation) and clofibrate and rosiglitazone (controls; solubilized in DMSO) were added
directly to the media. Although each ligand was examined at 10 µM, a dose of 100 µM
was also tested initially. This was followed by determination of adiponectin mRNA and
protein levels by qRT-PCR and Western blotting.
RNA isolation and qRT-PCR: Total RNA was extracted using the Taqman® Cellsto-CT kit (Ambion, Grand Island, NY) and reverse transcribed at 37°C for 60 minutes
followed by 95°C for 5 minutes on a Multigene thermocycler (Labnet International Inc.,
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Edison NJ). The expression of adiponectin, PPARα (control) and 18S rRNA (internal
control) was determined using the Taqman® Gene Expression Assays On Demand™
designed for these specific genes (human adiponectin, Hs00605917_m1 FAM ;hPPARα,
Hs00947536_m1 FAM; 18S, Hs99999901_s1 FAM). Briefly, 4 µl of each reverse
transcribed product served as a template in a 20 µl PCR containing 16 µl of a gene
specific mastermix (10 µl Taqman® Master Mix, 1 µl of respective Taqman® Gene
Expression Assays On Demand™ and 5 µl of nuclease-free water). The PCR was carried
out on a MicroAmp 96-well plate (Applied Biosystems, Grand Island, NY) and the
amplification was a carried using a StepOnePlus thermocycler (Applied BioSystems,
Grand Island, NY). The amplification conditions included 50°C for 4 minutes, 95°C for
10 minutes, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. Cycle
threshold (Ct values) thus obtained, were used to calculate the ΔΔCt and the fold change
for each gene and treatment condition as described previously (94).
Western Blotting Analysis: HepG2 cells treated with ligands as indicated above
were lysed by sonication in a buffer containing 5 mM HEPES, 0.4% triton X, 100 mM
Na3VO4, (sodium orthovanadate) 2 U of apritinin/ml, 5 U of Leupeptin/ml and 2 U of
pepstatin/ml. Whole-cell lysates were denatured by boiling in sodium dodecyl sulfate
(SDS) sample buffer and dithiothreitol and resolved on a 12% SDS-PAGE gel followed
by electrophoretic transfer to a nitrocellulose membrane. Proteins were detected using
specific antibodies against adiponectin (Abcam, ab22554), PPARα (Santacruz, sc-9000)
and β-actin (Sigma, A5316) followed by incubation in respective secondary antibody
(Sigma, St. Louis, MO) prior to visualization by enhanced chemiluminescence on the
Fujifilm LAS 4000 (Fujifilm Medical Systems USA Inc., Stamford, CT). The relative
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amount of a given protein for each condition was examined by densitometry (ImageJ)
and compared to controls.
Plasmids: Mammalian expression plasmids for the overexpression of hPPARα
(pSG5-hPPAR and hRXRα (pSG5-hRXRα) have already been described in chapter I
of this dissertation. In order to generate luciferase constructs with the adiponectin
promoter, a 2.4 kb fragment of the adiponectin promoter containing both putative PPRE
and the minimal transcriptional machinery was amplified from cDNA derived from
HepG2 cells with the following primers: 5'- cggtaccTTCACCATCTTCGTCAGGCT-3'
and 5'- cgagctcAGACTGCAGTCAGAATGGAA -3'. In these and subsequent primers,
lowercase represents nucleotides outside of the open reading frame with restriction sites
underlined. This PCR product was cloned into the pGEM®-T easy vector (Promega
Corp., Madison, WI), sequenced to confirm amplification and subsequently cloned into
the Kpn I and Sac I sites of the pGL4.17 luciferase construct (Promega Corp., Madison,
WI) to produce pHH 83
In order to test selective PPARα activation by one or the other response element
(PPRE1 or PPRE2), mutant luciferase constructs for adiponectin promoters were also
generated with either one or both PPRE abolished. In order to mutate PPRE1, pHH 83
was

amplified

using

cggtaccTCAGACTCCTTTAAAGGTCTGATCTGCCCGCCTCAG–3’

5’–
and

5'-

cgagctcAGACTGCAGTCAGAATGGAA such that the PCR product had the
mutated/scrambled nucleotides in place of the PPRE (marked in the primer). This PCR
product was cloned into the pGEM®-T easy vector (Promega Corp., Madison, WI),
sequenced to confirm amplification and subsequently cloned into the Kpn I and Sac I
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sites of the pGL4.17 luciferase construct (Promega Corp., Madison, WI) to produce
pHH 145. In order to mutate PPRE 2, pHH 83 was used to amplify 2 PCR products
using the following primers: 5'- cggtaccTTCACCATCTTCGTCAGGCT-3' and 5’ –
TGTCGACATATATGAAACCACAGCAGGAAAACAAGA – 3’ (giving a ~2.0 kb
fragment

with

mutated/scrambled

PPRE

GGTCGACATCTTCTGTTGCTGTTGTAGGAG

2)
–

3’

and

5’

–

and

5’

–

CgagctcAGACTGCAGTCAGAATGGAA – 3’ (giving a ~300 bp fragment with a
mutated/scrambled half of the PPRE 2). Both these fragments were individually cloned
into the pGEM®-T easy vector (Promega Corp., Madison, WI) followed by sequencing
to confirm amplification. These two fragments - Kpn I/Sal I fragment (~2.0 kb) and Sal
I/Sac I fragment (~300 bp), were subsequently directionally cloned into the Kpn I and
Sac I sites of the pGL4.17 luciferase construct (Promega Corp., Madison, WI) to
produce pHH 142. To mutate both PPRE 1 and PPRE 2, pHH 142 was used to amplify
a

PCR

product

using

the

following

primers:

cggtaccTCAGACTCCTTTAAAGGTCTGATCTGCCCGCCTCAG–3’

5’–

(containing

mutated/scrambled PPRE 1) and 5'- cgagctcAGACTGCAGTCAGAATGGAA. The
PCR product with both PPRE’s mutated/scrambled and was cloned into the pGEM®-T
easy vector (Promega Corp., Madison, WI), sequenced to confirm amplification and
sub-cloned into the Kpn I and Sac I sites of the pGL4.17 luciferase construct (Promega
Corp., Madison, WI) to produce pHH 146.
Transactivation assays: COS-7 cells are derived from CV-1 cells (African
green monkey kidney cells) and have classically been used in transactivation
experiments for nuclear receptors such as the PPARs (95). In addition to having the
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basal transcriptional machinery, they have low basal expression of PPARs and have
relatively high transfection efficiencies (96). COS-7 cells (ATCC, Manassas, VA) were
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand
Island, NY) at 37°C with 5% CO2 in a humidified chamber. Cells were seeded onto
24-well culture plates and transfected with Lipofectamine™ 2000 (Invitrogen, Grand
Island, NY) and 0.4 µg of each full-length mammalian expression vector (pSG5hPPARα, pSG5-hRXRα or both) or empty plasmid (pSG5), 0.4 µg of each luciferase
reporter construct (pHH 83, pHH 142, pHH 143, pHH 146) and 0.04 µg of the internal
transfection control plasmid pRL-CMV (Promega Corp., Madison, WI) as previously
described (92, 97). Following transfection incubation, medium was replaced with
serum-free medium for 2 h, ligands (1µM) were added, and the cells were grown for an
additional 20-24 h. Fatty acids were added as a complex with bovine serum albumin
(BSA) as described (98). Clofibrate and rosiglitazone (solubilized in DMSO) were
added directly to the media. Firefly luciferase activity, normalized to Renilla luciferase
(for transfection efficiency), was determined with the dual luciferase reporter assays
system (Promega, Madison, WI) and measured with a SAFIRE2 microtiter plate reader
(Tecan Systems, Inc. San Jose, CA).

No treatment samples overexpressing both

PPARα and RXRα were arbitrarily set to 1.
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Results and Discussion
Since the discovery of PPARα, it has been postulated that one of its main
functions is to sense LCFA and/or their metabolic intermediates as ligands and induce
downstream genes that are either directly or indirectly involved in fatty acid metabolism
(62-65). Adiponectin also functions to regulate energy homeostasis by promoting fatty
acid oxidation, glucose uptake and decreasing gluconeogenesis (26, 33). Studies also
suggest that PPARα agonists (69-71, 73, 77) and polyunsaturated fatty acids (PUFA) (66,
72, 99) could induce the expression of adiponectin. Given all the background on the lipidsensing role of PPARα, we anticipated that hPPARα plays an important role in ligand
dependent regulation of adiponectin.
Electrophoretic mobility shift assays (EMSAs): PPARα-RXRα heterodimers bind
to human adiponectin PPREs. Since adiponectin promoter analysis revealed two putative
PPRE (PPRE 1, -2345/-2358 and PPRE 2, -335/-368), EMSA were performed to confirm
the binding of PPARα-RXRα heterodimers to each of the identified PPRE. While
hPPARα alone or hRXRα alone did not bind to either adiponectin PPRE, hPPARαhRXRα incubated together with either PPRE 1 or PPRE 2 resulted in retarded movement
of the DNA – suggesting binding of hPPARα-hRXRα to these PPRE (Fig. 33A). The
signal of such band was diminished by 40-50 % when hPPARα-hRXRα were incubated
with mutant forms of these PPRE (Figure 33B and 33C). According to the classical mode
of action for nuclear receptors, ligand binding induces specific conformational changes
that promote heterodimerization and DNA binding (62-65, 100, 101). Previous mobility
shift assays have not only demonstrated the binding hPPARα-hRXRα heterodimers to
DNA in absence of ligand, but have also shown that such binding was enhanced in the
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presence of synthetic agonists such as Wy-14,643 (100, 101). Thus we anticipated
differences in DNA binding in the presence of hPPARα ligands. However, the addition of
hPPARα ligands such as stearic acid (C18:0), oleic acid (C18:1), eicosapentanoic acid
(EPA) or clofibrate did not cause any significant differences in DNA binding or
hPPARα-hRXRα-DNA band intensities (Figure 33B and 33C). Based on the outcome of
these experiments, three points specifically need to be addressed here. These include 1)
binding of unliganded hPPARα-hRXRα to PPRE, 2) no significant changes in ligand
induced DNA binding and 3) only 25-45% reduction in DNA binding with the use of
mutated or disrupted PPRE.
Firstly, in vitro binding of hPPARα-hRXRα to PPRE sequences even in the
absence of a ligand has been demonstrated by a large number of studies (almost 2
decades ago) (100, 101). While such binding of unliganded receptors to specific DNA
sequences has been attributed to the independent function of the DNA binding domain
(DBD) in the nuclear receptors, Brazda et. al. recently demonstrated that nuclear
receptors are in continuous motion, such that they rapidly bind and unbind DNA. The
addition of a ligand by and large only increases their residual time on the DNA (102).
These findings help explain the binding of nuclear receptors (hPPARα-hRXRα) to DNA
sequences (PPRE sequences) even in absence of a ligand. Secondly, addition of ligands
to the in vitro reactions did not alter DNA binding. Balanarasimha et al. also demonstrate
similar findings where the binding of hPPARα-hRXRα heterodimers to the ACOX PPRE
(classical PPARα responsive gene) is not affected by ligand binding (103). It is likely that
hPPARα-hRXRα heterodimers by themselves bind very well to the PPRE (in vitro) such
that no difference in DNA binding is seen in the presence of hPPARα ligands. Van der
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Meer et. al. utilized chromatin immunoprecipitation with genomic sequencing (ChIP-seq)
and transcriptomics to demonstrate that, of all the genomic binding sites for PPARα
(corresponding to about 2875 genes) about 82% of the genes are bound by PPARα
equally

well

in

the

presence

or

absence

of

ligand

(104).

Since

transactivation/transrepression is also a function of promoter occupancy and cofactor
binding to the nuclear receptor dimeric complex, DNA binding may not be representative
of the amount of ligand induced activation/repression seen in vivo (62-65, 102).
Lastly, we have demonstrated specific binding of hPPARα-hRXRα to both
PPRE1 and PPRE2 (Fig. 33A). However, we were able to achieve only 25-45% reduction
in DNA/PPRE binding with the use of mutant PPREs (as opposed to complete ablation of
such binding). Such binding of hPPARα-hRXRα to mutated PPRE1 and PPRE2 could be
a result of some non-specific binding to the DNA. Such non-specific interactions on a
gel-shift assay have also been observed with other transcription factors and could be
attributed to the conditions used in such assays or even the degeneracy of the
oligonucleotides (67, 105). The PPRE motif belongs to the direct repeat 1 category (DR1) and consists of two repeats of a hexameric core motif, separated by one nucleotide (6265). Since DR-1 motifs (constituting the PPRE) are quite degenerate in nature (62-65),
other factors may determine nuclear receptor specificity to the DR-1 such as the 5’
flanking extension (to DR1), spacing nucleotide or assisted binding to the response
elements (via other proteins or DNA sequences) (106-108). Competition based mobility
shift assays have shown that mutated unlabelled PPRE sequences also reduce the signal
of PPAR-RXR binding to wild-type labeled PPRE sequences (although not as
dramatically as wild-type unlabelled PPRE) (67). Similarly, Van der Meer et al. reported
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the binding of nuclear receptors to DNA even the absence of a consensus DR-1 motif (in
ChIP-chip studies) (104). These occurrences may be a result of the degeneracy of the
core motif, indirect protein-protein interactions and DNA looping (in case of ChIP-chip
studies), assisted binding to the DR-1 core motif as a result of the other nuclear receptor
partner (in our case either PPARα or RXRα) or due to aberrant binding due to structural
and electrostatic end-effects (105). However, having tested only one mutant per PPRE, it
is difficult to rule out the possibility of some non-specific binding of hPPARα-hRXRα to
the PPRE.
Albeit the many drawbacks, our data suggests that hPPARα-hRXRα heterodimers
may be capable of binding the two putative PPREs in the human adiponectin promoter.
One of these PPREs (PPRE 2, -335/-368) has also been previously reported to bind
PPARγ-RXRα heterodimers (67). It is possible that based on the cell-type/organ system
and the concentrations of PPARα versus PPARγ, adiponectin may be regulated by both
these nuclear receptors. Nonetheless, the effects of hPPARα ligands on adiponectin
transactivation/transrepression still remain elusive. It will be interesting to 1) see the
outcome of competitive inhibition of hPPARα-hRXRα heterodimer binding to these
PPREs and 2) to obtain PPARα promoter occupancy data from human heptoma cells
(HepG2 cells; from van der Meer et al. (104)) particularly to determine PPARα binding
sites in the adiponectin promoter.
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Fig. 33. Electrophoretic mobility shift assays (EMSAs): Oligonucleotides containing
putative PPRE from the human adiponectin promoter (PPRE 1 or PPRE 2) were
incubated with recombinant hPPARα and hRXRα in the presence or absence of ligands.
The position shifted hPPARα/hRXRα-oligonucleotide complex was labeled with SYBR
Green EMSA stain (DNA) and SYPRO Ruby EMSA stain (Protein). A) SYBR green
staining of the two PPREs incubated in the presence of hPPARα alone, hRXRα alone or
both hPPARα/hRXRα (absence of any ligands). B) SYBR green staining of the position
shifted hPPARα/hRXRα-oligonucleotide complex in the presence or absence of hPPARα
ligands. Ligands tested include stearic acid (C18:0), oleic acid (C18:1), eicosapentanoic
acid (C20:5) and clofibrate. C) SYBR green band intensities resulting from the
hPPARα/hRXRα-oligonucleotide complex in the presence or absence of hPPARα ligands
measured using ImageJ software, and plotted as relative mean bound DNA ± SEM, n ≥ 7.
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Adiponectin expression in HepG2 cells and its regulation by hPPARα ligands:
Fewer studies have demonstrated hepatic expression of adiponectin in humans as well as
mice (89, 90, 109-111). Therefore cultured human heptoma cells (HepG2) which
represent the most widely used cellular model for human liver cells (104), were used to
study the effect of hPPARα ligands on the mRNA and protein expression of adiponectin.
While we were not able to detect adiponectin mRNA using Taqman® Gene Expression
Assays specific for human adiponectin (qPCR), western blotting using a specific antibody
for adiponectin demonstrated the presence of adiponectin protein in the cell lysates from
all treatments (Fig. 34A). Adiponectin mRNA remained undetectable under different
conditions such as overexpression of PPARα-RXRα and/or treatment with various
hPPARα ligands.
Although we did not test any positive controls validating the Taqman® Gene
Expression Assays used to detect human adiponectin, these probes have been commonly
used for detection of adiponectin mRNA in other tissues (112-114). The lack of detection
of adiponectin mRNA in HepG2 cells was unexpected, especially because we were able
to detect adiponectin protein using specific antibodies in western blotting (Fig. 34A). It
was later determined that adiponectin was present in the fetal-bovine serum (FBS)
present in the EMEM media used to grow HepG2 cells. Thus, detection of adiponectin in
the western blots from cell lysates could be an artifact resulting from contamination of
media with bovine adiponectin (from FBS; Fig. 34B).
The lack of detection of adiponectin in cultured liver cells (HepG2) in our hands
was surprising and contrary to some studies in the literature (89, 90, 109-111). However,
upon careful review of the literature, we found that our results were also in agreement
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with some other reports (115, 116). Immunohistochemistry based studies done in human
and mouse livers revealed that adiponectin expression in the liver tissue was primarily
localized to the endothelial cells of portal vessels and/or liver sinusoids and hepatic
stellate cells (115, 116). It was also suggested that this staining could be a result of some
“contamination” from circulating plasma adiponectin (115, 116). Similarly, Knotts et al.
(using the same Taqman® Gene Expression Assay as our study) were also not able to
detect the expression of adiponectin mRNA in HepG2 cells (114).
One major cause of such differences in results for hepatic expression of
adiponectin could be due to the physiological/pathophysiological state of the
patient/mice/HepG2 cells. For example, morbidly obese patients with steatosis (90) or
mice treated with carbon tetrachloride (model for hepatic fibrosis) (117) or infected with
hepatitis B virus express adiponectin in the liver (110). Similarly, adiponectin was also
detected in HepG2 cells infected with hepatitis B virus (111) or stimulated with an
inflammatory cytokine such as interleukin-6 (IL-6) (117). In these experiments, the levels
of adiponectin in wild-type or control HepG2 cells were either very low (111) or not
detectable (117). Based on these observations, it is possible that adiponectin secretion
from HepG2 cells occurs only under situations that are far from normal homeostatic
conditions. Yoda-Murakami et al. demonstrated that treatment of mice with carbon
tetrachloride (to induce liver injury/fibrosis) resulted in a gradual increase in the
adiponectin mRNA with time (117). It is speculated that as the liver damage progresses,
there is increased production of inflammatory cytokines such as IL-6 which in turn
trigger the production of anti-inflammatory adiponectin locally in the liver. Thus under
conditions that were used in our experiments, we were not able to gather convincing data
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on the detection of adiponectin. Therefore it is difficult to predict the effect of PPARα
ligands on the expression of adiponectin in these cell lines/culture conditions/treatments.
The other possibility that needs to be considered is that the HepG2 cells do not
express adiponectin. Assuming that all the data showing adiponectin protein expression
in human or mouse livers and HepG2 cells was biased due to “contamination” from the
circulating forms of adiponectin or “contamination” from cell media, the question that
still remains unexplained is the detection of adiponectin mRNA in liver samples
(humans/mice). The human liver is composed of primarily hepatocytes (more than 60%)
(118). However, it also consists of other cell types such as the kupffer cells (20%) and
liver sinusoidal endothelial cells (15%) (118). Since immunohistochemistry based
staining of adiponectin was localized to these cells in certain studies (115, 116), it is
possible that adiponectin mRNA in the liver tissue arises from these cells (and not
hepatycytes).
To answer all these questions/concerns, it is important to test our hypothesis in
HepG2 cells under stimulation/stress (proinflammatory cytokines) or in a different cell
line that constitutively expresses adiponectin such as adipose tissue. PPARγ is
predominantly found in the adipose tissue where it plays a major role in adipogenesis.
Considering the PPARγ involvement in the regulation of adiponectin, it will be
challenging to test PPARα-mediated regulation of adiponectin in these cells. Several
groups have reported expression of PPARα in the adipose tissue (73, 119), where it plays
major role in lipolysis and fatty acid oxidation (119). Hiuge et al. also demonstrated that
PPARα agonists directly regulate the expression of adiponectin in white adipose tissue in
mice as well as mouse primary adipocytes and 3T3-L1 cultured adipocytes (73). This
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effect was not seen in PPARα knockout mice or cells where PPARα expression was
knocked down (73). It will be interesting to study the effects of PPARα ligands in PPARγ
knockdown adipocytes.
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Fig. 34. Adiponectin expression in HepG2 cells and its regulation by hPPARα ligands.
A) HepG2 cells treated with 10 µM of the indicated ligand and incubated for 18-20 hours
following which whole cell extracts were analyzed by SDS PAGE and probed with
indicated antibodies. B) Serially diluted fetal bovine serum (FBS) and EMEM media
(containing 10% FBS) were by SDS PAGE and probed for adiponectin.
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Transactivation assays: To examine whether PPARα is directly involved in
transactivation/transrepression of the adiponectin promoter, COS-7 cells were transfected
with mutant or wild-type adiponectin luciferase reporter constructs along with
mammalian expression plasmids for hPPARα alone, hRXRα alone, both hPPARα and
hRXRα and/or empty vector (pSG5). Transactivation was measured as percent firefly
luciferase activity normalized to Renilla luciferase (internal transfection control) is
depicted in figure 35. When compared to cells overexpressing empty vector (pSG5; Fig
35.D), PPARα alone (Fig. 35B) or RXRα alone (Fig. 35C), the basal transactivation for
the wild-type adiponectin promoter was significantly increased in cells overexpressing
both PPARα and RXRα (Fig. 35A). These findings are consistent with findings from
transactivation assays using PPRE×3 TK LUC reporter construct (Chapter I), suggesting
that both PPARα and RXRα work as heterodimeric partners to regulate gene expression.
Compared to the transactivation seen for the wild-type adiponectin promoter in cells
overexpressing both PPARα and RXRα, about 60 ± 9 % transactivation was even
observed in cells overexpressing RXRα alone (Fig. 35C) – suggesting that in addition to
the PPARα-RXRα heterodimers, other factors (possibly RXRα dependent/driven) may
also play a role in the regulation of the adiponectin promoter.
In cells overexpressing both PPARα and RXRα, mutating PPRE 1 versus PPRE 2
makes a considerable difference in the basal promoter activity (Fig. 35A). Mutating both
PPRE 1 and PPRE 2 in the adiponectin promoter caused a considerable decrease in
transactivation when compared to the wild-type promoter construct (50 ± 1%; Fig. 33A).
While such decrease in transactivation was also observed when only PPRE 2 was
mutated, no decrease in transactivation was seen when PPRE 1 was mutated
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(transactivation similar to wild-type). These findings, although in contrast with our data
from mobility shift assays, suggest that only one PPRE (PPRE 2) may be responsive to
PPARα activation (Fig. 35A). There were no differences in the DNA binding ability of
hPPARα-RXRα (to PPRE1 vs. PPRE2) in mobility shift assays. However,
transactivation/transrepression is also a function of cofactor binding to the hPPARαhRXRα complex (62-65, 102), and DNA binding reflected in our mobility shift assays
does not take this factor into consideration. Thus DNA binding in our mobility shift
assays may not be representative of the amount of ligand induced activation/repression
seen in reporter assays.
PPRE 2 is the same response element that has also been shown to be regulated by
PPARγ (67). Over the years, scientists have suggested sharing of response elements
between nuclear receptors. In fact genomic profiling of transcription factor binding sites
has revealed a lot of degeneracy and overlaps of binding sites (104, 105, 120). Boergenes
et al. have further demonstrated that there is substantial overlap between liver X receptor
(LXR) and PPARα binding sites. They further suggest that PPARα may bind to the
particular site in one cell type, whereas LXR may predominate such binding in another
cell type (120). Similarly, since PPARα and PPARγ share the same degenerate PPRE
motif in the adiponectin promoter (PPRE 2), it is likely based on the cell-type/tissue-type
each PPAR subtype plays a differential role in the regulation of adiponectin. This can be
extended to the physiological role of the tissue (example, liver vs. adipose tissue) and the
specific function of adiponectin desired (example, fatty acid oxidation, gluconeogenesis,
glucose uptake or anti-inflammatory function).
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The transactivation of the adiponectin promoter-luciferase construct or

mutants where one or both of the putative PPRE were disrupted w as m e as ur e d i n
COS-7 cells transfected with A) both PPARα and RXRα, B) PPARα alone, C) RXRα
alone or D) pSG5 empty vector. The y-axis represents values for firefly luciferase
activity that have been normalized to Renilla luciferase (internal control) The PPARα
and RXRα overexpressing cells with wild-type adiponectin promoter-luciferase
construct was arbitrarily set to 1 a n d the bar graph represents the mean values (n
≥ 3) ± standard error. * P < 0.001.
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Compared to the basal transactivation of the adiponectin promoter (Fig. 35), it is
not clear whether hPPARα ligands have any effect on the adiponectin promoter activity
(Fig. 36). While PPARα ligands such as stearic acid and clofibrate did cause any
significant changes in transactivation of the wild-type adiponectin promoter, the addition
docosahexanoic acid resulted in a significant decrease in such transactivation (Fig. 36A).
Since PPARγ has previously been shown to transactivate adiponectin (67), cells were
also treated with a synthetic PPARγ agonist (rosiglitazone) to account for the possible
PPARγ involvement in such regulation. Similar to docosahexanoic acid, the addition of
rosiglitazone also resulted in a significant decrease in transactivation of the adiponectin
promoter (Fig. 36A). Such decrease in transactivation (with C22:6 or rosiglitazone) was
seen consistently in all transfections, including mutant adiponectin promoter constructs or
cells overexpressing both PPARα and RXRα (Fig. 36A), PPARα alone (Fig. 36B), RXRα
alone (Fig. 36C) or pSG5 vector (Fig. 36D). This suggests that the resultant decrease in
transactivation could be resulting from indirect effects or effects that are independent of
the peroxisome proliferator-activated receptor response elements.
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Fig. 36. Effect of PPARα ligands on the transactivation of adiponectin promoter.
COS-7 cells transfected with A) both PPARα and RXRα, B) PPARα alone, C) RXRα
alone or D) pSG5 empty vector were analyzed for transactivation of the adiponectin
promoter-luciferase construct in the presence of bovi n e s er um al b u m i n ( B S A )
ba se d vehicle (controls for fatty acid ligands; open bars), d i m et h yl su l f ox i d e
(D MS O ) b as e d ve hi cl e ( co nt rol s f or d ru gs; diagonally upward bars), 10 µM
BSA linked-stearic

acid

(C18:0; diagonally downward bars), 10 µM

docosahexanoic acid (cross-hatched

bars), 10 µM

BSA-

clofibrate (PPARα agonist

solubilized in DMSO; horizontal lined bars), and 10 µM rosiglitazone (PPARγ
agonist solubilized in DMSO; vertically lined bars). The y-axis represents values for
firefly luciferase activity that have been normalized to Renilla luciferase (internal
control), where PPARα and RXRα overexpressing cells in the presence of BSA
vehicle controls were arbitrarily set to 1.

The bar graph represents the mean

values (n ≥ 3) ± standard error. * P < 0.05 in comparison to BSA controls and # P <
0.05 in comparison to DMSO controls.

234

Apart from PPARγ and the possible involvement of PPARα, the adiponectin gene
has been shown to be regulated by multiple transcription factors. Some of these
transcription factors include transcriptional activators such as CCAAT/enhancer binding
protein (C/EBP) (121, 122), nuclear factor Y (NF-Y) (121), adipocyte determination and
differentiation-dependent factor 1/Sterol regulatory element-binding protein 1c
(ADD/SREBP1-c) (60), and transcriptional repressors like activating transcription factor
(ATF3) (123), cAMP response element binding protein (61), nuclear factor of activated T
cells (NFAT) (123). Although these transcription factors are reported to regulate the
expression of adiponectin, the significance of some of these results are not clear. For
example, subjects with insulin resistance, obesity or metabolic syndrome (with low levels
of adiponectin) do not have any changes in their levels or activity of C/EBP (a positive
regulator of adiponectin (124). Nonetheless, the regulation by multiple transcription
factors suggests the transcription of adiponectin is under intricate regulation by various
upstream signals.
Upon manually analyzing the adiponectin promoter constructs in our experiments,
it was found that the putative binding sites for all of these transcription factors are located
in the region of the adiponectin promoter that was cloned upstream of the luciferase gene.
Thus, the possible involvement of these transcription factors could not be ruled out.
Alternatively, since increased transactivation is only seen when both PPARα and RXRα
are overexpressed (and not when PPARα ligands are added or PPARα alone or RXRα
alone are overexpressed), it is also possible that these effects are mediated indirectly by
PPARα-RXRα heterodimers – via regulation/cross-talk of other transcription factors. For
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example, human SREPB-1c (positive regulator of adiponectin) is also under regulation of
PPARα through a PPRE in its promoter (125).
Genomic profiling of transcription factor binding sites has revealed a lot of
degeneracy and overlaps of binding sites (105, 120, 126). Thus it has been suggested that
there might be clustering of transcription factors and/or other accessory proteins to the
regulatory regions of genes resulting in stabilization of protein-protein interactions such
that, they function as a complex (105, 120, 126). Profiling of PPAR binding sites has
revealed that genes that are activated by the PPARs are enriched in specific transcription
factor binding sites other than the PPARs (104, 127). For example, genes containing a
PPRE-like motif are likely to have a C/EBP binding element, TATA binding protein
binding motif and signal transducer of transcription (STAT) binding motifs in their
vicinity (104, 127). Such clustering has also been demonstrated for estrogen receptor with
C/EBP and octamer transcription factor 1 (Oct1) binding elements in its vicinity (128). It
is possible that PPARα-RXRα heterodimers are a part of a cluster of transcription factors
that aid in transactivation of the adiponectin gene such that, activation is not achieved by
PPARα ligands but rather by just the presence of the PPAR-RXR heterodimer.
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Future Directions
Owing to the drawbacks of our study, it is not clear whether PPARα has any role
in the regulation of adiponectin. Clinical and preclinical evidences strongly suggest that
PPARα agonists induce the expression of adiponectin. However, it is not clear whether its
involvement in such regulation is a direct or an indirect effect of PPARα activation. In
addition, adiponectin is speculated to be under complex regulation by a number of
transcription factors and upstream signals (59). Thus it is challenging to tease apart the
involvement of PPARα in such regulation. Some of the drawbacks of this study include
lack of competition based gel-shift assays, lack of a cell line that constitutively expresses
adiponectin and lack of consideration of other transcription factor involvement in the
regulation of adiponectin. Future studies should address some of these concerns and lay
emphasis on the kind techniques used (example, avoid use of media/FBS containing
adiponectin) and cell lines used. Considering the involvement of PPARγ and the presence
of a common PPRE in the adiponectin promoter it is essential to tease apart the effects of
PPARγ versus PPARα. One way of doing this it to make use of a cell line that lacks
either PPARα or PPARγ.
Another aspect of adiponectin regulation that has not been approached in this
study is the involvement of adiponectin receptors (AdipoR1 and AdipoR2). The
expression of these receptors is speculated to be under complex regulation by adiponectin
itself, insulin/feeding/fasting conditions as well as nuclear receptors such as PPARα and
PPARγ (27-31). While the expression of AdipoR’s was downregulated in obese patients
with coronary artery disease (129), livers of obese mice (51, 52) and in hyperglycemia
(130), their levels were upregulated upon fasting (51) and upon treatment with a PPARα
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agonist (52). These observations warrant further study mainly because the cause/effect
relationship of such regulation is largely unknown. For example, decreases in levels of
AdipoRs could be a result of low circulating levels of adiponectin (auto-regulation) and
increases in levels of adiponectin receptors due to a PPARα or PPARγ agonists could be
the result of increased expression of adiponectin or vice versa (31). Since strategies that
would either increase the expression of adiponectin or its signaling (via its AdipoR) could
improve a number of parameters associated with the metabolic syndrome, it is crucial to
understand the molecular mechanism of the adiponectin system.
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LIST OF ABREVIATIONS

ABCA1

ATP-cassette transporter A1

ACBP

Acyl-CoA binding protein

ACC

Acetyl CoA carboxylase

ACOX

Acyl-CoA oxidase

ACOX-/-

Acyl-CoA oxidase knockout mice

ACS

Acyl-CoA synthetase

ACSL

Long chain acyl-CoA synthase

ADD/SREBP1-c

Adipocyte determination and differentiation-dependent factor
1/Sterol regulatory element-binding protein 1c

AdipoR

Adiponectin receptors

AdipoR1

Adiponectin receptor 1

AdipoR2

Adiponectin receptor 2

AF-1

Ligand-independent transactivation function

AF-2

Ligand-dependent transactivation function

AMPK

Adenosine monophosphate (AMP)-activated protein kinase

(AMPK)
Apo

Apolipoprotein

APPL1

Adaptor protein containing a pleckstrin homology domain, a
phosphotyrosine domain and a leucine zipper motif
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ATF-3

Activating transcription factor

BSA

Bovine serum albumin

C/EBP

CCAAT/enhancer binding protein

CARLA

Coactivator-dependent receptor ligand binding assays

CD

Circular dichroism

ChIP-seq

Chromatin immunoprecipitation and sequencing

COX-2

Cyclooxygenase-2

CPTI

Carnitine palmitoyl transferase I

CTE

COOH-terminal extension

CVD

Cardiovascular disease

CYP7A

Cholesterol 7α-hydroxylase

DBD

DNA binding domain

DEHA

Di-(2-ethylhexyl)-adipate

DEHP

Di-(2-ethylhexyl)-phthalate

DMEM

Dubelco’s modified Eagle’s media

DMSO

Dimethyl sulfoxide

DR1

Direct repeat 1

EMEM

Eagle’s minimum essential medium

EMSA

Electrophoretic mobility shift assays
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eNOS

Indothelial nitric acid synthase

FABP

Fatty acid binding protein

FA-CoA

Fatty acyl-coenzyme A

FAS

Fatty acid synthase

FAT/CD36

Fatty acid translocase

FATP

Fatty acid transport protein

FBS

Fetal-bovine serum

FCS

Fluorescence correlation spectroscopy

FRAP

Fluorescence recovery after photobleaching

HAT

Histone acetyltransferase activity

HDAC

Histone deacetylase activity

HDL

High density lipoprotein

HepG2 cells

Human hepatoma cells

HETE

Hydroxyeicosatetraenoic acid

HMW

High molecular weight

hPPARα

human peroxisome proliferator activated receptor α

HSP-90

Heat-shock protein-90

IL-1

Interleukin-1

IL-6

Interleukin-6
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iNOS

Inducible nitric acid synthase

KCL

2-ethylphenylpropanoic acid derivative

LBD

Ligand binding domain

LCFA

Long chain fatty acid

LCFA-CoA

Long chain fatty acyl-CoA

LDL

Low density lipoprotein

LIC

Ligand induced assays

LMW

Low molecular weight

LPL

Lipoprotein lipase

LSD

Least significant difference

LTB4

Leukotriene B4

LXRE

LXR response element

LXRα

Liver X receptor alpha

MCAD

Medium chain acyl CoA dehydrogenase

MMW

Medium molecular weight

mPPARα

murine peroxisome proliferator activated receptor α

NCoR

Nuclear receptor corepressor

NFAT

Nuclear factor of activated T cells

NF-Y

Nuclear factor-Y
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NfκB

Nuclear factor κ B

NURR1

Nuclear receptor related protein 1

P450

Cytochrome P450 fatty acid ω-hydroxylase

PC

Photon counting spectrofluorometry

PGC-1

PPARγ coactivator-1

PPAR

Peroxisome proliferator activated receptor

PPARα (-/-) mice

Peroxisome proliferator activated receptor α knockout/null mice

PPARα

Peroxisome proliferator activated receptor alpha

PPARβ/δ

Peroxisome proliferator activated receptor beta/delta

PPARγ

Peroxisome proliferator activated receptor gamma

PPbP

Peroxisome proliferator-binding protein

PPRE

Peroxisome proliferator response element

PUFA

Polyunsaturated fatty acids

qRT-PCR

Quantitative real-time polymerase chain reaction

RAR

Retinoic acid receptor

RXR

Retinoid X receptor

SDS PAGE

Sodium dodecyl sulphate polyacrylamide gel electrophoresis

SMRT

Silencing mediator of retinoid and thyroid hormone receptors

SNP

Single nucleotide polymorphisms
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SRC-1

Steroid receptor coactivator

SREBP

Sterol regulatory element-binding protein

STAT

Signal transducer of transcription

TBP

TATA binding protein

TG

Triglycerides

TIF-2

Transcriptional mediators/intermediary factor 2

TK

Thymidine kinase

TNFα

Tumor necrosis factor α

TR

Thyroid receptor

UCP-1

Uncoupling protein-1

VDR

Vitamin D receptor

VLDL

Very low density lipoproteins

WHO

World health organization
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